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Abstract 
Th ding r gi n d t nninant binding pr t in ( - P) pla a r le in m cane r 
r gulating gen pr 
R c nt 
mutat dan or 
interacti n ther [! r 
i the aim of thi th 
pre ent d h r u mg 
n thr ugh In traffi r, and tran lati nal repr 
RD- P binding t m - apr 
d in an er, leading t up-regul ati n. 
ent an v 1 therapeuti pp rtunity t 
nc gen frequently 
mRN 
-dri en cancer and 
lectr ph retic m bilit and immun precipitati n experiment 
-mutan t RD- P ariant h w D ur K-hom 1 gy domain are 
required to bind a 57-nucleotide minimum binding equ nee in the coding region ofKRA 
RNA· the e mutati n d not c mpromi e pr teinD lding a e idenced by circul ar di chr i m 
spectro copy. DNA-ba ed anti- en e oligonu cleotid inhibitor were devel ped ba ed on the 
'minimun1 binding quence that ucce sfull y abroga te the RD-BP-KRA mRNA interaction in 
vitro. Finally a RD-BP KHl toKH4 construct purified using a nove l "on-co lumn"-re[i !ding 
scheme suggests a pos ible role for RRM-domains a negative regulators of RNA-binding. 
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Chapter 1 
Introduction 
llular r p n t th ide an g1 al c nditi n that rgam m are 
regularly e p d t d p nd h a il nth appr priat r gu lati n f g n pr n . uch 
pr CI c ntr 1 m c mpl y tem f igna lling m I cule capabl 
of erting influenc nth ari u bi h m i al pathway in d in cell activitie . rom 
borneo ta i t bl d cl tting t indu ti n f und h aling the abil ity t el ctiv ly m dulate 
vari u protein 1 el ithin th cell i ritical [! r appr priate re p n e t timuli and optima] 
functioning. Fir t d fm d in th lat 1950 , the central d gma of molecular bi logy state that 
D A i transcribed into an RN m nger m olecul e (mRNA) and ub equentl y translated into 
a tring of amino acids with defined tructur known a protein. Much work ha focu ed on the 
fme details of tllis proce and tho e efforts have delivered an ever-growing body of knowledge 
regarding the preci e workings of how genetic sequences tored in D A tum into the full y 
functioning mol ecular m achine and building blocks that cell are largely m ade of. As 
astonishing as this proce s of protein production m ay be, it i not enough to imply have protein 
being made in the cell ; to avoid diseases like cancer, they must also be regulated. 
1.1 Importance of gene expression in cancer 
Cancer is a particularly devastating disease among a host of other , and i there ult of 
genetic instability fostering the deregulation of biochemical pathway effecting cell growth, cell 
death (apoptosis), proliferation, repli cative inm1ortality, angiogene i , and metastasi (re iew ed 
in Hanahan and W einberg, 2011) . enetic mutation affecting tran c1iption or altering th 
functioning of important nzyme in terms of reaction rat can lead to change in pathway 
activity. When thes altered pathways affect ell cycl event , notable abnon11aliti e can ari e 
1 
2 
that impa t th h alth and 11-b ing fan afflict d indi idual. F r 1nple appr imat ly 40% 
of 1nelan ma ntain mutati n in th ignalling m 1 cui -Raf r ulting in n tituti 
indu ti n f the P-Kina path . hi lead t nhan d tran ripti n and pr n f 
many gen in luding -
2010 . bn nnal pr 
hi h in tum au chang a 1 and amu 1 , 
f th a cular end th lial gr th fact r ( )gn 1 ftn 
a iated with hyp ic di rd r nd n gem ignalling, and p tentiat height n d c 11 
receptor ignalling in ol din th un-g ern d bl d el fo1mati n r quir d by aggre 1ve 
olid tum ur (Ferrara 2010 . Th can nical epithelial -me nchymal tran iti n ( MT) i a key 
tep in the initiation f carcin ma meta ta i and can re ult from the ct pic inducti n and 
chronic o ere pr n f e era! tran cription fac t r in luding Zeb 1/2 and wi t a reviewed 
by Yang and Weinberg (2008 . Gen expre ion i influenced by many cellular proc ses and 
between tran ctiption and the final protein product po t-transcriptional regulation mechani m 
provides a major source of gene control. 
1.2 Post transcriptional gene regulation and mRNA stabili ty 
Control of cell activities, stability and even the complex tring of events that guide 
embryo development i dependent on mRNA encoded information the trength of th ese signal 
affected by steady-state mRNA levels- the balance between tnRNA production and destruction 
(Brewer 2003) . Initial transcription rates, RNA plicing, RNA transp011, and mRNA degradation 
all play major roles in determining steady-state mRNA levels and in pm1icular the modulation of 
the mo lecu le's longev ity, or half-life , within the cell is proving to be increasingly important 
(reviewed in Filipowicz eta!., 2008). Evidence for the importance of tabilizing/destabilizing 
effects on steady state mRNA level com from global eDNA array experiment comparing 
stress-induced transcription rate and steady- tate mRNA level f many gene , a well a kin tic 
3 
tudi fmR de a . tabiliz ti n f m a £1 und t nhan th g ne e pre i n f 
man g n gr up und r an u tr 
r du g n e pr min d mammali an ll ( an ' fa/ . 2 2) . riti ca ll y, it ha b n 
mR half-li£1 hang are n t a 
n mall chang tabilit can dramati all alt r g n ef a /. 1 5). 
act r af£1 ting mR ng it in th ll are di , and ur und r tanding f th 
ha b n a rapid! mg pr e . With th di ry f interil r nee by ire 
and Mel! ( 19 ), it ha b c m I ar that p t-tran cripti nalle el regulatJ n 1 a c r mean f 
tight! regulating mRN in the 11. In gen ral a dynamic c mbinati n f ci -element and 
tran acting fa ct r pr du e the ari ati n in m A tability. i -element are intrin ic 
qu nee that i t thr ugh ut th I ngth fa tran cript, £1 und in th e c ding regi n , 5' R, 
and the 3' TR, that ar a cia ted ith mR (in tability, with the latt r being the m t 
c mmon region of de tabilizing i -element in the form f 
-ri ch equence element , r 
ARE ( haw et a/. 19 6) . i -el ment can exi t ingly or together with ther regulatory 
element on a ingle tran cript and collectively provide rapid , adaptive re p n to a number of 
different cell signal ( hen et a!. 199 ). Ci -element often act in concert with tran -acting 
factors to achieve their effect, a group con i ting of prot in and non-coding nucleic ac id , uch 
as tibonuclea e , RNA-binding protein (RPB ) and microRNA capable of recognizing the 
mature RNA tran cript and modulating it phy iological urvivability (Neugarbauer et al. 2002). 
1.3 RNA binding proteins and mRNA turnover 
Mechani m of gene regulati n are multipl e, and the pecific interplay b tween r gu lating 
factors increa e in complexity in eukaryotic cell (Hayne 1999). ntrol of gene expre ion by 
mRNA regulati n begin irmnedi at ly foil wing tran cription in the nucl u , and ' n e p 11 
int the yt pla m a het r g n u nu l ar rib nucl pr t in nRNP) patii 1 r qmr an 
unp rtant la f prot in call d RN -binding pr t in ( r r 200 ). prot in larger than 
50 kDa ann t fr 1 diffu 
regulat p rt are r qu ired 
pore compl (D nig t a/. 2 00) . 
and are of particular int r t b cau 
th nu lear m mbran , pecific nuclear p rt ignal that 
P :D r rec gniti nand tran it tl11· ugh the nuclear 
pia an in trum ntaJ r 1 in R metab li m , 
a an adapt r betw n mRN regulat ry 
equen and m dulat d pr ion f th g ne . RBP ar a large f mily of pr t in and 
hundred e i t (mo tly un hara t riz d) within the human gen m . Together with all the REP-
binding ite within the tran criptome, the e RPB form an imp rtant tier of gene regulation 
ba don equ nee el ti it and p cific affinity llecti ely t rmed the' po ttran criptional 
r gu latory cod "(Ke n 2007) . v ral type ofRN binding protein have been identified and 
each function in different way by identifying uniqu ci -elem nt , binding different mRNA 
regions and altering tran lation rate or tabilizing/de tabilizing the mRNA transcript. P27Kipl 
for example is a regulator of cyclin during G l phase, and its activity is down-regulated by the 
association of its 5'UTR mRNA with AU-rich binding protein , HuR and HuD. Such physical 
interaction restricts ribosome access to the tran cript and therein reduce tran lation (Yeh eta!., 
2008). BRF-1 is another RNA binding protein which functions not by regulating tran lation, 
instead achieving its effect by destabilizing AU-rich mRNA target tran cripts (interleukin-3 , 
interleukin-6 and TNF-alpha) through deadenylation (Raineri eta/., 2004) . RBP canaL o erve 
to stabilize mRNAs and increase relative gene expression, a phenomenon that when kept in-
check serves to appropriately regulate various cell events. Enoneous over-expres ion of RBPs 
however can bolster multiple downstremn mRNA targets simultaneously, leading to global cell 
4 
m 1 ular pr fil hift impli at d in th d 
dy fun ti n, and n anc r ( in t a/., 200 an t a I., 2 4 · b d a t a I ., 2 0 1 1 ) . 
1.4 A brief hi tory of RD-BP 
ding R gi n tability t 1min nt inding Pr t in ( R - P) i an RN -binding 
prot in that wa fir t hara t riz d aft r -cr linking e periment re al d an P of 
appr imately 70 a that 1 cti el bind and tabiliz th c ding r gi n d t nninant 
equ nc f c-myc mRN Bern t in eta!. 1 92) . R - P i a m mber f th "VI KZ" 
protein fmnil (al kn wn a zipc de-binding pr tein ), a mall gr up f highly con erved (77-
9 %identity it and tandmi, 2002) orth I g u RBP with imilar functi n that include 
VglRBP RA (X nopu lae1•i ), IMP-1,2, H omo api n ) RDBP (Mus musculus ), K 
(Homo apien ) and ZBP 1 ( Gallu allu dome ti u ) (reviewed in Yi raeli 2005) . There is 
however no e tablished tandard for the naming, and th de ignati n are ft n used 
interchangeably depending on the laboratory. For example, Patel t a!., (20 11) refer to ZBP 1 a 
IMP1 , with IGF2BP1 (another name for CRD-BP) li ted in bracket . Member ofthi family 
have been identified as important po t-transcriptional mRNA regulators with roles in mRNA 
stability, as well as translational control and mRNA localization involved in lamellipodia 
formation and bleb extensions in motile cell types (Bern tein et al. 1992; Condeeli and Singer, 
2005 ; Poincloix eta!., 2011) . VICKZ proteins are therefore each multifunctional and have been 
further implicated in early developmental stages where they are involved in critical events uch 
as oogenesis , synaptogenesis, cell motility, and embryo polarization (Boylan et a!., 2008). 
Of particular intere tis CRD-BP ' ability regulate gene e pres ion by affecting the half- li fe 
of mRNA targets which influences protein level . Demon trating the potency of CRD-BP ' s 
effect on steady-state n1RNA levels, an experiment utilizing tran genic mice over-e pre mg 
5 
6 
RD-BP r p rt d a dramatic l 0-:fl ld incr a in I II n , an tabli h d targ t f th 
prot in. i1nilarly B n1 t in 2 , h d that -myc mRN 1 v 1 wer tabiliz d by at 
RD-BP in a 11-fr mRN d ca a a . h re are num r u amp! f thi 
pr t in ' ffe t n target mR le 
pictur and it ntributi n t di a 
I and path a 
i n t yet fu ll 
ign I ling, t h it fi t int an verall 
d. 
and in ol em nt in rtain path a are b ginning t r al th imp rtance f P. 
1.5 CRD-BP in ea rl development and carcin o ene i 
RD-BP i n rmally und r tri t pati t mp ral c ntr 1 with pre i n p aking between th 
zygote and arl mbr tage n mbry rue day 12.5 in mice. In th day leading up to birth, 
CRD-BP becom und tectabl or 1 pre d at ry 1 w le el in all r d nt ti ue (Han en et 
al. 2004). in1ilarly, adult human ti ue h w li ttl IMP-1 xpre ion compared to the robu t 
level found in variou embryo tage (Leed et al. 1997 · iel en et al. 1999; L et a!. 20 12) . 
Ilnportantly, CRD-BP expre ion in rats does not re-emerge during liver ti ue regeneration 
(partial hepatectomy) agreeing with the standing theory that CRD-BP i normally limited to 
developmental stage only and not ju t ti ue growth/regeneration (Leed eta!. 1997) . Also 
consistent with the notion that CRD-BP i an important player in the earliest life stage in 
mammals, CRD-BP-deficient mice generated by gene trap insertion show severe abnormalitie 
such as dwarfism, improper gut fonnation and higher perinatal mortality rates (Hansen eta!. , 
2004). On the other hand, over-expression ofCRD-BP in a mouse model allowed for nonnal 
development, but produced populations with a high incidence of mammary adenocarcinomas 
(95% occurrence compared to no tumours in the non-transgenic mice) demonstrating a potent 
proto-oncogene feature of CRD-BP (Tes i r et a!. 2004). 
f RD- P IMP- I in 1 t r liD tag an ur and i trongl a iated R -e pr 
with v ra l typ f anc r. Ind d, a tud a1nining r a t anc r pati ent tum ur r al d 
1 at d pre 1 n f -BP in % f human pri1nar br a t car in rna , with - 1 %a 
a r ult of g ne duplicati ninth 17q21 band r gi n h r th R -BP g n i 1 cat d 
(I annidi 1 a!. 200 ). In imilar tudi half f n ur pith li al (brain tum ur , nearl y a third 
f n n- mall lllung ar in rna , 7 % f mali gn nt m en hymal tum ur and 69% f varian 
cancer w r fl und t te t p iti fl r RD- P I annidi t a/. 200 1, 200 ; K bel I a/. 2007). 
en more in riminating id n e r gardin g thi pr tin · mv m nt in n opla ia i a tud y 
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that found 81 % (1 7 out f 21) f t t d c 1 rectal tumour w r p itive fl r ignificant RD-BP 
expre ion, while normal colon ti ue and inflammatory b w 1 di ea ed ti ue howed no 
detectable level (Ro et al. 200 1 ). Rea on fo r thi re- xpre i n are mo tl y unkn wn howev r 
recent tudy of CRD-BP in melanoma cell cultured under hypox ic conditi n that mimi c the 
tumour microenvironment ha hown CRD-BP modulation by th e HIF J a (hypox ia indu ced 
factor 1 alpha) tran cription factor through acetylation of the CRD-BP gene. MT cell 
proliferation assays in the same paper also uncovered a strong link between CRD-BP and the 
melanoma cell' s proliferative capacity, as sh-RNA ( h011 hairpin RNA) directed against RD-
BP was able to abrogate the cancer 's growth (Crai g et al . 20 12) . Interestin gly, HIF I a indu ction 
is al o seen in other cancers where CRD-BP appears to play a role, such as breast and colorectal 
tumours (Kieth et al. 201 2). Hypoxia-independent induction ha also been observed by Noubissi 
et al. (2006) , where the researchers demonstrated that CRD-BP can be indu ced by enhanced ~­
catenin/Tcf signalling, a common feature in many colorectal cancer (Morin eta/. 1997). 
The clinical value of RD-BP is evident in prognostic stati stics, and in general, human CRD-
BP expression level correlate with the diagnosed grad of malignancy for evera l cancer 
Yani and Yi ra li 2 2 . dditi nall it ha b n [! und that n !at ith 
r du d r CUIT n -fr and 
ingl ariat and multi riat 
rall u i al rat m anan cancer. far b ed n 
it i un lear heth r a tu I pr gn ti [! r 
anan can r pati nt ith r e r h requiring larg r mple iz (K b 1 t a/. 2 07) . In 
h re R -
tr ngl ith erall aggr 
(Dimitriadi 1 a/. 2 7 . Whil 
n 1 m t r va l nt, p iti e te ting c n elated 
nd ffcr a m lecul ar fact r 111 pr gn 
me can er m rc ignificant than in 
th r , it i lear that R -BP i g nerall an imp rtant ingr dient D r carcin g ne 1 lth ugh 
it preci e ontributi n and m d facti n appear t b c mple , kn wledge fit target and 
how preci el it intera ith th ill all w cienti t t take aim at RD- P in a 
progno tic and e en th rapeutic n e. nD rtunately th re i much gr und yet t tread in thi 
realm, but h w thi RBP d e it j b i pr gr ming t li ght . 
1.6 VICKZ protein famil y tructure and function 
8 
I KZ protein have been h wn t bind multiple target including the mRNA fi r c-myc, 
IGF-II, beta-actin, Hl9, tau and other (reviewed in Yi raeli 2005). How they accompli h thi 
through the multiple RNA-binding domain present in the e protein . RD-BP and other VI KZ 
family member are composed of six RNA-binding domain ; 4 K-homology domain (KHl -4) 
with a ~a.a~~a. topology, and 2 RNA recognition motif (RRM 1-2) with a 0a.~ ~a.~ topology that 
make up the majority of the protein' tructure . Hi gh eq uence con ervation f the VI KZ 
family RNA-binding domain , as well a the linker region between KH l -KH2 and KH -KH4, 
ugge t that the domain may function together a did main (KH 12 and KH34) (Git and 
Standart, 2002). lnd ed, tudie f the ZBP 1 hom log how that linker region amino acid ar 
critical [i r proper protein function . In thi e periment, a trun a ted KH 4 ZBP 1 con tru twa 
ynthe iz d and the link r armn a id j ining Z P 1 KH and KH4 p udo-d mam w r 
replac d with th e fr m th adjac nt KHl - KH2 link r r gi n . nl the id ntity [ th amm 
a id wa chang d, maintaining th ralll ngth f th link r. hang in the amin a id 
id ntitie al n produc d a mark d negati af[i ct n th b rved Kd D r zip d binding a 
d tennin d thr ugh M , indi ating th imp rtant r le the e link r r gi n play in RN 
binding ( hao t a!. 2010 . h i 1 gical ignificance a d termin d thr ugh ell-ba ed 
experimentati n wh r a FP-fu d ZBP 1 linker mutant full length pr t in c ntaining th am 
linker mutation) a pr ed in mou e embryonic fibr bla t t a any functional impact. 
When analyzed by confocal micr copy the linker mutant n 1 nger r tained the wild-type ub-
cellular localization and wa found t with th in-b tween amin acid erving a more than 
ju t a hinge ( hao eta /. 201 0) . 
Part of RD-BP' function i to bind and localize mR within the cell. How it 
accompli she thi task and the question of which, if any, individual domains are primarily 
re ponsible for binding has been an wered with varying results by tudying CRD-BP and its 
clo ely related orthologs. Granular RNP formation as ists in localizing vmiou mRNA 
tran cripts within the cell, and systematic deletion of the individual domains of IMP 1 revealed 
nuclear export signals (NES) in KH2 and KH4 domains (Nielsen et al. 2004) . To addre s the 
question of domain redundancy in target-binding, Nielsen et al. (2002) de igned an experiment 
using GFP-tagged deletion constructs of IMP 1 that had the RRM and KH domains 
systematically removed, and subsequently analyzed for presence of IMP ! -containing RNP 
granule fonnation, sub-cellular localization and mRNA binding capacity. It was found that in 
terms of cytoplasmic trafficking, loss of both RRM domains had little impact on subcytopla mic 
localization, with all four KH domain proving nece ary and uffi cient for nonnal IMP-1 
9 
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di tributi nand granular app aranc . imilar r ult btain d with regard t RN -binding 
to kn wn targ t Hl mRN h r th an u d l ti n n truct er a ayed u ing 
1 tr ph r tic m bilit 
£ r f£ cti binding 
hift a a M 
n t a/. 2 02 . 
d d main 1-4 r all £ und t b r quired 
n er el Z 1 - th £ unding memb r fthe 
I KZ pr tein fami1 , wa £ und through imilar p riment nly r quir KH -4 d mam 
t bind it targ t b ta-a tin mR ith the th r ~ ur d main (RRMl-2 and Kl 1-2 con truct) 
unabl t bind ith an appreciable Kd ( ha Jf a/ . 20 1 0) . e pit high imilarity and therwi e 
identical b ha i ur in am - ub trat binding a a , the different d main r quirem nt 
demon trat that I KZ prot in (including RD-BP) may interact differently nan individual 
target ba i (VI KZ protein truncati n tudi ummarized in Table 1.1 ). 
Further in ight into the tructural detail of VI KZ family pr tein and h w they bind 
RNA wa addre ed by mean of X-ray cry tallography. tudying ZBPl in complex with beta-
actin mRNA, it was found that binding of RNA wa mediated by interaction with a minimum 29 
nt RNA fragment in 2 spots with both the KH3 and KH4 domain arranged in an anti-parallel 
fashion such that the RNA binding urface ran in oppo ite directions (revealed by a IMP-1 
KH3-KH4 crystal structure). This didomain configuration was found to induce a unique 180° 
looping of the RNA strand with two non-sequential, spaced RNA sequences bound. It i thought 
that this is likely the in vivo confonnation and mechanism of binding for VICKZ proteins 
because the interaction of the KH domains is stabilized by sequestering a large surface area and 
several hydrophobic residues present in all VICKZ homologs (Chao eta/. 201 0). Adding another 
level of complexity, surface plasmon resonance and NMR experiments have demonstrated that 
the KH3-4 didomain contains a dimerization motif. Weak protein-protein interaction between 
the separate KH-3-4 didomains was observed and this interaction is stabilized by the pre ence of 
RN 1 ading t alt n1ati ibiliti m I KZ RNP and granul 
c mp iti n ( it tan dart 2002 · t a! . 2000) . In fur1h r upp rt f thi n ti n, kin ti 
analy i and ad an ed at mic D rc mi r p f l 
multipl IMP-1 m 1 ule binding t a ingl mR 
2007). Pr t in-RN int ra ti n in thi m d 1 ur 
1 ugg t p iti c p rati ity with 
n t a/. 20 4; J n n t a!. 
ith th fir t binding ent 
characterized by a highl tran i nt int rm diat f 1 w tabili ty, [! 11 w d by a c nd IMP 1 
binding. Prot in-pr t in int ra ti n ia a KH -4 dimeriza ti n m ti f th n further tabilize the 
1 
RNP comple , l nding planati n t the hyp r- table P granule re n ible D r tran p rting 
target mRN aero th c 11 i 1 n eta /. 2004 ). Littl information r garding the actual 
tran port of the e protecti e RNP c mple e i t . H wever, immun - taining and con[! cal 
microscopy r v aled that IMP-I doe co-localize with mi cr tubule and f-ac tin , ugge ting 
cytoskeleton a ociation with TP-dependent movement ( iel en eta!. 2002). 
Despite the numer us studie di playing tight a ociation with whittl ed-down target 
mRNA regions, and even X-ray structural model no con en us binding equence fo r VI KZ 
proteins as a family or individually, has been identified with only case- pecific generalizations 
having been made that do not fully account for observed binding. For example, CRD-BP 
interaction with c-myc mRNA has been shown to predominantly occur in the region 
corresponding to nucleotides 1763 to 1777 (5 '-AGCCACAGCAUACAU-3 '), but it i unknown 
which nucleotides comprise the actual binding motif (Coulis et al. 1999). Even between 
experiments using identical proteins in similar conditions, different conclusions have been 
drawn. Jonsen et al. (2007) , concluded that ZBPl has a high affinity for guano ine-1ich and 
cytosine-poor RNA regions, and putati ve ly identified a 5' -CCYHH -3' binding motif (Y=C or 
U, H = A or or U) . Using a different experimental approach, other re earchers later c n luded 
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that th ZBP l c n n u binding m tif a n nn hm nt f '- - ' r peal in th targ t 
tran ript (Hafn r t a/ ., 2010 . I KZ pr t in R -binding r quir m nt ~ r mRN 
tran cript are till1arg 1 t ntati , h r Pat 1 r al. (2011 , d m n trat d a tri t binding 
r quir m nt fl r ju t th Z P 1 KH 4 did mam, ith the KH4 d main r c gnizin g a 5 '-
qu nc , and th KH d m 111 re 
. . gmzmg equ n e, in line with th 
afl r m nti n d "R -1 ping" m d I (Pat I eta /. 2 11 · ha ct a/. 2010 . Tb e di cr pancie 
rna ay m thing ab ut th m th d u ed, r it ma b that the dif~ r nt identifi d equence 
tern fr m diffl r nt KH d main pr fl r n . It ma al be that the multi-RN -binding-
domain pr tein ar targ ting a c rnm n thre -dimen iona1 tru ture a opp ed t ju t a linear 
equence. 
Table 1.1. ummary of mention ed VICKZ protein mutation stu di e 
CRD-BP Type of Type of Study Conclusion Ref. 
Ortholog Mutation 
IMPl Deletion construct Cell-based, NES pre ent in KH2 & Niel en et al. 
GFP-tagged KH4 2004 
ZBPl KH3-4 linker In vitro EMSA Increa ed zipcode RNA Chao et al. 2010 
binding Kd . 
ZBPl KH3 -4 linker Cell-based, Reduced granulation Chao et al. 2010 
GFP-tagged and cytopla rnic sub-
localization 
IMPl Deletion construct In vitro, EMSA KH domains 1-4 all Nielsen et a/. 
Cell-based, required for effective 2002 
GFP-tagged binding ofH- egment 
(173 nt fragment) H 19 
RNA 
ZBPl Deletion construct In Vitro, EMSA KH 3-4 didomain Chao et al. 2010 
impm1ant in binding 
beta-actin mRNA (54 
nt binding region) 
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1.7 Onco enic KRA ne pre ion and RD-BP 
r gulati n f riti al path m nt m d in c 11 ignalling and ll- c l ntr 
ar t th f an r.Mn fth nc g 111 p th a 11 har t nd ar 
trun n f an r taL pan rea ti , nd m tri al, 
mpl that h w up-rcgulati n f p c ifi c 
path a including th Wn b ta- at nin . PI J R pathway kaha hi ' I a/. 
1995 ; R drigu z I a/. 19 nne eta/. 2 5 . mm n t c ch the 1 a n tituent 
TPa ignalling pr t in all d th Kir t n rat arc rna iral nc gene h m 1 g (K ). 
Abn rmaliti in thi ignall ing m le ul ar implica t d in 0% f pancrea ti cancer , 60% f 
color ctal anc r ( R ), and 50% flung cancer ergham 7 / a! . 19 7; B ' I a/. 1987; 
. Ma cau 1 al. 200 ). c n1n1 n mutati ninth glycine- 12 p iti n t a parti e acid tr ngly 
reduc TPa e ac ti it , effecti 
"' 
I eking the m lecul e in the" n" tate by 
preventing hydrol y i f the ac ti ating TP mol cule nee it ha bound , and i con idered an 
impotiant biological factor in many cancer (Ge rge et a! . 1993; Pylayeva- upta el a! . 20 11 ). 
Thi in effect bypas e externally regulated ignalling and prov ide the nece ary biochemi cal 
environment to induce the cancer phenotype and i in fact the ing le mo t con1mon acti ating 
mutation in human cancer ( haw el a /. 2011 ). R A interferen e experiment ha e fu rth r 
hown that change in KRA expre ion can independently regulate the down tr am effector of 
all the aforementioned pathway uch a the mitoti c fa ctor eye linD 1, tran lation enhancing 6K, 
V F, and apoptoti c fa ctor F X m aking Kra a lucrativ target for future antineop la ti 
therapie (Miura l a/. 2005) . 
an r h e r an al an fr m r r gulat d KRA a ti ity in man 
th wild-typ D rm. Inde d a c mpr h 
pati nt found that high ild-typ K 
tud f 1 i n 111 nd m trial carcin rna 
pre 1 n rrelat ith r 
rat and unfa urabl tr atm nt utc m than did an mutant ariati n . 1 ated 
nand KRA g n amplifi ati n p ci IC lly c ne lat d ith an aggre 1 e 
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11 a in r a d fr m primary t m ta tatic le i n ( irkeland t a/. 20 12). r le 
for wild-typ K l11 ch db alt 1ia t a/. 20 13) wh dem n trated 
KRA gen amplificati n c IT lat ith anti- FR antib dy th rapy re i tance with cetuximab 
and panitumumab in me R pati nt . KRA inducti n i ind pendently abl e t induce a 
cancer phenotyp in rat pancrea , and kn ckd wn ha demon trated that many pancreatic cancer 
cell line ar dep nd nt n KRA o er-e pre ion Tuve n et a l. 2004; Zhang e/ a l. 2006) 
IMP1 has been found to be a maj or player in the regulati n of KRA level by binding directly 
to the mRNA transcript (Mongroo et al. 2011 ). V -cro slinking ha demonstrated that IMP -1 
directly interacts with KRA mRN in the coding region ( D ) and the 3' TR and that down-
regulation of IMP 1 directl y results in the reduced mRN A level and protein level of Kras in RC 
cell lines (Mongroo et al. 2011 ). Positive regulation ofKRAS expre ion by IMP l!CRD-BP 
therefore presents a novel opportunity to target KRAS in cancer that co-express CRD-BP . 
1.8 Targeting KRAS in KRAS-driven cancers 
KRAS driven malignancies are very cmnmon, effecting up to a third of all cancers but most 
prominent in leukemias, colorectal, pancreatic and lung cancers and as such, a diverse range of 
anti-KRAS therapeutic strategies have been pursed. There i still no prescti bable go-to drug for 
targeting KRAS in cancer, with many experim ental treatments falling short due to systemic 
toxicity or poor inhibition, which ha limited the degree to which KRA cancer can be treated 
(Bain tal.20ll).H 
pr du ed h p ful candidat 
Directly targ ting th 
thu far. The pr t in· hall 
pr 
gr 
ral pr m1mga 
rec ntl . 
t in ith mall m 1 ul 
and lack f binding p 
thi ar a t m lecul in apabl ub tantiall m dulating K 
nu fr arch that ha 
ha pr nan ill-fat d trat gy 
ck t ha e limit d th u ce lll 
acti ity due t 1 w-affinity 
binding intera ti n (Maur r t a!. 2 12; un r a!. 20 1 ; hima et a!. 20 13 ). H wever, trem 
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tal. (201 ) mad a r c nt KRA targeting br akthr ugh h n p riment utilizing thi 1-based 
inhibit r h w d tr ng pr t in binding character. The e inhibit r f01m a di ulphide b nd with 
nth KRA pr t in, and are abl t c ax KRA int it inactive D 1m by 
tabilizing the DP-bound c n£ rmati n. Furthermore, th t p candidate m lecule di play an 
inherent preference for cell ex pre ing the 12D mutant ver ion f KRA commonly found in 
many cancer and achieve ome pecific anti-proliferati n activity. However despite the 
promising binding data, it is empha ized that the e thiol-based inhibitors are un uitable as cancer 
drugs in the current form, a Ras ignalling wa only marginally reduced. Development of thi s 
class of inhibitors remains an active area of re earch pursing chemical "warhead ''more capable 
of inhibiting KRAS signalling. 
Famesyl-transferase inhibitors (FTl's) have been thoroughly explored in the laboratory and 
in the clininc (reviewed in Appels et al. 2005). This class of KRAS inhibitor di rupts a po t-
translational farnesylation modification of the KRAS protein, whereby non11ally a large 15-
carbon hydrophobic tail is added to allow effective membrane as ociation. A KRAS achieves it 
signalling function through interactions with other proteins near the cell membrane, failure to 
attach a lipid anchor results in a significant inhibition of KRAS signalling. In practice, FTis such 
as Lonafarnib and Tipifamib only proved effective against the le common H-RA and N-RA 
me1nb r f the RA up rfamil . nlik th th r pr t in 
alt tnati 1y p t-tran lati nail m difi d b geran 1 tran f ra 
a it turn ut c n b 
n inhibiti n f fa1n yJ 
tran :D ra nzym mp n at r r dund an larg 1 limiting th ucce TI 
again t KRA dri n an r . Targ ting th th f n 1 and g ran 1 tran fera e nzym 
imu1tan u I pr d 1 th 1 t n n-can r u and c c r u cell alike, a many pr tein 
ary £ r ba ic cell fun ti n ar ub trat f th e am enz me . 
Pre enting KRA fr m fun ti ning at the cell m mbrane r main d an enduring therapeutic 
trat gy ith th intr du ti n f P inhibit r . i th d Ita ubunit of c MP 
pho phodie t ra and i a KRA binding partner that preferentially interact with fame ylated 
KRAS and aid in th tran lo ation of KRA to the membrane ( handra eta/. 20 12). m all 
molecul dev loped to inhibit thi critica l tep, b pec ifi ca ll interruptin g P ciati on 
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with the famesylated tail of KRA but till allowing the actual fane ylation tep to occur 
culminated in the introduction and pre-clinical trial of Deltarasin. Do e-dependent delocalization 
of famesylated KRAS using deltrarasin was recently demonstrated in human pancreatic cancer 
cell line and in a mouse model of pancreatic ductal adenocarcinoma where tumour growth wa 
noticeably reduced, providing promi ing evidence that thi strategy is a valid method to target 
KRAS . However, the drug's lack of specificity produces hi gh ystemic toxicity and future work 
still needs to be done before pushing tllis proto-drug to human trials (Zimmerman eta!. 2013 ). 
Salirasib (S-trans,trans-fatnesylthiosalicylic acid) is another small molecule that has been 
shown to interfere with proper membrane as ociation of KRA . Salirasib however doe not 
directly target any protein or enzym e important in the po t-translational modification or 
intracellular transport of KRAS , instead binding th hydrophobic famesyl tail directly, reducing 
the overall hydrophobicity of the tail and impairing it effectivene to interact with the cell 
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m mbran (W i z tal. 1 99) . R cent pre-clinical and lini al d 1 pm nt n alira ib ha 
furth r h wn that them 1 cul i 11-t 1 rat d in pati nt ith meta t ti pan reati du tal 
ad n car in rna (PD ) and nhan e th ffecti n gemcitabin h moth rapy wh n u d 
in c mbination ( ah ru t al. 2012 . imilar pr bl m limit th ef.[i cti ne f alira ib as it 
uni er ally aH ct all RA i D rm ith n cane r cell p cifici ty. 
Inhibit r d ign d t bl k K fr m reaching. r int racting with th membrane ar nly 
trategy, but an th r pr mi ing a enue i pr enting th ac ti ati n f KRA by inhibiting the 
RA guanin nucle tid chang fact r : Ra - F , required t induce TP-binding and 
turn KRA "on '. Th chang f DP D r 
KRA and ha been th p ific targ t of Patgiri et a/. (20 11 ) wh have produced a mall 
molecule, a ynthetic a-helix that mimic the binding m tif of the protein, that competes 
with the KRA -Ra -GEF protein-protein interaction blocking the exchange of GDP for 
GTP and hindering KRAS activation through receptor tyrosine kinase stimulation. Whil e thi 
work has been limited thus far to cell line only, it is undoubtedly a promising avenue of 
research. 
Attacking KRAS at a genetic level by altering the rate of transcription is a more recent 
approach pioneered by Cogoi et al. (20 13 ). Within the promoter region of the KRAS gene, it was 
detennined that stretches of the DNA fonn G4-quandruplex structures which are recognized by a 
myc-associated zinc finger transcription factor (MAZ). MAZ protein binding promotes KRA 
transcription, and by using a synthetic DNA oligonucleotide G4-quadruplex rnin1ic that acts as a 
MAZ decoy, KRAS expression could be effectively reduced in human pancreatic cell lines 
(Pane-l) and reduce KRAS-driven tumour growth in mice by 64%. The pancreati c cancer cell 
were shown to display increa ed apopto i upon admini tration of the MAZ-decoy and validate 
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th con pt of Z- p cifi 4 quadrupl c mp tit r m 1 ul . urt.h r w rk in t.hi ar a will 
£ cu n in rea ing ph t bili fth rn 1 cul a larg d a r quired to 
achie e the f£ t pr umabl du t degr dati n fth -b d rn 1 cul . 
It i cl ar that 1 urr nt t pi , and trategic th rap utic t. rg t in th war n cane r 
h e rd pit lit rall d fr ear h, r rnam an lu i target in th linic. 
mpl ity in targeting thi TPa ignalling m lecule ari e fr rn the true turall y imilar, but 
functi nally di tinct memb r f th Ra famil hereb targeting K u ually inadv rtently 
target th oth r relat d pr t in unint nti nally. ppr ache wh r by KRA i dire tly targeted 
have only rec ntly ho n m d rat u c , u ing a thi 1-ba ed binding cheme, but the e till 
are limit d in ability t actuall kn ckd wn KRA acti ity. FTI h wed gr at early promi e by 
preventing a critical po t-tran lati nallipid modification nece ary for KRA m mbrane 
a ociation, but the co-acti ity ofb th fame yl- and geranyl-tran fera e inhibitors pr ved toxic 
to cell . Similar toxicity plagues the alira ib approach, where ob truction of the hydrophobic 
tail of KRAS by a masking molecule delocalize the protein. Interfering with the proper transport 
of fame ylated KRA protein to the inner cell membrane u ing a PDE8 inhibitor has hown 
some promise in mou e model but again ystemic toxicity and poor drug tolerance ha limited 
the effectiveness of this molecule and requires further optimization till . Inhibiting the activation 
of KRAS showed moderate success. Ras-GEF SOS is required to induce KRAS to bind GTP, a 
necessary step in KRA signalling, and with the u e of ynthetic a.-helix mimic de igned to 
mimic the KRAS binding site, KRAS docking with the guanine nucleotide exchange factor could 
be inhibited and overall activity reduced. Perhaps the single mo t promi ing work, including cell 
and mouse-model data wa the G4-quadiuplex MAZ-decoy approach, a it wa able to 
specifically target KRAS at the genetic level, and not the other RAS i oforms, but ha not yet 
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pr gr d t human clinical trial . n£ rtunat 1 d pite the di r atTa f trat gi 
mpl targ t KRA n il r bull t ha b en pr n alth ugh th r ar ome I r m1 mg 
1 ad ne itating th n d £ r fut1h r r arch int th 
a w 11 a new no 1 appr a h 
1. 9 Re earch Goal 
RD-BP ha a prrm r le in th initiati nand pr gr n f ral ancer . f 
pat1icular int re t i th recent di c ry that R - P bind th KRA mRN tran cript, 
11-e tabli hed nc g n pre alent inc lor ctal, pancreatic 
and lung can r . Targ ting KRA -dri n can er ha proven e tremely difficult and de pite 
thorough in e tigati n of a wid variety f anti-KRA trategie there remain till n effective 
target d therapy. Importantly, RD-BP i an one fetal pr tein , and i nonnally only expr ed 
during early zygotic and embryonic tage of development. Adult ti ue nonnall y ha virtually 
no detectable levels of CRD-BP; however robust re-expression occur in many cancer cell s and 
therein lies a novel therapeutic oppm1unity that targets the core of some cancers and also i 
inherently specific. Abrogating the KRAS mRNA interaction with CRD-BP therefore may be an 
effective means of attacking some KRAS-driven cancers, and is the focus of thi re earch. 
The first major research aim was to confirm that CRD-BP binds KRAS mRNA in the 
coding region and 3'UTR using the EMSA assay and to further thi s work by mapping CRD-BP 
binding sites on the KRAS mRNA transcript using pmified recombinant CRD-BP protein and 
IVT generated KRAS sub-regions. Determination of a minimum binding sequence wa the end 
goal for these experiment c ntributing elements toward a fmal CRD-BP consen u equence 
and serv ing as a focus for further study of the mol ecular nature ofth RD-BP-KRA mRNA 
interaction. The second major goal was the development of binding inhibitor , pearheaded u ing 
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D -ba d lig nu 1 tid that c m 1 m ntaril bind thr ugh Wat n- ri k ba pairing t 
c ntigu u tr t h fa minimum binding uld all m nt 
f th ir ability t bl ck K 
drug m 11 a a and m u 
r c gniti n and ha p ible u e a pr t -
t u a minimum binding equ n and 
d main r quir ment ~ r K inding. 
-dri n cancer . h third maj r g al wa 
nal anal i t gain in ight int th KH 
abr ga ting R - P interacti n ar an ultimat 
goal of I KZ pr t in re earch kn ledge f th unique KH d main r quirement II r each 
mRNA targ t hed light nt ary pr perti e mall m I cule inhibit r mu t have -
which ub- et fKH d main n db bl eked. The final bj ecti e wa t elucidate tructural 
properti or RD-BP . Pr t in cry tallizati n fl r u e in X-ray di ffracti n wa to be explored t 
re eal the preci me hani m f RD -BP I KZ protein RN -binding. dditi nally, circular 
dich.roi m wa to be employed in order to a es the po ibility fa dynamic RD-BP pr tein 
that undergoes confonnational hift in econdary structure upon target- pecific mRNA-binding. 
Determining tructural change that occur upon binding target RNA would offer an additional 
means of creening potential RNA target molecule u ing CD spectroscopy. 
Chapter 2 
In vitro characterization of KRA mRN binding to CRD-
BP and development of anti en e oligonucleotide inhibitors. 
h [! ll mg h t r ver p rim nt arried ut t d t m1ine a minimum binding 
qu nc forK mR r quircd to bind 'R -BP. dditi nally. the devel pment of anti-
int raction will b pre ent d and di cu ed. 
2.1 Methodology - Mapping of RD-BP binding ite on KR ' mR A 
2.1.1 Tran formati on of BL2l (D 3) cell with p T28b- RD-BP pia mid. 
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Pia mid containing wild-typ R -BP v.a pre iou I acquired fr m the r. J. Ross lab . 
F':Jll-l ngth mou RD-BP coding equ n cut with Nc I and Xhol wa ubcl ned int 
p T28b(+) (No agen). -flank d by an 
T p ro m o tt>r 68 
amino tem1inu FLAG epitope and a -
terminu 6x Hi -tag. The pla mid contain 
a kanamycin resistance gene and 
expression is driven by a T7 promoter as 
depicted in Figure 2.1. Approxi1nately 100 
1 7 tt>rminator 2D·B 
111 of competent BL21 (D 3) cells were 
thawed from -80°C storage on ice for 
one half hour before adding 1 0 ng of Figure 2.1. Plas mid map of pET28b(+)-CRD-BP 
p -< T28b-CRD-BP plasmid DNA. ells were ubsequently placed on ice for an additional 25 
minute followed by 90 seconds at 42° . el l were immediately upplemented with 00 ~LI of 
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L.B. br th (In itr g n) and in ubat d at 7° 
(In itr g n) plat ntaining 25 ug/ml kanam cin ulfat ( i h r ci ntifi ) antibi ti . Plat 
w r th n all d t in ubat rnight D r appr imat 1 1 h ur , i lding col nie f 
tran D nnant harb uring th 
2.1.2 Induction and rowth of pET28b- RD-BP .c li c II 
Tran D tmant c 1 nie ntaining th R - P e t r wer u edt 
inoculat 100 ml f . . br th (In itr g n) c ntaining 25 ug/ml kanamycin ulfate ( i her 
cientific in a 250 ml rl enm r f1a k. 11 u p n i n wa plac d n an incubator- haker 
ew Brun wick ientific, m d 1 Inn a 40) et at 200 rpm, 1 inch tr ke, at 3 7° for 3 h ur 
before being tran £ n d to a 1 L e111bach fla k containing 900 ml of L. . broth with 25 IJ. g/ml 
kanamycin. Culture wa gr wn until cell .D .60o equal ed 0.5 at which point the cell were 
_induced with 1mM I opropyl-~-D-1-thiogalact pyrano ide (IPT Bio Ba ic lnc.) and incubated 
under the same conditions for another 6 hour . Centrifugation of 1 L culture at 4 °C, 2, 100 xg, for 
15 minute (sub-divided into 4 volume of 250 ml) produced 4 cell pellets which were tored at -
80 °C. 
2.1.3 Purifica tion & qu antification of recombinant CRD-BP protein 
Recombinant CRD-BP purification was achieved using the following buffers and schem e 
as outlined in table 2.1 below . 
Table 2.1. Composition of buffers used in denaturing purification of recombinant CRD-BP 
t . f t f d BL 21(DE3) E r ll pro em rom rans orme - .co 1 ce s. 
Buffer NaH2P04 Tris-Cl Urea pH 
B lOOmM lOmM 8M 8 
c 100mM lOmM 8M 6.5 
D lOOmM 10mM 8M 6.3 
E 100mM lOmM 8M 5.9 
F 100mM lOmM 8M 4 .5 
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.c li 21 ( ) 11 pellet d n 1 fi r 1 5 min u t 
u p nd dint 12 ml f 1 buf~ r ell in 1 buf~ r re in u bated .G r 1 h ur n 1 
whil b ing agitat d u ing a a r n m dium tting ( i ntifi Pr u t ) . y at w 
clear db ntrifugati nat 2 1 g ~ r minut at 4 ° , pr ducing a p 11 t f c 11 debri . 
up 111atant wa th n yring filter d 0. J.ll11 ) nd pr par d [! r batch-binding by mi ing in l 
1nl f pre- quilibrat d (bufD r nick 1-nitril tri ti a id 1- T agar ad iag n) 
and incubating th lurr n 1 £ r 1 h ur. R in-1 at m1 a applied t a m1m-c lumn 
(Qiag n) and wa hed u ing ml f buf~ r B, £ 11 d by 5 ml f buffe r and finally 5 ml f 
buf~ rD. RD-BP pr t in a lut d b pa ing 12 ml of buffer r the c lumn £ 11 wed by 
l2mlofbufferF,colle ting 0.5ml frac ti n f pr tein !uti n. naturedprotein ampl e were 
immediat ly tored at - 0 ° . 
Purified recombinant mou e RD-BP ampl e were re-natured using 3,5 00 MW mm1 
dialysis units (Thermo cientific) in a multi- tep buffer exchange. Denatured pr tein samples 
containing 8M urea were dialyzed again t a 500-fold volume of refolding buffer for 24 hours. 
Following the protein refolding stage, ample wa then di alyzed again t a 500-fo ld volume of 
fmal buffer (buffer recipe below in table 2 .2) for 2 hours follow ed by another dialysis against a 
2,500-fold volume of final buffer to completely remove all traces of urea. Finally concentration 
of protein was determined using a BCA Protein Assay Kit (Thermo Scientific). 
T bl 2 2 B ff df f ld' d t f 'fi d b ' CRD BP a e .. u ers use or reo mg an s orage o pun 1e recom mant - protem. 
Refolding buffer Storage (final) buffer 
200 mM NaCl 200 n1MNaCl 
20 mM Tris-Cl 20 mM Tris-Cl 
2 M urea 10% glycerol 
10% glycerol 0.01 % triton-X 
0.01 % triton-X pH 7.4 
1 mM Glutathione - reduced -
0.1 mM Glutathione - oxidized -
pH 7.4 -
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2.1.4 neration of KRA mR ub-r ion cD t mplat 
In rd r t a K mR u -r g1 n ffinit [! r R , mall r fra gm nt 
fir t g nerat b hain re c ti n P R u ing prim r ign d t m lify 
ntigu u tr t h hi ch inclu th full 
c ding equ n parti I · untran lat d r gi n R ( n g ne, ). 
Prim r pair r d ign d t am lif p ifi ub-rcgi n mR c with 7 
pr m t r qu n e Ill 5' nd fall~ r ard prim r t dri 111 itr tr n cripti n 
f cD t mplat [! r ub qu nt u in binding a a (table , 4 and 5) and P R reacti n 
carri d uta c rding t the t mplat 
Templat 10 ng 
10 P R buf:D r 3.5 J ..d h nn cycler pr gram 
d TP (2.5 mM) .5 ~~ 94° 30 ec 
forward prim r 100 ng 50° 30 ec 30 cycle 
revere pnm r 100 ng 72° 45 c 
Taq. Polymera e (5 ,000 /ml) 0.5 ~~ 
Water t 35 ~I 
Table 2.3 . PCR primer used for the generation of KRAS mRNA ub-region cD 
templates A-F for in vitro transcription. KRA mRNA ub-regi n nucl tide po ition 111 
bracket are relative to the KRAS A G tart codon. 
Region Primer DNA se9.uence 
A(l-185) forward 5'GGAT CTAATACGACT TT 3' 
rever e 5' -TCATGAC TG T TGT G-3' 
B(175-401) forward 5'-GGATCCTAATAC A TCA TATAGG G AGGTCATG GGA T -3' 
reverse 5' -G TAAGT TGAG TGT-3' 
C(388-610) forward 5'-G A GATT GA-3' 
rever e 5' -
D(568-793) forward 5'-G T A TATAGGAT TT-3' 
rever e 5'- TT - ' 
E(772-988) forward 5 '- T A T T G .., . __ ,
rever e 5'-
F(971-1155) :£1 rward TA TT T TT -3' 
Table 2.4. P R prim r u ed f r th n 
template KRA - (1-4) f r in vitr tran 
p iti n in br k t ar r lati t th 
A3-4 93-185) 
A4(139-185) 
A3(93-138) 
m 
d n. 
Table 2.5. P R primers u ed for the oeneration of KRA mRN 
template KRA -A34(a-.f) for in vitro tran cription . KRA mRN 
po ition in bracket are relati e to th KRA A tart cod n. 
Re ion 
A3-4a (111-185) 
A3-4b(l29-185) 
rever e 
A3-4c(l4 7 -185) forward 
reverse 
A3-4d(93-167) forward 
reverse 
A3-4e(93-149) forward 
reverse 
A3-4f{93-131) forward 
reverse 
25 
ub- r gion cD 
ub-r gi n nu 1 tid 
ub-region cD 
ub-regi n nucl e tide 
3' 
3' 
3' 
3' 
26 
2.1.5 Generation of e2P)-labelled KRA R ub trate b IVT 
In itr tran ripti n (IV ) f ub-r gi n c t pl at in th pr nc f 
e2P]-lab 11 d TP a u d t int 111all lab 11 ub trat . I r acti n 
mitur w r prepar d £ r a h t mplat ace rding t table 2 .. 
Table 2.6. IVT reagent u d for KRA mRN ub-r ion R nthe i . 
IVT reagent mount in 20 ul reaction volume 
5x tran cripti n buf£ r 4 )l l 
100mMDTT 2 )ll 
20 U/ul RNa in 1 )ll 
10 mMATP 1 )ll 
10 mMCTP 1 )ll 
10mMGTP 1 Ill 
100 J.1M UTP 2. 5 )ll 
15 U/ul T7 RNA polyrnera e 1 Jll 
DEPC H20 To 20 Jll 
(32P]-UTP 2. 5 )ll 
IVT reactions were mixed and incubated at 3 7°C for 1 hour prior to a 10 min incubation with 10 
)ll ofRNase-free DNase (l U/ )ll) at 37°C. IVT reactions were topped with a urea loading dye 
(9M urea, 0.01 % bromophenol Blue, 0.01 % xylene cyanol , 0.01 % phenol) and RNA transcripts 
gel purified using an 8% polyacrylamide (29: 1 bi :acrylamide) denaturing gel (7M urea) ran at 
25 rnA for 1 hour with 0.5x TBE buffer. Excised gel-slices were cru hed and RNA extracted in 
400 )ll of H20 at 70 °C for 5 minutes prior to further purification by Performa DTR gel-filtration 
cartridges (Edge Bio) . RNA wa then subj ected to phenol -chloroform extraction and ethanol 
precipitation before being resuspended in 25 )ll ofDEPC H20 . Purified [32P]-labelled IVT 
products were quantified using a liquid scintill ation counter (Hidex) and stored at -20 ° . 
2.1.6 M mappm of RD-BP bindin it n KRA mRN 
Binding r a tion h g n rat d e2 ]-lab ll d 
r g1 n RN a c rding t tabl 2.7 and 4 nM. M 
n u d £ r mapping high affini t binding it ntain d 20 0 cpm 
RN pr b . 
T able 2.7 . EM A reagent u ed for KRA - RD-BP affini mapping and ere nin g of 
anti en e oligonucleotide inhibitor . 
EMSA binding reaction reagent (1 ul) Volume Final C oncentration 
Binding buffer ( e b 1 r) 4 ~1 -
10 mg/ml bak r' ea t tRN 1 ~~ 0.53 mg/ml 
(Sigma Aldrich) 
10 mg/ml B A 1 ~~ 0.53 mg/ml 
(New England Biolab ;) 
40 U/~1 rRNa in 1 ul 2 /~1 
(Promega) 
CRD-BP X Ot 540nM 
[ 32P]-labelled RNA probe 2 ~1 20,000 cpm/reaction 
H20 to 19 ~~ -
Bindin g buffer r eagents (per 1 ml) 
1M tris-Cl pH 7.4 50~~ 50InM 
0.5 M EDTA (pH 8.0) 25 ~1 12.5 mM 
100mM DTT 100 ~1 101nM 
50% glycerol 500 ~1 25% 
10% triton X-1 00 1 ~1 0.01 % 
H20 324 ~1 -
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RNA probes prior to reagent mixing were first heated to 55 ° for 5 minutes and allowed to cool 
to room temperature for 7 minutes in order to facilitate proper fo lding. Reagents were added 
separately in a 1.5 ml eppendorf tube and centrifuged at 3000 g for 10 seconds to begin binding 
reaction; mixtures wer then incubated at 3 7 ° for 10 minute follow d by a 5 minute 
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in ubati n n 1 , an th r 1 minut at 7 ° nd a final minute t p n 1 t tailing 
11 i ting f 2 mM ri -H 1, .2°-o r m ph n 1 blue 
.2% 1 11 an 1 an 40% add d t h amp! edb 1 ading l 5 ~1 
nt an % p -r d n n-d naturing g 1 in 0. 
[! r minut at 2 m . M gel w r 
e p d and i ualiz d u ing a 
mplet d n ptiqua11 t 
ftwar er 1 11 4.0 Packard In trum nt mpan Inc . 
2.2 - Methodology - nti en e oligonucleotide inhibitor 
2.2.1 EM A ompetition a ay with pecific anti- en e oligonucleotide 
I3-adiolab lled KRA - (nt 1-1 5) wa ynthe iz d u ing in vitro tran cripti n in th pre ence 
of e2P] - TP (m th d de cribed in ecti n 2.1.5 and u ed in M with the parallel addition f 
Table 2.8. DNA sequences (5' to 3') of candidate 
inhibition antisense oligo nucleotide u ed in 
EMSA inhibition assays. 
AON DNA sequence 
SMl 5'ACCACAAGTTTATATTCAGT AT3' 
SM2 
SM3 
SM4 
SMS 
SM6 
SM7 
SMS 
Technologie Inc. (table 2.8). creening of th anti- n 
competit r molecul . M A 
experim ental conditi on wer identical t 
pre iou I y de cribed 
experiment and can be reviewed in 
ection 2. 1.6. Anti- en e oligonucleotid 
(A N ) of 23-24-m r were d igned to 
cov r the entir ty of the KRA - r g10n 
in a complem ntary fa hion nd-to-end, 
and w re ynth ized by Integrat d D 
lig nucleotid , labelled - M(l 
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thr ugh d d ini tial! u ing tw c nc ntrati n : 1 0-~ ld and 5 -~ ld r lativ t th 
KRA - RN pr b c nc ntrati n . r mpl D r apr b n ntrati n f 1, th ibit r 
w uld b f th indi idual w r gauged by th ir ability t 
abrogat the int raction b tw n - RN and - P a indicat d th l fan 
upper high r m 1 cular ight g I band. inding data wa analyz d by d n it m try f 
th EM aut radi graph u ing the cl ne t rag Ph ph r- y t m and ptiquant ftware 
t quantify th d gr f comple inhibiti nand quantitati ly a th ffectiven f 
candidate A ul . urther 
characterizati n a 
pur ued u ing a great r c ncentrati n 
range from lX to 4000X molar-fold 
concentration (equivalent to 11 pM - 4 72 nM, 
see table 2.9). Additionally AO M-2 wa 
further characterized as a negative control for 
inhibition with concentration tested from 1 X to 
1 OOOX molar-fold (118 pM to 11.8 nM). 
Densitometry analysis using Optiquant software 
was utilized to produce inhibition plots using 
KaleidaGraph™ software. 
Table 2.9. oncentration of anti sen e oli go 
nucleotide (AO ) u ed in M A 
inhibition a ays . M lar-fold c ncentrations 
are ba d n a calculated 1 l 8 pM KRA -
probe. 
AON molar- Concentration (nM) 
fold 
lX 0.118 
sx 0.590 
lOX 1.18 
25X 2.95 
sox 5.9 
lOOX 11.8 
250X 29 .5 
so ox 59 
750X 88 .5 
lOOOX 118 
2000X 236 
4000X 472 
30 
2.3 Re ult and Di cu ion 
2.3 .1 ynthe i of KRA mRN ub-r egion by IVT 
n ration f KRA ub-r gi n t mplat [I r u in in ' 'ifro tran cripti n 
b m an f P R a ucc fu l wi th all 1 fragm nt , 1 b 11 d thr ugh and are 
r pr nt d graphi all in figur 2.2. 
0 (56 - 93) • (97 1- 1155) 
A( l -185) .. .. 
. . . . 
. . . . 
. . . . . . . .
. . . 
5 - ,...--------.,....-------.,....-------...,..-------"""T ·,· ·. -3' 
900 1200 
F igure 2.2. G raphical r epresenta tion of KRA mRN ub-region la bell ed KRA -(A 
through F) coverin g the entire codin g sequ nee a nd pa rti a l 3' UTR . ucleo tide p siti n m 
bracket ar r lati e to the KRA mR tart codon ( G) and th remaining un tudi d 3' 
UTR region i repre ented by the double-peak dotted line . 
506 
: 6 
~44 
_9R 
220 
154 
Figure 2.3. IVT eD NA templates for KRAS sub-
regions A through F. DNA samples were run on a 
1% agarose gel with invitrogen 1 Kb ladder and 
visualized with ethidium bromide staining. 
DNA bands were of the expected size 
as determine d by ethidium bromide 
UV visualization on a 1% agarose gel 
analysis (figure 2.3} . Subsequent T7-
driven in vitro transcription reactions 
produ ced e2P]-i nterna lly labelled 
ra d ioactive RNA probes of the 
expected relative size with the gel extraction purification method typically yielding 30 111 of 0.5 -
2 million cpm/~-tl. RNA sub-regions were de igned to contain a small amount of sequence overlap 
with the neighboring fragments (approxin1ately 20 nucleotide ) to avoid plitting a potential 
binding-sequ ence or di srupting a pecific RNA tructure such as a hairpin loop. While the full 
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KRA Ri a pr in I ngth , nl th fir t nu I red. he 
rati nal il r thi id in th fa t th t R - t i all ind ith r in th 
ding r gi na th ~ r ~ r PL 11 ' -m nd -m m 
' 
r v ithin th fir t ~ w 
hundr d nu I tid fth \) ith ~- tin F u 1 I a/. 2 ubi i 7/ 
al. 2 09; Pr kipcak ' I a/. 1 4· 
' 
ha I a/. 2 1 
' 
ffil I a/. 2 
2.3.2 EM RD-BP affini ty mappin f 
RD-BP affinit il r d u ing el ctr ph r ti c 
m bilit hift a a ( M . Radi a ti pr be (20, 0 cpr r acti n) 
ring th entir din g r gi n and parti al R w r titrat d with - P and th ir ability 
to £ rm a c mple a ed b th £ rmati n fa band wi th r duced mi grati n di tan e, 
indicati e of a hi gh r m 1 cul ar w ight c mpl D rm d by binding f RD-BP with the RNA 
fragment. Fir tl KRA c ding r gion fragm nt · '(nt 1- 1 5) . · 8 ' ( I 75-40 I) and ' · (3 -6 l 0) 
were te ted (figure 2.4 .) 
CRD-BP: 
(nl\ J) 
Bound [ 
R~ 
lJnhou nd 
RN 
KR r gi n 
(nt l- 185) 
2 3 4 5 6 
KRA revion B 
(n t 175-40 1) 
7 8 9 
KR.\ . region 
(nt 388-61 0) 
10 II 12 13 1-t 15 
Figure 2.4. EMSA asse ing KRAS coding equence RNA ub-region to for CRD-BP 
binding. e2P] -labelled unbound RNA (20,000 cpm/reacti n) with no prot in add d (lan L6 
and 11) form a larg r m le ular weight compl up n titrati n with RD-BP, a indicat d b 
the bound RNA fracti n (Ian 2-5, 7- 10, 12- 15). Binding r a ti on wer in ubat d il r a total of 
20 minu te at 37° and 10 minute on ic b £ re ing re lved n an % polyacr ]amide gel. 
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R lati tr ng -BP affinit a D und £i r ub -r gi n K and K 
b th ing abl t £i rm a high r- rd r band ugge ting th fl 1mati -pr tein 
compl . Wh n mparing Ian - (Ian 1- t 1 n K - (1 an e 1 1 -1 ) th tw 
f the fir t l 5 nucle tid f the c ding 
qu nc fl rm a m r di tin t c mpl and h larger b und fra ti n f R at 540 nM f 
RD-BP . In c ntra t, KRA -B (lan 6-1 0) c n i tentl y h wed a weak affinity with the gradual 
app aranc of tw faint high r band ut ith an gligibl change in th unbound R fracti n 
up to 540 nM concentrati n, and thu a c n ider d t be a relativ ly low affinity regi nand 
inve tigated no furth r. RN fragm nt repr enting ub -r g io n of th partial KRA 3' R 
mRNA were ne t te ted for affinity in the arne manner. 
CRD-BP: 
(n~'l) 
Bound 
Rl\A 
nbound 
RNA 
~ 
KR 
(nt 
::0 
'\,: 
2 
region D 
568-793) 
,~ ,..,~ ~ 
'\. ,.,~ 
3 4 5 
KR reo ion E ~ 
(nt 772-988) 
::0 'o ,.:,~ '""~ ~ 'V ~ 
6 7 8 9 10 11 
KRA reojon F 
(nt · 971-1155) 
~ '\,.\:) 
':¥'>. 
'""'); 
' 
'V ,.., 
.. 
12 13 14 15 
Figure 2.5. EMSA assessing KRAS 3' UTR RNA sub-regions D to F for CRD-BP binding. 
[ 32P] -labelled unbound RNA (20,000 cpn11reaction) with no protein added (lane 1,6 and 11) 
forms a larger molecular weight complex upon titration with CRD-BP, a indicated by the bound 
RNA fraction (lanes 2-5, 7 - l 0, 12- 15). Binding reactions were incubat d for a total of 20 minute 
at 37° and 10 minute on ice before being resolved on an 8% po lyacrylamide gel. 
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RN KRA - and th di pla d th ability t bind - P and a ignificant 
chang in th unbound fracti n fRN c un d ith in rea ing n ntrati n 
Inter tingly th KRA -F r gi nand t a le er t nt th K - r gi n , D rm multiple 
high r rd r c mpl ith a faint band D nning ju t ab th unb und R frac ti n in 
tandem with a m re pr min nt band ab 
that fl r on] the regi n (nt 7 1- 11 5 and 772- , tw binding e ent ccur eparately; 
how er the phen m n n d n t appear t c ith rail affinity fl r - P. th 
binding m de ha e b n rep rt d pr i u 1 ith ari u targ t of KZ pr tein . 
IMP-1, which ha a % quenc id ntity t RD-BP, and i capabl e f binding a a ingle 
pecw to H 19 mRN and app ar ry imilar to the M hift pattern f KRA - . The I 
II mR 'zip ode" reg ion bind IMP-I in a quential dim riza ti n m de a detennined by 
EMSA much like KRA -F and KRA -E (Niel n et al. 2002· hao et al. 201 0) . Binding data 
for all six fragments was analyzed by den itometry of the autoradiog:raph u ing the yclone 
Storage Phosphor-System and Optiquant oftware and Kd plot generated by fitting to the Hill 
equation for quantitative comparison (figure 2.6). KRAS-C region was not included in the Kd 
calculation due to repeated inability to achieve greater than 70% bound fraction in the EM A . 
KRAS mRNA regions D (nts 568-793) and F (nts 971-1155) , representing the first 588 
nucleotides of the 3' UTR, also revealed multiple binding sites for CRD-BP (figure 2.5, lanes 1-
5, and 11-15 respectively) . 
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KRAS reg1on F 
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Figure 2.6 Kd plot for KRA 
two bioi gi al t f triplicat 
(Hill c effi i nt = 2) · IT r bar 
mR ub-r 1 n D and F. ata p int ar a eraged fr m 
p nm nt and fit t the Hill quati n D r Kd d terminati n 
r pr ent tandard d iati n . 
mparing th calculat d Kd alue d ubl c nfirm d K a th K mRN 
ub-region p ing the highe t affinity binding ite f th e amin d fragment the calculated 
Kd value£ r KRA - (171.10 ± 17.71 nM) being lower than KRA - and alm t 1.6-fo ld 1 wer 
than KRAS-D (220.1 ± 21.45 nM and 277 .63 ± 64 .13 nM, re pecti ve1y) . urther binding 
characterization of the KRA -A fragment wa done with additional RD-BP concentration to 
more accurately detennine the binding character and similarly a aturation binding curve plotted 
to determine the Kd and Hill Coefficient (figure 2.7 and 2.8, re pectively) . 
RD-BP: 
(oM) 
Bound 
R~A 
Unbound 
R. 
2 3 4 5 6 
~t • 
7 8 9 JU 11 12 13 14 15 16 17 
Figure 2.7. EMSA saturation binding experiment between CRD-BP and KRAS-A (nts 1-
185). RNA (20,000 cpm) with no protein added (lane 1) fon11s a larger molecular weight 
complex upon titration with RD-BP, as indicat d by the bound RNA fraction (lane 2-17). 
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Figure 2.8. EMSA Saturation binding curve for CRD-BP vs KRAS-A (nts 1-185). Data wa 
derived in t1iplicate from aturation EM e periments where RD-BP wa incubated with 
e2P]-labelled KRAS-A RNA(20 ,000 cpm) and fit to the Hill equation. 
Further refmement of the KRAS binding equence was pursued in a imilar manner by 
producing 5' and 3' truncations of the high affinity KRAS-A region. Small eDNA templates 
covering arbitrarily assigned sub-regions ofKRAS-A (1 through 4) were succes fully generated 
using PCR (figure 2.1 0) . If upon retention or removal of one of the four approximately 50 
nucleotide regions resulted in drastic changes in CRD-BP affinity, it could be deduced by 
combining data where the high affinity site(s) is located. IVT reactions canied out in the 
presence of radio-labelled UTP were used to synthesize RNA trands corresponding to the 
repre entative mRNA regions a depicted in figure 2.9. 
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Figure 2.9. Graphical repre entati n of KRA - (1 through 4) R . ragm nt c ver th 
qu nee and nucle tid p iti n in brack t are relati ve t 
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Figure 2.10. KRAS sub-region eDNA templates for in vitro tran cription. ( ) 5' and "' 
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truncation of KRAS region A and (B) 5' and 3' truncati on of KRA region A34 r I ed on a 
1% agaro e gel vi ualized by V -ethidium bromide taining . 
Synthe ized RNA fra gment were agam a e ed for relativ affinity u ing EM and 
[
32P] -labelled RNA probe (20 ,000 cpm/ reaction) titrat d w ith RD-BP up to 540 nM. Re ult f 
the binding a ay for the ' trun at d fra gment 1 , A 12 and I an b e n in figure 2.11 in 
lane 1-5, -10 and 11 -15 r pecti e ly. 
KRA 
~ 
RO~B P : ' 
(n~l) 
13ound [ 
R .A 
Un bound 
R l 
5 6 
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Figure 2.11. EMSA asses ing KRAS-A 3 trunca ted ub-regions Al 3, 12 and AI fo r RD-
BP binding. e2P]-labelled unbound RN 20,000 cpm/reacti n) with no pr tein added (lane 
1 _6 and 11) form a larger molecular weight complex with RD-BP (lane 2-5, 7- 10, 12-15). 
Binding reaction were incubated for a total of 20 minute at 3 7° and 10 minute on ice before 
being re olved on an 8% polyacrylamide gel. 
It is immediately apparent upon visual in pection of lane l to 5 (figure 2. 11 ) that only the 
KRAS-Al3 region corresponding, to nucleotide po itions 1-141 ofKRAS mRNA retained the 
ability to bind CRD-BP with measurable affi nity. From the systematic 3' truncation of KRA -A, 
it was detennined that KRAS-A1 2, one full half ofKRAS-A consisting of 92 nucleotides, did 
not likely possess any binding information. Further EMSA binding experiments were carried out 
using 5' truncated fra gments of KRA -A to examine the po sibility of a binding equence 
present in the 3' end f KRAS-A (figure 2. 12). 
RD-BP : 
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Figure 2.12. EM A as es ing KRA -A 5' trun cated ub-region 24, 34 and A4 for RD-
BP binding. [32P] -labelled unb und RNA (20 000 cpn reaction) with n pr tein added (lane 
1_ 6 and 11 ) form a larger m lecular weight complex with RD -BP (lanes 2-5, 7- 10, 12- 15) . 
Binding reaction were incubated fo r a total of 20 minute at 3 7° and 10 minute on ice before 
being resolved on an 8% polyacrylamide gel. 
From the EM A binding a ay with 5 · truncati on of KRA - in figu re 2. 12 It can be 
seen that both KRAS-A24 and KRAS -A34 are both capable offmming a protein-RNA complex 
while KRAS-A4, the ta iling 47 nucleotide 3' end, shows no interacti on. A faint band in KRA -
A4 can be seen directly above the unbound RNA, however it is pre ent in the ab enc of any 
protein and its magnitude does not change with increasing CRD-BP concentration and i thus 
considered a non-binding region. To further confinn the binding di parity between KRA -Al2 
and KRAS-A34, another experiment was completed pitting the two fragments side-by-side on 
the same gel and effectively doubling the protein concentration to achieve binding aturation for 
Kd detennination (figures 2. 13 and 2. 14). Direct compari son ofthe 2 regions how that KRA -
A34 bind to RD-BP more aggress iv ly than KRA -Al 2, de pite a ize diffl renee of only one 
39 
nu 1 tid h ing that th r i a ifi r gniz d l m nt in th 4 r gi n nd that th 
affini ty i n t u t n n- ifi binding. R turning t R - 2 and K 4, it an b 
d that hil th 1 arl h mpl fl nnati n, th 1 rg r - 24 ( 1 nt h an 
affini t imi lar t th ragm nt ith n arl 11 f th nt in th und 
fra ti n 540 nM nu ti f 
with lit ratur in that m t pr tein binding R 1 m nt ar gr at r than 100 
nu I tid , ' ith th ~- a tin zi i raeli et a/. 1 icl en ' / a/. 
200 ; Pr kip ak 1 a/. 19 . K it elf pr d t b a p r inding r gi n, 
ugg ting that p rha it a r gr n th t c ntain d the binding qu nee a nJ y 
fragm nt ntaining regi n- di pla ed binding. Hen , a mall e2P]- Ia ell d RN 
prob (20,000 cpr r a ti n) ith qu enc repr nting r gion K 
te ted fo r RD-BP affinity b th am meth d (fi gur 2.15). 
RD-BP: 
(n\1) 
Bound [ 
R~A 
nbound [ 
·~ ' 
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KRA 
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wa ynth e ized and 
10 II 12 
Figure 2.13. EM A assessing RNA KRA -Al2 and KRAS-A34 for CRD-BP bindi ng. (~P]­
labelled unbound KRA -Al 2 and KRA -A3 4 (20,000 cpm/ reaction) with no protein add d (lane 
1 and 7, re pectively) fmm a larger molecular w ight mpl upon titration with RD-BP fo r 
the KRA -A34 RNA fragm nt but onl y to a limited e tent with KRA - 12 up t 1200 nM, a 
indicated by th b und RNA fraction (KRA - 12: lane 2-6; KRA - 4: Ian - 12) . 
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Figure 2.14. aturation bindin g curve fo r RD-BP vs KRA - 34 R A (nt 93-185). Data 
wa produced from aturation M xperiment ho n in figure 13 where RD-BP was 
incubated with [32P]-labelled KRA - 34 and KRA - 12 RNA(20 000 cpm) and fit to the Hill 
equation. 
KRA -
(nts 1-185) 
RD-BP: ~ 
(n:\rl) 
Bound[ 
R~ 
Unbound 
R!\A 
1 2 3 4 5 6 7 8 9 
Figure 2.15. EMSA assessing KRAS-A3 RNA for CRD-BP binding. [32P]-labelled unbound 
RNA (20,000 cpm/reaction) with no protein added (lane 1 and 4) fom1 a larger molecular 
weight complex upon titration with RD-BP only for the control KRA - RNA fragment but 
not with A3 , as indicated by the bound RNA fraction (lane 2) . 
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KRA - did n t h any ignifi ant inding 
972 nM. Thi un p ted r ult rna ha 
qu nee r gi n ( p cifi r n n- p cific) ut ide regi n 
n with RD- P concentrati n u t 
n requir m nt f nearby 
that ar in trum ntal in pr per 
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RNA :D lding :D r r c gniti n b uld b that inding f K achi v 
trand t fa ilitat 
whil an ther ite( ) 
thr ugh a bipartit m d , wher b multipl binding ite e i t al ng th 
full binding. In thi c nari , a ingl ite ma fall ithin r gi n K 
may i t in th flanking regi n K - 2 and KRA - 4 uch that nly a c mbinati n f tw 
binding e ent ar r quir d :D r tabl binding. id n :G r thi cenari c me fr m L X 
and RlP- hip p rim nt id nti fyi ng on erved 5 · and 3 · quen in man amplified R A 
target of I KZ prot in , ugg ting multiple binding ite are i1np rtant :D r any given RNA 
target. Howe er among the coh rt of amplified RNA target , ome equ ence were pre ent that 
did not share any obviou equenc imilarity with the other identified (Farina et al. 2003 ; Patel 
et al. 20 12). 
Further mapping of the CRD-BP binding sequence identified in KRA -A34 wa canied 
out in one more set of 5 · and 3' truncations of KRA -A34 according to the graphic below (figure 
2.16). While the previous systematic truncation of KRAS-A into four roughly equally ized 
segments (regions 1 through 4 ), this series of truncations aimed instead to simply have off 
terminal nucleotides from both the 5' and 3' end of KRAS-A34, to fmd the smallest fragment 
that can still produce a complex as detennined by EMSA. 
Figure 2.1 6. Graphica l representation of KRAS-A34(a-f) RN . Fragment repre ent ub-
divi ions of the KRA -A34 r gion covering nucleotide 93-185 f the coding equ nee. 
ucleotide po ition in bracket are relati e t the KRA mRNA tart c d n (A G) . 
To further nanow down a minimum CRD-BP binding equ ence, an additional et f RNA 
fragments representing ub-division of the parent KRAS-A34 positive binding region were 
synthesized. The ability of the 3' truncated fragments to bind CRD-BP was a sessed by EMSA 
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and the results for RNAs labelled KRAS-A34( d, e or f) can be seen in figure 2.17. Analyzing the 
results of the 3' truncated fragments of binding region KRA -A34 showed virtually no binding. 
As with the previously discussed fraginent KRAS-A4 which presented with a faint upper band 
but did not conelated with CRD-BP concentration it can be seen that KRA -A34(d)- covering 
nucleotides 93-167, also presents with a similar pattern, and is concluded to be a non-binding 
fragment. 
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F igure 2.17. EM A a e ing the KRA -A34(d e a nd f) RNA , for RD-BP binding. e2P]-
labelled unbound RNA 20 000 cpr reac6on) with n pr t in added (lane 1, 3, 8 and 13) fonn 
a larg r molecular weight c mpl upon titrati n with RD-BP only in theca e f the KRA -A 
probe which wa u ed a po itive contr 1 and included t d m n trate binding c ntra t for the e 
nQn-binding fragment . Binding reactions were incubated fo r a total of 20 minute at 3 7° and 
10 minute on ice before being r ol ed on an 8% polyacrylamide gel. 
To en ure that the lack of compl ex fo rmation in any of the 3' truncated fragm ent was not 
due to experimental eiTor, a positive control previously determined to bind (KRAS-A) wa 
included. From this, it was concluded that the initi al 3' truncati on, the large t of the three whi ch 
removed 19 nucleotides to produce region KRAS -A34(d) likely contained binding elements. 
The complementary 5' truncated fragment , labelled as KRA -A34(a, b and c) which retained 
the aforementioned 19 nucleotide sequence, were also te ted for binding using EMSA (figure 
2.18 .) Complex formation can be readily observed as a di tinct band above the unbound fraction 
of RNA in fra gments KRAS -A34(a) and KRA -A34(b) with binding almo t entirely lo tin 
KRAS-A34(c). 
KR 
fb 
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nbound 
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F igure 2.18. EM A a e sin g KRA - 34(a b and c) for RD-BP bindin g. e2P]-labell ed 
unbound RN (20,000 cpn reacti n) with n pr tein add d (lane 1, 6 and 11) .fi nn a larg r 
mol cular weight c mple upon titration ith RD-BP a indicated by D rmati n of a band in 
the area labelled' b und R ".Binding reacti n wer in ubat d :D r a total of20 minute at 
3 7° and 10 minute on ice beD reb ing re lv d nan % polyacrylamide g 1. 
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Oddly, the addition of CRD-BP appear to shift the unbound KRA -A34(c) RNA further 
down the gel, increasing 1nigration di tance a indicated by the increa ingly den e 
autoradiographic expo ure appearing below the free RNA in lanes 11 to 15. While this may be 
considered binding, a lack of a di tinct band sugge ts at mo t non-specific interaction and wa 
left as an anomaly. Interestingly it is possible to di tingui h an intem1ediate band between the 
upper shifted complexes, and the unbound RNA which was not readily apparent in the non-
truncated KRAS-A34 fragment. Hence, the smallest region ofKRAS mRNA presented here 
capable of binding CRD-BP as dete1mined by EMSA i the 57 nucleotide region labelled KRA -
A34(b) ; nucleotides 129-185. 
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2.3.3 Development of pecific anti n oli onucleotid e inhibi tor 
D 1 pm nt f m lecular inhibit r n 1 p ram unt t 
th 1 ng t rm g al f tud ing RD- P nd it m targ t . With R - P und r trict 
pati t mporal ntr 1 during th arli t k g n i and tap nng ff t e tr m 1y 
1 w r und t tabl 1 1 in later li:D , it pr nc and ti ity in tum r ti ue 1 a clear anti-
pr li:D rati targ t gi n it in th path ay . ignalling 
ha be n d mon trated t dri c rtain cane r and it ha b n h wn that -BPi capable f 
enhancing pr i n f thi tal. 201 1) ingling ut th KRA - RD- P 
interaction a an ideal target :D r m 1 cular inte1 nti n . T approach tlu ta k 23-24 mer 
ba ed anti en oligonu le tide ere de igned t contigu u ly c ver the entire regi n f 
KRA -A in a compl m ntary fa hion (nt 1-1 S) with the rational being that important RNA 
sequence or tructural element within KRA -A, one bound thr ugh Wat on- rick base 
pairing, will impede RD-BP binding to KRA mRNA. Any di covered DNA-based 
oligonucleotide inhibitors could ub equently be synthesized a an 0-methyl RNA 
oligonucleotide derivative and used in the context of cell-based anti-proliferative as ays for 
further development. Under binding conditions identical to the previou ly outlined EMSA 
binding experiments, [32P]-labelled KRAS-A (nts 1-18S) RNA was incubated with 216 nM 
CRD-BP in the presence of eight potential inhibitor oligos at 1 OX and SOX molar-fold 
concentrations (figure 2.19). Protein concentration wa cho en to only fractionally bind the RNA 
probe (as opposed to full shift at S40 nM) to avoid over saturation of the RNA and increase the 
protein-RNA complex sensitivity to the inhibitory effe t f the oligonucleotide for scr erung. In 
vitro transcribed unlabelled KRAS-A RNA was also incubated with CRD-BP at 1 OX and SOX 
concentrations to erve a a positive control for inhibition (figure 2.19, Ian s 3-4 ). Concentration 
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of radio-lab 11 d KRA - pr wa d termin d t b 11 pM and thu mp tit rm 1 cui 
w r mad t 1.1 nM and 5.9 nM r 10 and 0 . uc r w r th n 
ba ed n abilit t r du th b und fra ti n f in th M 
Bound [ 
RN 
nbound [ 
RNA 
1 
Oligon ucleotide Inhibitor 
4 5 6 7 10 11 12 13 14 15 16 17 I 19 20 
Figure 2.19. EMSA creen of anti sense oli gonucJ eotid e 0 -SM(l-8) inhibitor . e2P]-
labelled KRA - RN probe (-/lane 1) wa partiall y hifted by 216 nM RD-BP (+/lane 2) in 
t~e pre ence of 23-24-mer anti n e oligonucleotide in 2 concentration : 1 OX molar exces 
relative to 118 pM radioactive probe (1.1 nM), and SOX (5 .9 nM) in lane 3-20. Effectivene 
of potential inhibitor i evidenced by a reduction in the bound RNA fraction indicated on th 
figure left. Enor bars are standard deviation. 
Screening of SM1 to SM8 inhibitor oligonucleotide was completed in triplicate and when the 
bound RNA in the protein-only reaction (lane 2) i compared to those with inhibitors added, it 
can be seen in the representative figure that a reduction in complex fonnation occuned for 
inhibitors SM6 (lanes 15-16), SM7 (lanes17-18) and to a lesser extent SM4 (lanes 11-1 2). Cold, 
unlabelled KRAS-A which was used as a positive control for inhibition did display a reduction 
of the complex as expected, however the extent of inllibition wa omewhat less than predicted 
possibly due to error in RNA quantification of either the radioactive pr be, or the unlab lled 
competitor RNA. Densitometry of the autoradiographs using the Cyclone Storage Pho phor-
System and Optiquant software was used to construct a graphical repre ntation of the EM A 
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(figur 2 .21 , ian 1 - 17) . tat d arli r in th intr du ti n a bit f a mi d bag n 
in additi n t a ting a an n g n m me cir um tan it an a t a a tum r UJ pr r 
(Zhang t a/. 2001 ). In u h ca rr lat d K c pr ting a 
a tum r uppr r, nhan mg inding u ing Ji g nu le tid r m ll m 1 u 1 e with 
th am f[i t rna ha enefi ial u 
Furth r qu ntifi ati n f nd M7 wa n1 d ut b panding the c n entra ti n 
rang f th inhibit r lig nu tid fr m 1 t , r 11 p t 1 I n fi gure 2 . 2 1 ) . 
M c nditi n remain d th am ept [! r - P c n ntrati n a ct at 54 nM t 
a hie rna imal KRA - hift, and all chara t riza ti n f M and M 7 ver th entire 
KRA - RD-BP binding rang . H r , M 2 a al included [! r c mpan n b ed nth initi al 
anti- en ligonucl tid r ning that ugg t d it may functi n a a g d negati e c ntr 1. 
;\Jolar-fold: -
'nbound [ 
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(KRA ~ -A) 
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F igure 2.21. EMSA cha racterizing CRD-BP-KRA -A RNA complex inhibition by A O N-
SM6. [32P] -labelled RNA - regi n KRA -A probe (unbound in lane 1) wa incubated with 540 
nM RD-BP (lane 2). Inhibitor M6 wa pre ent (lane 3- 12) in otherwi identi cal ondition 
to lane 2, ranging in concentration from 1 X molar-fo ld relative to probe cone ntration ( 11 pM) 
to 1000 molar-fold (11 nM) which COlT lated with a lo of RD-BP- bound RN . In contra t 
A N- M2 di play d dra ti cally r duced ability to interrupt the RD-BP-KRA - RN 
compl ex. 
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ofradi -labell d KRA - pr b a d t rmin d t b ll M and thu c mp tit r m 1 cul 
wremad t 1.1 nMand .9 nMr pctiel 10 and50 ). uc ful inhibit r w r then 
lect d ba d on ability t r du th b und fracti n f in th M 
molar-fo ld : (-
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RNA 
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F igure 2.19. EMSA scr een of anti ense olioonucl eotide AON- M (l -8) inhibitors. [32P]-
labelled KRA -A RN probe (-/lane 1) wa partially hif1ed by 216 nM RD-BP (+/lane 2) in 
the pre ence of23-24-mer anti en e oligonucleotide in 2 concentrations: lOX molar exce s 
~elative to 11 pM radioactive probe (1.1 nM), and 50X (5.9 nM) in lane 3-20. Effectivene s 
of potential inhibitor i evidenced by a reduction in the bound RNA fraction indicated on the 
figure left. Error bar are tandard deviation. 
Screening of SM1 to SM8 inhibitor oligonucleotides wa completed in triplicate and when the 
bound RNA in the protein-only reaction (lane 2) is compared to those with inhibitors added, it 
can be seen in the representative figure that a reduction in complex formation occurred for 
inhibitors SM6 (lanes 15-16), SM7 (lanesl7-18) and to a lesser extent SM4 (lanes 11-12). Cold, 
unlabelled KRAS-A which was used as a positive control for inhibition did di splay a reduction 
of the complex as expected, however the extent of inhibition was somewhat le than predicted 
possibly due to eiTor in RNA quantification of either the radioactive probe, or the unlabelled 
competitor RNA. Den itometry of the autoradiograph u ing th yclone Storage Pho phor-
System and ptiquant oftware was used to construct a graphical repre entation of th EM 
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a r du ti n in th mpl inten it , with 0% 
b ing n hang and 10 % b ing mpl t f th b und band (fi gur 2.2 . 
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Figure 2.20. Bar graph of anti en e oli gonucleotide molecul e M(l-8) inhibitory effect on 
CRD-BP-KRA R A comple form ation . Data i pr ented a the av rage percent reduction 
of bound RNA compar d to a control with no inhibit r pre ent in an electr phoretic m bility 
hift a ay. Data wa ubj ected to tati ti cal analy i u ing a ne-way VA · F=3.47, p<0.02, 
n=3 and student' t-te t (p<O.OS ). Anti en e oligonucleotide (23-24 mer) wer pre ent in 2 
concentration : 1 OX molar exce relative to 11 8 pM radioactive probe ( 1. 1 nM), and SOX ( S. 9 
nM). 
Plotting the anti sen e inhibitor data a a bar graph in figure 2.20 more clearl y depict the 
relatively trong ability for M6 and M7 to reduce the RD-BP-KRA RNA complex 
formation . At SOX molar excess (S .9 nM), M6 and M 7 both achi eved appr imately half 
reduction f the bound RNA band, twic the ffectivene of the ne t mo t ffecti v inhibitor. 
Intere tingly, M2 and M 3 appeared to be capable f trengthening the KRA -A-CRD-BP 
complex fonnati n in the experimental co nditi n . Thi phen m n n f increa ing the bound 
RNA fracti n wa repeatable in the initial ere n, but wa not e ident at high r con entration 
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(figur 2.21 Ian 1 -17 . tat d arli r in th intr du ti n it f m1 d bag n 
in additi n t a ting a an n g n m m e cir urn tan it an act a tum r uppr r 
(Zhang t a/. 2 01 ). In u h a 
a tum r uppr r, nhan mg R - binding u ing lig nucl tid ( r mall m 1 ul with 
th am f[i t ma ha n fi ial u 
Furth r quantifi ati n f nd M7 a n1 d ut b e panding the c ncentrati n 
rang f the inhibit r li g nu 1 tid fr m 1 t 1 , r 11 p t 11 nM (figure 2.21 ). 
M c nditi n r main d th am pt [! r R -BP c n cntrati n wa et at 540 nM t 
a hi hift, and all charac t rizati n f M 6 and M 7 er the entire 
KRA - RD-BP binding rang . H r , M2 a al included .D r c mpari n ba ed n the initi al 
anti- n lig nu 1 tid cr ening that ugge ted it may fun cti n a a g d negati e c ntr J. 
;\lola ·-fold: - + 
Bound [ 
Rl'iA 
'nbound [ 
R~ 
(KRA -A) 
2 3 4 5 6 7 8 9 10 11 )2 13 14 15 16 17 
Figure 2.21. EMSA characterizing CRD-BP-KRA -A RNA complex inhibition by AON-
SM6. [32P] -labelled RNA - region KRAS -A probe (unbound in lane 1) wa incubated with 540 
nM RD-BP (lane 2) . Inhibitor M6 wa pre ent (Ian 3- 12) in otherwi e identi cal condi tion 
to lane 2, ranging in concentration from 1 X molar-.D ld relative t pr be cone ntration ( 11 pM) 
to 1000 molar-fold (118 nM) which coiTelat d with a lo of CRD-BP- bound R A . In ntra t 
A N- M2 di played dra ti call y redu ed ability to inteiTupt the RD-BP-KRA - RN 
compl ex . 
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In p cti n ffigure 2.21 re al M a a apabl K - P inhibit r, a 
e id nc d by the gradual di app aran f th b und fracti n f r th lig 
con ntration rang . Whil thi f£ t i mirr r d t 111 M2 with a i ibl mer a 
in th fre RN fracti n r th am c nc ntrati n rang , it i cl ar M i farm r active 
and ugg t a d gre f p ifi it rv d f~ ct bey nd non- p cific int racti n. 
Inhibit r - M7 hara t rizati n a al d in parallel under id ntical c ndition . 
However in an art mJ t t rem e the R - P- mple entirely, th c ncentrati n rang 
of M7 wa e t nd d to 4000-fold ( 4 72 nM) a can be e n in figure 2.22 . 
Molar-fold: -
Bou.nd [ 
R:'\ 
nbound [ 
RNA 
(KRAS-A) 
+ 
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
Figure 2.22. EMSA characterizing CRD-BP-KRAS-A RNA complex inhibition by AON-
SM7. [32P] -labelled RNA- region KRAS-A probe (unbound in lane 1) was incubated with 540 
nM CRD-BP (lane 2). Inhibitor SM7 was present (lanes 3-14) in otherwise identical conditions 
to lane 2 ranging in concentration from lX molar-fold relative to probe concentration (118 pM) 
to 4000 molar-fold (472 nM) which con-elated with a loss ofCRD-BP complexed bound RNA. 
AON SM2, in contrast displayed reduced ability to inten-upt the CRD-BP-KRA -A RNA 
complex . 
As can be seen in the SM7 inhibition assay (figure 2.22), a simi lar trend occurred with 
SM7 as with SM6. Both inhibitors show a reduction of the bound RNA fraction and a 
proportional increase in unbound RNA, indicative of a lo of stability of the CRD-BP-KRA 
RNA complex. nee again the SM2 oligonucleotide displayed a imilar pattern a in figure 2.2 1, 
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ith n a ti ity again t P .D 1mati n . Pu hing th u p r limit f th inhibit r c n ntrati 11 
rang to 4000-:fi ld pr due d n1y a marginal furth r r du ti 11 in th b und RN fra ti nand 
can be e n t b ffi ti e far thi nc ntr ti n lane 11 -1 n it m try analy i of 
wa complet d u ing th ph ph imag r tern and ptiquant ft ar . u1n rical data D r b th 
up t I 0 0 n ntrati n v a pi tt d gr phi ally u ing Kal ida raph ™ 
oftware a (figur 2.2 ). 
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Figure 2.23. Inhibition plot of AON SM6 (A) and SM7 (B) against CRD-BP-KRAS-A RNA 
complex formation. Graphs represent quantified data from densitometry analy i of 
electrophoretic mobility hift assays with inhibitor oligonucleotide concentrations ranging from 
118 pM at lX molar-fold to 118 nM at 1000X molar-fold excess. [32P]-labelled KRA -A probe 
was 118 pM with CRD-BP protein maintained at 540 nM. 
Graphical presentation more clearly depicts a tr nd whereby both AON M6 and SM7 
inhibitors show effective do e-dependent abrogation of the RNA-protein interaction; howe er 
SM7 is more active at low r concentrations (I 50 of approximately 1 OOX or 1.18 nM for M7, 
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c mpared t 400X r 4.72 nM £ r M ) and i rall d 111 d th m t f[i c ti ingl N 
olig nu 1 tid f th t. n ther 1 kat th inhibit r in parall 1 ith mput r imulat d 
RN £ !ding f KRA - with n~j( ld lace M6 (lab 11 in blu ) and M7 (lab 11 d in black) a 
compl m ntary t adjacent t m-1 p tru ture p ibl impli ting th 1 p tru tur a 
rmp rtant £ r RD-BP r c gni ti n (fi gur 2.2 ). in th arne fi gur , th K 4(b) 
RN r gion i indicated in r d - th mall t R - P-binding frag1nent identified tlu· ugh 
EM A mapping ( ecti n 2 .. 2), and erl ap can be n ith b th th M6 and M7 inhibit r . 
Thi triking re ult complem nt th pre i u affinity mapping data, and reinforc the 
conclu i n that the KRA - 4(b) r gion i important for KRA mRN binding and likely i li1 
direct contact with the RD-BP pr t in, at lea tin the e in vitro a ay . Mongr e/ al. (20 1 l ) 
howed that th KRA mRN coding region dir ctl y interact with IMP- I (Human rtholog f 
CRD-BP) in ivo thr ugh UV cro s-linking and ba ed on the de cribed experim ents here, that 
interaction likely occur in the KRA -A34(b) region between nucleotides 129-185 relative to the 
start codon. To explain the reduction in overall affinity of this smaller 57 nucleotide region 
compared to the larger KRAS -A (1 85 nt), it must be con idered that CRD-BP po sess multiple 
domains that each contribute to an overall Kd for a given RNA ub trate, as is theca e for 
hnRNP K and FMRl where multiple KH-domains are required for a stable interaction with RNA 
(Siomi et al, 1994). Further emphasis on the requirement for multiple KH-domain interactions 
comes from experunents involving IMP-1, the Human ortholog ofCRD-BP, where all four KH-
domains were shown to be necessary for proper cytoplasmic traffi cking and RNA binding 
(Nielsen et al. 2002) . As a result of this property, it is pos ible that the smalle t equence 
identified capable of forming a complex with the protein - KRA -A34(b) may only b 
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nteracting ith a ub- t of th R -binding K domain . and that th truncati n pr ce ma 
1a e r m d ther lo r-affinit it that w uld n rmall llecti ely c ntribute t binding. 
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Figure 2 .24. Computer simulated RNA foldin g of KRAS-A RNA w ith KRA -A3 -' (b) and 
AON inhibitors SM6 and SM7 target regions indicated. RNA fo ldi ng of KRA ~ - (nt 1-185) 
wa compl ted u ing the mfold web server: the prese nted tructu r hav ing a pred icted free 
~ne rgy of d = -3 8.63 [initi all y -46.91 Kcal/mol. 
inter ting with a ub- t of th R -binding KI l d m in , nd that the truncati n proces rna 
ha e rem d ther low r-affinit ite that ould n rmall c llectivel ontribute to binding. 
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Figure 2.24. Computer simula ted RNA folding of KRA -A RNA with KRAS-A34(b) and 
AON inhibitors SM6 and SM7 ta rget regions indicated. RNA folding of KRA - (nts 1 -185) 
was completed u ing the mfold web se rver~ the pre ented structure having a predicted free 
energy of dG = -3 8.63 [initia lly -46.9] Kcal/mol. 
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2.3.4 KRA RN minimum bindin qu nee analy i 
Ph i al parati n f the KH d main and their pr ci e g m try relati to n anoth r 
play a critical rol in th ele ti n of RN targ t a well nucle tid equence. KH-d main 
archit cture d e n tall w [! r rec gniti n f 1 ng equ nc but in t ad direct int raction 
betwe n an RNA ub trate and an indi idual d main i limit d to only to 4 or 5 nucleotide and 
i of w ak affinity ( ha tal. 201 0). T try and identify om f the equence that may be 
ilnportant in facilitating thi interacti n, a earch for putative RNA-binding equences for the 
VICKZ prot in family wa undertaken and local sequence aligrnnent were completed u ing 
previou ly identified con en us equences and the putative KRAS 1nRN A binding region. While 
there is little agreement regarding a precise con ensu binding equence for thi family of 
protein , with different experiments returning largely different conclu ions a few intere ting 
results are mentioned here that positions KRA -A34(b) in relation to the available literature. 
VglRBP is a closely related ortholog ofCRD-BP who e known mRNA targets : VLE and 
V gJ, contain a sequencing clustering of 5 '-UUUCUA-3' or 5 '-UUCAC-3' (Git and tandart, 
2002). In KRAS-A34(b) RNA, a sequence very similar to those aforementioned, 5 '-UU C-3 ·, 
appears in close proximity to a repeat which runs in the opposite direction, separated by only 5 
nucleotides. Strikingly Du et al. (2008) suggest that a minimum of exactly 5 nucleotide between 
binding-sequences could fill the gap between KH-domains and i required for efficient binding 
for hnRNP and P B l/2, which are related RNA-binding protein that contain only three KH 
domains . Furthen11ore, the RNA target reported for hnRNP and P B 112 r quire a minimum of 2 
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r p at fa 19 nucl tid qu nc : 5' A 'which c ntain th 5 '-
- ' equ n found in KRA - rtantly in d el ping am del for binding, 
the ambiguity f binding- quence rd r ithin a tran cript ha been d mon trat d by hao 1 
a!. (20 1 0) with nly th rall p la1it r lati t th KH-d main being an imp rtant factor. 
Thi group al d t nnin d fr m r und f el ction and amplificati n ( X) fa 
deg 11 rat RN library 11 1 ting rand m mutati n intr due d int th targ t "zipcode" 
equence, that ZBP 1 recogniz d tw d ub- qu n : 5'- -"''and 5'-A A-3. 
KRA -A34(b) regi n d e n t p e the p1i r identified equence wi thin its 57 nucleotide 
length. h e r th latt r eq uenc appear d twice in partial v rlap a 5 '-A A-3' which i 
not urpri ing gi 11 the impli ity ofthe 5'- A-3' sequence and it likeliho d of appearing by 
chance. However, later w rk with ZBP 1 completed by Patel eta!. (20 12), focu ing on the ZBPl 
KH3 -4 didomain only, eparately determined imilar binding elements except for a lightly 
lengthier 3' bipartite sequence (5 · -ACAC-3 ') and thi s still matche th at found in the KRAS-
A34(b) region. Additionally, using 1H-15N H QC NMR it was also reported by Patel that the 
5 '-ACAC-3' motif interacts with the IMP-1 KH3 domain as evidenced by resonance hifts 
within the residues of the KH3 domain when free protein wa complexed with this small 
oligonucleotide. Pairing RNA sequence with a specific KH d01nain is useful informati n for 
constructing a model of KRAS RNA binding. 
PAR-CLIP (photoactivateable-ribonucleoside-enhanced crosslinking and 
imrnunoprecipitation) experiments, where UV-reactive nucleosides are added to cell culture to 
be incorporated into nlRNA transcripts, as well as other RNA molecules, revealed that IGF2BP 1 
(aka IMP-1) co-precipitates with cross- linked RNA sequence: 5'- AUH-3' (where H=A,C or 
U). This was in fact the only ingle consensus sequence found , from thi tudy, however the 
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actual cro -link d r idu ccurr d within thi m tif nly 90% fth tim with th th r 10% 
mTing within a nt range i1nplying me fl ibility (Hafner t a/, 201 0) . KRA - 4(b) d e 
ntain thi 5 ' - H- m tif. H r, th I ightl larg r KRA - 24, m ntioned 
pr i u ly t ha affinity imilar t th full! ngth K ( cti n 2 .. 2), doe c ntain thi 
m tif in th ~ rm of 5 ' - - · that ur nc at nucl tid p iti n 79 thu ffering a 
p t ntial RRE qu nc t r an up tr am binding equenc hyp the iz din ecti on 2 .3.2 to work 
coop rativ ly with th ther pre i u ly m nti ned ithin K 4(b). Keeping in mind that 
KRA - 12 which in Jude th n th at ha th a~ rementi ned 5 '- H-3' motif, do 
not m to bind RD-BP, it i thu not uffic i nt n it wn a a binding m tif and seems t 
requir information in the KRA - 4 regi n, which doe bind RD-BP, albeit with reduced 
affinity. 
ielsen et al. ( 1999) propo ed a ingle putative binding sequ ence fo r IMP- 1: 5 '-
UUCACGUUCAC-3 · ba ed on EM A and V -crosslinking methods with mRNA target IGF-II. 
By aligning DNA equivalents of KRA -A34 with the propo ed I F-II binding equence, a 
region of highest imilarity can be een and this fa ll within the KRAS-A34(b) region. The RNA 
equivalent is 5 '-UUCUCGACAC-3' in the KRA -A34(b) region. A propo ed binding sequence 
for ZBP 1 is 5 '-ACACCC-3' (Ross et a!. 1997) and a similar alignment placed the region of 
possible irnpm1ance within the same range. Po1y-C and poly-U pyrimidine homopolymers 
compete significantly better than poly-A and poly-G purine homopolymer aga inst VLE mRNA 
with VglRBP (Git& Standat1 2002). Transcripts with more C/U content hould therefore bind 
better, however the total composition of A3 4(b) doe not agree with high and high U; 44% 
/U and 56% AG. However binding a says with poly- h mopolymer do how that the binding 
mode with these oligonucleotides is different, being additive and competing away the a tual 
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LE targ t quenc in a lin ar n n- p rati fa hi n a pp ed t th target VL quenc 
whi h bind operati n t fall und r 
Perhap it i n t mu h th ra rall c nt nt, but in t ad a c rtain I -1i h ub-
qu n that aid in binding KZ pr t 111 tab! m nti n d 5'- -3' 
equ n e r peat in KRA - 4(b) a we ll a th 5'- - ' ma fall in-line with thi 
idea. 
A lignmen t f hvo D sequence 
AT~TGATCC ·CAA ~GAGGA-TCC -AC GGAAGC GTAGT AT-GATGGAGAAACCTGICTCTTGG~TATTC CG -CACAGC~GG CATGA 9 
II I 
-- -- -- - - - --------------------------------------------------------------TTCACGTTCAC------------ 94 
·equence l 
A A GA CC.A.ACAA AGAGGA- CC'ACAGGAAGCAAG.,-AG AA"GATGGAGAAACC GTC - C,....-GGA-A c - CGA-CJ 
Sequence 2 
- -------------ICACG CAC--
B Alignment of h\·o DNA sequences 
AT TGA CCAA.CAA A.Gt<GGA T CCTACAGGAAGCAAGTAG AAr GA GGAGAAACCTG CTC TTGGATt..TTCTCGACACAGU..GG CATGA ?3 
II 
--------------------------------------------------------------------------- - -A.CACCC---------- 93 
Sequence 1 
ATA GATCCAACAATAGAGGA I CCTACAGGAAGCAAG AGIAAT GA- GGAGAAACc- G- CTCIGGA A--c CGACA 
Sequence 2 
-------------------------------ACACCC----
Figure 2.25. Local DNA alignment of KRAS-A34 and putative binding sequences for IMP-
I and ZBPI CRD-BP orthologs. (A) lMP-1 proposed binding equence and aligned with 
KRAS-A3 4 and (B) ZBPl proposed binding equence aligned with KRAS-A 4. DN equenc 
were converted from their RNA sequence origins forth purpo e of the aligm11ent, and both 
highlight an overlapping pos ible binding region. 
Chapter 3 
Assessing the role of CRD-BP KH domains involved in 
KRAS mRNA binding in vitro and in cells. 
57 
Thi hapt r utlin th perim nt und rtaken t d t rmin f each f th .G ur 
indi idual RD-BP KH d mam in binding K 
el ctroph r tic m bility hift a ay ( M xp riment u ing p int mutation RD-BP pr t in 
ariant . Th cond cti n ~ cu e n d t rmining th imp rtance f KH d main in cell , 
u ing RNA irnrnuno-pr cipitati n c upl d with quantitati e rever e tran cripta P R (RT-
qP R). 
3.1 Methodology- CRD-BP KH domain requirements for binding KRA mRNA in vitro. 
3.1.1 Purification of CRD-BP KH domain va riants 
CRD-BP variant w re previously generated by another member in Dr. Lee' lab u in g 
site-directed mutagenesis again t the first glycine (to a partate) in each of the four G-X-X-G 
motifs within each KH domain (G212D, G293D, G422D, G504D). The e motifs are cri tical for 
the interaction of the KH domain with target mRNA, and by mutating each individually a well 
as in tandem as double-KH mutants, individual KH domain importance in binding KRAS mRNA 
cou ld be assessed. Proteins harbouring a specific single mutation were labelled as ''KH 1" 
through "KH4" depending on the KH domain affected, with double mutant harbouring two 
affected domains labe ll ed as "KH 1-2" through "KH3-4 "· information ummarized in Table 3.1. 
Table 3.1. ummary of enerated RD-BP KH domain variant . KH d mam are 
indi iduall af:D t d a a r ult f it -dir ct d mutati n in th can nical - - - m tif. 
CRD-BP mutant KH domain mutated 
KHl KH2 KH3 KH4 
K.Hl • 
KH2 • 
KH3 • 
KH4 • 
KHl-2 • • 
KHl-3 • • 
KHl-4 • • 
KH2-3 • • 
KH2-4 • • 
KH3-4 • • 
E. oli BL2 1 (D 3) cell w re heat- h ck tran fonned with p T2 b- RD-BP variant 
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pla mid and purified u ing a i- T agar e c Iumn D llowed by dialy i into th e final buffer: 
200 mM aCl 20 mM Tri - 1, 10% glycero l, 0.0 1% Trit n-X, pH 7.4 as described in section 
2.1.1. Quantification of each protein ample wa compl t d using a B A Protein As ay Kit 
(Thenno Scientific) with RD-BP protein samples typically ranging between 3 and 7 J.lM. 
3.1.2 Generation of e2P]-labell ed RNA substrates by IVT 
Experiments with CRD-BP KH domain variants were completed using the KRAS -A 
RNA fragment (nts 1-185) detennined to possess strong binding affinity (section 2.3 .2), a well 
as the coding region dete1minant region of c-myc mRN A (nts 1705-1886), an established mRN A 
target of CRD-BP (Prokipcak et al. 1994) . T7 -driven in vitro transcription of both [32P ]-labell ed 
RNA regions from eDNA templates was completed as described previou ly in ection 2.1.5. 
3.1.3 EMSA experiments with CRD-BP KH domain variants 
MSA binding reactions were compl et d for each generated [32P]-labe1led KRA and c-
myc sub-region and contained RD-BP KH-mutant concentration varied from 0 to 540 nM. 11 
MSA reactions used for KH domain binding a ment contained KRAS or -m c prob at 
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20,000 pm. Prot in-RN mi ture w re incubated at 7 ° :D r n half h ur and c mpl 
re o l d on an % p lya r lrunid (29: 1 crylamid Bi -rad) n n-denaturing g 1 in 0.5 x 
TB running buffer and ubj ct d t :D r 0 minut at 25 1nA in a in1ilar fa hi n 
t cti n 2.1. . iati n c n tant wer calculated ba d n data acquir d from 
d n it m try analy i f th M aut radi graph u ing the y 1 n torage Ph ph r- y t m 
and pti uant ftw ar . 
3.2 Methodology - RD-BP KH domain requirement for KRA mRNA binding in cell . 
3.2.1 Preparation of IP-RNA from HeLa cell 
Pr parati n of purified imn1un precipitated (IP) RNA wa part f previ us pr j ect and 
wa already on hand for the d cribed experim ent · a conden ed description of meth d u ed to 
acquire the IP-RNA follow . CRD-BP KH domain mutant variant as de cribed in the previou 
ection (3 .1.1) were ub-cloned into a pcD A m ammalian expre ion vector (+FLA ) and 
transfected into HeLa cells u ing Lipofectamine 2000 reagent (Invitrogen) follow ed by a 48 hour 
incubation. Cells were lysed with total cellly i (T L) buffer in the pre ence of RNa in and 
protease inhibitor tablet (Roche diagnostic ) and lysate incubated with anti -FLAG antib dy 
overnight at 4 °C. Immunoprecipitation (IP) of the different CRD-BP variants containing point 
mutations in the GXXG motif (single and double mutants) using Protein G-agarose bead was 
performed and equal amounts of irmnune-precipitated CRD-BP wa recovered as detennined by 
SDS-PAGE, followed by treatment with Proteinase Kanda final phenol-chloroform-isoamyl 
alcohol extraction. IP-RNA was quantified u ing a Nanodrop Spectrophotometer (Thermo 
Scientific). RT-qPCR to measure the relative amounts ofKRA mRN associated with each of 
the variants as compared to a wild-type control. 
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3.2.2 cD nthe i from IP-RN 
11 ur n ntamin ti ninth RT-qP R r ti 11 hi h m ha 
pr ith th pr t in granul 
' 
th . f " - r r m a l kit m 1 n) wa 
mpl d. ir tl t h 1 ~g f I -pr ipitated w ith a h KH ari ant mpl 
(all ingl an d ubl mut nt in tri li pt KH2 and KH , f hich n1 y 1 bi 1 gi a1 
r pli at a a a i1 able), 1 ~~ f a 1 ( a a ) ( m i n), l 1-tl 1 b u f~ r and l 2 
mad u 10 1-d r a ti n v lum . R a ti n re incubated at 7 ° [! r 0 min ~ 11 wed by 
th additi n f 2 ~1 f rD a e deacti ating reagent aft r hi h a 2 min r m temp rature 
incubati n p ri d ~ 11 w d . D acti ated rea ti n wer pun at I 0,000 g [! r 1.5 mint 
dim nt rD a 1 m 1 ul and 10 ~I f th upernatant c ntaining the purifi ed IP -R A wa 
drawn ff fi r u in cD ynth i pri r t qP R. 
ynth i of mpl mentary D A fr m purifi ed IP -RN ampl e wa ace mpli hed 
u ing a Biorad i cript cD A ynthe i kit ; 20 ~~ reaction prepared w ith 4 ~~ 5x i cript buffer 
mix containing random hexamer prim er , 5 ~1 nuclea e-fr e H2 , 10 ~I of D -fre IP-RNA, 
and 1 ~1 rever e tran cripta e (RTa e) a embled pecificall y in that rder. A embl ed reaction 
were placed in a thermocycler and ubj ected to incubation at 25 ° [! r 5 min (rand m hexamer 
primer annealing), 42 °C for one half hour (eDNA ynthe i ), 85 ° fo r 5 min (RTa e 
inactivation) followed by 4 ° torage until u e. a control, each KH variant IP ample wa 
also ubj ected to the arne procedure without the addition f r ver e tran cripta e (- RT/no 
template) to account for the po ibility of genomic DNA tability. 
3.2.3 KRA mRNA RT -qP R 
uantitative P R wa u ed t mea ure relati ve amount f KRA mRN a o iat d ~ ith 
the RD-BP vari ant t determin in ol ement/ imp rtan c f indi idua l KH domain . Fir tl , 
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KRA ifi mplifi ati n nm r d ign t am lify a 12 nu tid r gi n f 
ding qu n nth ized b lnt grated t hn 1 g1c In . (l ), a a 
mpl m ntar TaqMan pr 
q R prim r nd qMan pr b ( able .2) wer 
ba d n d rib d nt ith an r a ti ancer c lllin ting lig nucle tid 
g n tr n ripti n ( g i I a/. 2 1 ). 
Table 3.2. KRA RT -qP R amplificati n prim r an d aqMa n prob 
Primer/probe 
Forward primer: 
KRA TaqMan probe: 
uantitati P R amp! were etup a 25 ~1 reac ti on and c mpleted in triplica te [! r 
each bi l gical repli at t tally 9 reacti n p r RD-BP ari ant. pr v i u ly m nti ned , nl y 
a ingle biolog i a! replicate wa a ail able for KH2 and KH3 RD-BP vari ant and a uch, nJ y 
3 value w re obtained forth e. dditi nally, D r each RIP ampl e a no RT contr I wa 
m ea ured in an otherwi e identi cal fa hion to en ure no genomic D contamination . In a 96 
w ell P R microplate (Axygen cientific Inc .) rea ti on were a em bled according to table .3 
from an iQ™ upermi kit (Bio-R ad). In an attempt to reduce pipetting error and inter- ample 
variability, all qP R experiment were completed by fir t creating a m a ter-mix that contain d 
all reagent except the cDN . To each ample well of the P R microplate, 24 111 of ma tcr mix 
wa added, with the final 1 111 eDNA vo lume added la t. 11 wing additi on of all reagent , th 
u ed P R mic ropl ate w 11 w re ea l d with ealing film uitabl e for rea l time P R ( x g n 
c ientifi c Inc). As a final tep, the P R micropl ate were c ntrifuged at 200 g for 1 minute at 
ro m temperatur t en ure pr per mi ing. o il wing rea ti n a embl , qP R wa perf nncd 
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d u ing i 5 ptical 
y t m ftwar (Bi -Rad) . 
Table 3.3. Reagent u ed for KRA qP R r eaction . I up nni i fr m th i -Rad i TM 
up 1mi kit and contain all n c buf:D r ingr dient d P and ym . 11 r acti n 
w re a mbled in triplicat D r a h - P mutant ariant and mi d a a rna t r mi prior to 
adding final D 
qPCR reagent Volume u ed per qPCR reaction 
Forward primer (lOJ.tM) 0.5 J-tl 
Rever e primer (1 0 J.tM) 0.5 J-tl 
KRA TaqMan probe (5 J.tl\1) 0.5 J-tl 
IQ™ uperm1 (2X) 12.5 J-tl 
eDNA 1 J-tl 
H20 1 0 J-tl 
Total volume 25 J-tl 
3.3 Results and Di cussion - KH domain requirements for binding KRA mRNA 
3.3.1 CRD-BP ingle KH domain va riant EM A binding assays 
To inve tigate the functional rol e of each individual KH domain in binding KRA 
mRNA, CRD-BP variant harboring mutation in each GXXG motif of the four KH domain 
were used in EMSA binding a ays with the high affinity KRAS sub-region A ( ection 2.3.2) 
[ 32P]-labelled probe. EMSA containing the KH mutant and KRAS-A probe was can·ied out with 
all single and double mutants beginning with KHl through KH4 single mutant variant and were 
performed in a manner identical to chapter 2 describing KRAS mRNA affinity mapping. Re ult 
from the ingle KH mutant displayed a stark contrast in binding capacity when compared to 
wild-type CRD-BP (figure 3.1). Beginning with figure 3.1A, it can be seen that the wild-type 
RD-BP fully shifts the free KRAS -A RNA probe within the experimental protein cone ntration 
range of 0-540 nM (lanes 1-6). However, with a single GXXG motif point mutation in either 
KH 1 or KH2 (lanes 7- 11 and 12- 16 respectively) , the binding pattern change con iderably, both 
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mutant di playing limit d mobility hift f th fr . lnt re tingly KH 1 and KH2 b th 
ha uniqu binding patt rn · KHl r main capable ffl1ming a p cific mol cular weight 
compl of th am 1z a wild-typ , albeit at a reduc d quantity figure .1 lane 7-11 ), 
while KH2 app ar t ha a c mplet ab ence f thi band. faint , much larg r complex can 
b n n ar th t p fth gel fl r KH2 (figur .1 , lan 12-1 ) a a 1n ar that i ab nt in the 
KHl Ian but till pre ent in th iJd-type hift patt m . RD-B variant KH3 and KH4 were 
a ed for KRA - RN binding capacity in th am perim nt and imilar r ult were 
found. A with KHl a X mutati n in the KH d main yield d dra ti cally reduced binding 
ability with only an e tremely faint trace of the pecific compl x that is so prominent in the 
wild-type er ion of RD-BP , and to a 1 r ex tent the KHl mutant variant (figure 3. 1B, lanes 
7-11). Higher molecular weight mearing wa al o not a prominent when compared to wild-
type. KH4 domain mutation in CRD-BP produced a very clear re ult with no hint of any 
significant binding whatsoever, neither a a pecific complex band , nor a a higher molecular 
weight smearing. This high molecular weight mearing observed may sugge t partial binding of 
the protein to KRAS RNA. 
Due to the striking reduction in KRAS-A probe binding affinity when any single CRD-
BP KH domain GXXG motif is mutated, we wondered if perhap these mutant protein amples 
had somehow mis-folded or were otherwise producing artifact data . To test this possibility, an 
additional set of EMSA experiments were completed utilizing a positive control where the 
binding pattern with CRD-BP KH mutants was already known. c-myc mRNA contains a region 
known as the coding-region instability detenninant (CRD) , and is a well establi hed RNA targ t 
sequence of RD-BP (Ben1stein eta!. 1992; Prokipcak ct a!. 1994; Leed eta!. 1997). 
I RO-RP jn. 1: 
Fr [ R:"A 
lane 
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I RD-BPj n\1 : 
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R;\ \ 
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h..lll 
F igure 3.1. EM SA assessing CRD-BP KH varia nt with single poin t mutation for bind ing to 
sub-region KRAS-A RNA; (A) KH I and KH2 variants, (B) KH3 and KH4 va ri ants. C2P]-
labelled unbound KRAS-A (nts 1-1 85). RNA probe (2 0,000 cpm/reaction) with no protein added 
(lanes 1, A and B) fonns a larger molecular weight complex upon titration with WT CRD-BP 
and single KH vmiants po sessing GXXG motif mutation (first glycine to aspartate), a indicated 
by the bound RNA fraction (lanes 2- 16, A and B) . 
This RNA probe consisting of 182 nucleotide , was synthesized by IVT and wa u ed in 
additional EMS As (figure 3 .2). Finally, it is worth noting that higher radioactivity (80,000 
cpm/reaction) was used in this latter et of EMSA experiment in order to increa e en itivity to 
complex formation, and the re ults can be en a the pr ence of a weak KRA -CRD-BP 
complex fonnation in all four KH mutant sample . This is in contra t to the previou set of 
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M (figur nl K.Hl £ 1m d a i ibl band f n tabl int n ity and wa abl t 
r due th amount f fre RN . H w erall patt 111 fKHl pr du ing th trong t 
hift d RN int n it till remain un hang d, al ugge ting that th K 1 d main ha a 
nee ary (£ r full binding) but reduc d r 1 in binding the KRA - ub-r gi n fragm ent. 
M p riment inc rp rating th -my RN a a p iti c ntr 1 (fi gur .2, - ) yield d 
data hich a ry imilar to th pr 1 u et f ingle KH mutant RD- P variant , but al 
pro id d om compari n r garding the binding m de f KRA RN a c mpar d to c-myc 
RNA. Fir tl y, it can b en that RD-BP di play r dundancy in binding c-myc mRN with a 
ingle mutation in an n KH-dom ain fa iling t tr ngly affect verall binding. 
Furtherm r , RD-BP app ar t bind c-myc (and the KH mutant vari ant ) cooperatively 
as a dimer with two parate Kd value a evidence by two distinct band clearly v i ible at 108 
riM (figure 3.1 A-D lane 8). First, RD-BP binding likely occur a a single protein c mpl x, 
with the dimer forming ub equently. On the other hand , KRA -A RNA does not appear to form 
a strong complex with a single CRD-BP molecule, with only an extremely faint intermedi ate 
band visible in the wild -type lanes (fi gure 3.1 A -D, lane 2-6). The c-myc and KRAS RNA 
formed a dominant upper complex with similar migra tion distance, and the RNA m olecules 
being of similar size (1 82 and 185 nucleotides respectively), hence it is also likely that KRAS-A 
RNA binds almost exclusively in the dimerized fmm with 2 CRD-BP molecules attached in one 
complex. It could be that an initial binding event with a single CRD-BP m olecule induces an 
RNA conformation change that produces or reveals a second RD-BP binding site of very high 
affinity, which is immediately bound . In tllis induced fit model, the initial binding ev nt forming 
complex 1 (one molecul e bound) is rate-limiting and the second RD-BP molecul e ( comple 2) 
binds almost imultaneou ly. Thi s idea is in parti al contras t to a pr viou ly propo ed binding 
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dim rizati n n th 
I F-II mRN targ t, ith a fa t initial binding nt ( mpl 1) and a much 1 w r, cl arl y 
quential fl rmati n f c mpl II. In thi am m d 1 put ~ rward by i 1 en t a/. (2004 ), th 
mpl 1 i c n idered n n- cifi c and a r lati ly 1 w tability pr cur r 
intermediat , and it i th u c ful ~ rm ati on f mpl 2 that " I k " th targ t mRN int a 
table RNP compl . If thi m d l i ind d ITect then the K ub-r gi n i a b na fid 
target f RD-BP with uniqu binding haract r in that th dimeriza ti n ev nt occur either 
imultan ou ly with th fl rmation f mpl x l or at th ery lea t, extremely rapidly. An ther 
po sibility i that up n an iru tial -BP binding, not the RN , but rather the pr tein 
experien e a dynamic confl nnati nal hift, a mecharu m ugge t d by W ang et a /. ( 1999) for 
the binding of a rel ated KH domain c ntaining protein: Poly- binding protein (PABP) with 
target a-globin mRNA. Thi change in fo lding character may then lead to the creati on f a 
protein-protein interaction ite recognized by the second RD-BP that can lead to the 
dimerization event apparent in the EMSA figure presented here. In support of either model (i) 
RNA or (ii) protein conformation change, experiment conducted to determine if IMP -1 can 
dimerize independent of an RNA ubstrate indicate that RNA-binding i a prerequisite for 
dimerization and that complex I precedes the formation of complex II (Niel en et al . 2004). 
3.3.2 CRD-BP double KH domain mutant EMSA binding assays 
Further work in assessing the pecific requirements of KH domain in binding KRA 
mRNA was also completed using the EMSA. CRD-BP KH variants harbouring point mutations 
at two GXXG motif sites located in separate KH domain ere u ed in a simi lar fa hi on to 
assess whether or not all traces of binding could be aboli hed. Indeed with the mutation of any 
tw o KH domains, absolutely no binding wa obs rved (figure .3 A-D). 
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Figure 3.2. EM A as essing CRD-BP KH variants with ingle point mutation for· binding to 
KRA -A and c-myc RNA ; (A) KHI variant, (B) KH2 variant, ( ) KH3 va.-iant, (D) KH4 
variant. [32P] -Iabelled unb und KRA - (nt 1- 1 5) and -m yc (nt 1705- 1 6) RN ( 0,000 
cpm/ reacti n) with no protein add d (lane I and 7, -D) 
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F igure 3.3. EMSA assessing the CRD-BP KH variant with two point mu tations for binding 
to sub-region KRAS-A RNA; (A) KHI-2, KHI-3 (B) KHI-4, KH2-3 (C) KH2-4 and KH3-4. 
[ 32P] -labelled unbound KRAS-A (nts 1-185) RNA probe (80,000 cpm/reaction) with no protein 
added (lanes 1 in all gel images) fom1s a larger molecular weight compl x upon titration with 
WT RD-BP and double KH variants posses ing GXXG motif mutations (fir t glycin to 
aspartate) , a indicated by the bound RNA fraction (lane 2- 16, A and B). Binding reaction were 
incubated for a total of 20 minutes at 3 7 ° and 10 minutes on ic before being resol ed on an 
8% polyacrylamide gel. 
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mpl te li1nina ti n f binding in the d ubl K l mutant M p nm nt pr ide 
!ling that KRA mRN int ra t primaril and lik 1 ntir ly thr ugh the 
p regi n , and n t b an th r n n-can ni al m hani m . 
3.3.3 . KH domain requirement for KRA mR 
RD-BP KH d main binding requir ment [! r K 
bindin in H e a cell 
mRN a al a e ed in II 
thr ugh th u [ immun -pr c ipitati n (RIP m th d upl d ith R -qP R . H a cell 
pia mid c ntaining KH mutant ariant a w II 
a a ild-typ n. nti - L antib dy \ a then u ed t immune-pr cipitate th 
rib nucle pr t inc mple -precipitated K mRN a ciated with ach f th 
BP KH mutant wa th n analyz db RT-qP R . a c ntr 1 [! r ea h KH ariant ample a n 
rever e tran cripta (- RT/n t mplat ) amp! c n i ting nly f the purifi d mR co-
precipitated with RD-BP wa run under identical qP R conditi n . Thi control pr duced n 
detectable fluore c nee within the 40 cycle limit of the y tem and confirmed that no genomic 
D A c ntamination wa pre ent in any of th amp! te ted. 
The KRA qP R primer were te ted for effi c iency u ing pla mid dilution c ntaining 
KRAS eDNA template and d termined to be 97. %with an R2 of 0.99 . Data group t alue 
(figure 3.4) from RT-qP R ample were then analyzed u ing a ne Way Analy i of Variance 
(one-way AN OVA) te t and a <0.0001 p-value (a suming null hypothe i of all group being of 
the same population) wa calculated with an F- tat value of 19 .1, indicating a ignificant 
difference between one or more of the analyzed group . From th rej tion of null hypoth 
that all sample were equal r from the same population, a p t-hoc Tuke ' I I D multiple 
c mpari on te twa calculated fl reach RD-BP KH mutant pair, and re ult re al d that 
level ofKRA mRNA as ociated with wild-type RD- P were ignificantl dif[i r nt than the 
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KI-f -mutant . Fw1h tm r KHl KRA mRN ere al [t und t b ignifi cantly lli gh r 
than th th r r maining RD-BP mutant (p=O.Ol ). Finally an unpair d t-t twa c ndu t d t 
compar th t- alu betw n ild-type and ach ind i idu al RD- P mutant ampl . Thi 
analy i al o bowed that all f th qP R data gr up (K ingle nd d uble mutant were 
ignificantl diffi rent fr m ild-typ at p=O.O 1. ycle thr h ld alu wer n rmaliz d t wild -
typ RD-BP and pl tt d n a 1 garithmi cal hich wa r quired c nsidering the large 
r lati di ffi r nee in m le el b tw n wi ld-type and the d ubl e KH mutant (figure 3.5) . 
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Figure 3.4. Box plot pf the RT -qPCR cycl e threshold values from immune-precipitated 
KRAS mRNA associated with CRD-BP KH variants. H01izontal middle line in the 
encompassing box represents the overall mean, the top box repre ents the third quartile and 
bottom box the first quartile. Bars are the absolute minimum and maximum Ct value obtain d. 
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Figure 3.5. R elative KRAS mRNA associa ted with KH domain variants from immune 
precipitation of CRD-BP in HeLa cells as determined by RlP RT -qPCR. ach cycle 
threshold value i from averaging 3 biological ample in triplicate and en or bar h re represent 
the standard deviation, with the exception of KH2 and KH3 of whi ch only a single biological 
replicate was available for RT-qPCR. One-way AN VA determined P<O.OOOl and po t-hoc 
Tukey HSD and Student' s t-test revealed significance between pairs. 
To understand the molecular nature of how RD-BP bind KRAS mRNA, experiment 
in the form of EMSA gel shift assays and also RT -qPCR analysis were undertaken. Data from in 
vitro EMSA experin1ents conelated well with the re ult from IP experiments u ing HeLa cell . 
Together, the data presented in thi s chapter trongly upport a model where all four KH domains 
of CRD-BP are required for KRAS mRN to maximally bind RD-BP. Mutation of th fir t 
XXG motif glycine to aspmiate in of any on of the four KH domain resulted in a near 1000-
fold reduction in pull-down KRAS mRNA, save for KHI. The conclu ion of a redu ed role for 
KH 1, that wa initially ugge ted by the M A data (fi gure 3. 1 A and 3.2A), i fu1iher echoed by 
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tb RT-qP R data . mparing KH 1 ( t - 0.00 ) it can b e n that KRA tnRN 1 vel ar 
about 1 -fl ld 1 w r than wild-type ( t-27 . 1 0) 1 th th r RD- P KH mutant are 
appro imatel 1000-fl ld 1 r (fi gur .5). g th r, th M and IP-qP R data upp rt the 
n ti n that ind d all fl ur KH d main ar r quir d [! r - P t bind KRA mRN , with 
p rhap a mitigat d but till nece ary r fl r th KHl d main. Thi c nclu ion infl r that th 
int racti n i highly p cific· [! ur RN quence 1 ment vid ntly r quir d to contact each 
KH domain fl r binding, and i in-lin wi th th lit rature n ti n that many RN -binding pr tein 
achieve th ir p cificit through int racti n w ith multipl d main . 
R ult by Bam e t a/. (20 1 ) found imi lar R -qP R re ult with c-m yc and D44 
tnRNA . B th mRN like KRA were found t di play reduced as ociation with KH single 
and double mutant v ruiant of RD-BP ( e cept KH4, which retained affinity [! r c-myc ). 
However in stark contra t to KRA data, EMSA CRD-BP binding result fo r these same 
mRNAs (c-myc and CD44) di play an oppo ite result, with single KH mutations having no 
effect on binding (except KH4 did not bind CD44 mRNA) . RNP granule f01mation in zebrafish 
was also analyzed to search fo r a con elation with in vitro binding data, with inj ection of the 
identical CRD-BP KH mutant' s mRNAs directl y into the embryo. These in vivo result better 
support the EMSA binding data, with the single KH mutant CRD-BP granules appearing in cells 
at the same rate as wild-type, and KH double mutants having much lower numbers of grruml e 
(except for KHl-2 and KH3-4; the CRD-BP didomains). KRAS mRNA, which did not bind 
strongly with any single KH-mutant, may therefore not contribute signi ficantly to the CRD-BP 
granule core structure, as the granules continue to form under mutant conditions that do not 
allow KRAS mRNA to bind. While KRAS mRNA, at least in vitro and in HeLa cell doe not 
have a pattern that conelate well with granul e formation in zebrafi sh, it cellular rele an e i 
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not 1 t. KRA mRN and many oth r mRN may n t [! 1m th c r tru tur f th 
granul but may i1nply b pre nt in 1 r c py numb r r inter-di p r d thr ugh ut th 
granul a t rminal a ociati n within th m h rk n t [! nning the c r caffl lding tructur 
Intere tingly a a id n t , the e z brafi h granule data all w for the p ibility that an intact 
KH did mam p ing n mutati n ( eith r KH 1-2 r KH -4) i uffici nt [! r granule 
[i rmati n, but that mutati n in both (all ther K d ubl mutant ) did mam may mo t 
trongly impair functi n. 
Thi conclu i n i irnilarl upp rted by i 1 en I a!. (2002) wh h wed with IMP-1 
truncation tudie (KH 1 to KH4, KH2 t KH4, and KH 1 t KH3) that both intact KH did main 
(KHl -2 and KH3-4) are required fo r IMP-1 to bind H l9 RN in imilar M A studi . Whil e 
CRD-BP truncation were not a e ed for bind ing to KRA mRNA, the re ult do complement 
the IMP- l -Hl9 binding re ults in that all KH domain are required. The group also [! und that 
only the wild-type and KHl to4 recombinant protein (no RRM domains) was able to fonn RNP 
granules and exhibit lamellipodia anchoring as detennined by confocal micro copy in NIH 3T3 
cells (mouse embryo), unlike the Barnes et a!. (2015) paper where the KH3to4 truncation could 
still form granules. Given the evolutionary distance between zebrafi h and mice, the compared 
KH3to4 data could be clues to a specie -specific intracellular regulator of CRD-BP. The e two 
groups also chose different amino-tetn1inus truncation position for the KH3to4 construct; 
Barnes et al. (2015): 409-577 and Nielsen eta!. (2002): 344-577, re pectively and perhap the 
unique granule fonning characteristics lie in the differential re idue . 
It has b en demon trated that in th Xenopus ortholog Vg lRBP, all four KH domains are 
required for high affinity binding to a 340 nucleotide region of V g l mRNA, and in fa t the two 
didomains (KHl t 2 and KH3to4) can act cooperatively, much like what appear to b the ca e 
for KRA mRN ( it and tandart, 2002). nth th r hand, nly the KH t 4 did mam f 
IMP-1 i r quired to bind th beta-a tin 54 nucle tid "z ip d ' r gion ith affinity imi lar to 
th full-length ver i n ha tal. 201 0) . imilarl in hicken embry , th Z P 1 1ih log 
utilize nly the tw ut nn t -te1minal KH d main : K and KH4 t bind beta-a tin 
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mRNA (Farina t a!. 200 . While tudi pertaining p cifically t th KH-d main inv lvem nt 
in I KZ pr tein binding th ir ari u m targ t are limi ted, it can alr ady be c nfidently 
conclud d that difD r nt mRN reqmr unique KH-d main combination , with KRA 
appearing to requir all D ur d main t achi e e a high affini ty interacti n. 
Chapter 4 
Assessing the structural impact on GXXG mutations in KH 
domains on CRD-BP, conformational change upon RNA 
binding, and KH1to4 crystallization 
In thi final p rim ntal chapt r, the m lecule i ubject d t multiple 
tru . Th e ffe t mutati n f th e · " m ti f ha n verall gl bal condary 
tru tur f RD-BP i in e ti ga ted by m an f ir ul ar dichr i m ( D) p ctr c py· the 
aforem enti n d ingl and d ubi KH mutant R -BP ari ant analyzed and c mpared to a 
wild-type pecu·a. ing D p ctro c py in a imilar fa hion, the po ibility of RD-BP 
undergoing ignifi ant conformati nal change up n RN binding i al o addre ed, a well as 
what effect said binding may have on overall RD-BP thermal tability. Finally, attempt to 
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produce a cry tal tructure of RD-BP areal o detailed and cover variou a pect of the process 
including pla mid ub-cloning recombinant protein expre ion, and the multiple purifica ti on 
technique employed. While no diffraction data wa ultimately achieved fr om a CRD-BP pro tein 
crystal, much was learned that may help pave the way to eventual success with this particular 
ongoing proj ect; the finding appearing at the end of thi s chapter. 
4.1 Methodology - Multiple stru ctural analyses of the CRD-BP protein-RNA interaction 
4.1.1 Production of CRD-BP KH variants 
CRD-BP mutants harbouring the identical XXG mutations previou ly described in 
section 3.3 .1 and 3.3 .2 (same clones), were u ed for structural analysis. De-natured amples 
stored in 8 M urea at -80 ° were dialyzed again t refolding buffer: 200 1nM Na L 20 mM Tris-
l, 10% glycerol , 0.01 % Triton-X I 00, pH 7.4 as de cribed in ection 2.1.1 however an 
additional di aly is buffer exchange tep was includ d to optimize CD pectra data acqui iti n, as 
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uruqu buf[i r n traint p tral anning in th [; r- 1 - 2 nm) . inal 
uf:D r :D r pr t in m f 2 0 mM ri - 1, 20 mM I, 10% glyc r 1, pH 7.4 
and la ked th additi n f rit n- 1 whi hi kn n t ntribut it n ignal. 
uantifi ati n f a h pr t in mpl \ a c mpl t d u ing a Pr t m a Kit ( henn 
ntifi ) ith R -BP pr t in ampl i all ranging bet n and 7 J.lM . 
4.1.2 ircular dichroi m p ctra 
ircular dichr i m p ctr larim tr canmn g a p r[i nn d n wild-typ R - P a 
w 11 a th KH ingl and d ubi mutant u ing a Ja c J- 15 pectr p larim ter (J a c 
Inc.). 11 a length pe tra r mea ured in a .1-cm path-length quartz cu tte; ample 
ann d in th far rang (260 - I 5 nm ) to a a-heli and 0- h et c ntent. R - P 
protein ample er dilut d int D bu ffer (20 mM Tri - l, 2 0 mM a 1 10% glycer 1, pH 
7.4) to between 1 and 2 J.lM ace rding to th B protein a ay (Thermo i cher cientifi c Inc.) 
and canned at a con tant temp rature of 25 ° maintained by a Pelti er t mperature c ntroll r. A 
blank reading coni ting of D buffer only wa ubtracted fr m each pectrum. Ja co J-8 15 D 
pectra acqui ition parameters were et accord ing to the :D llowing (Table 4.1 ): 
Table 4.1. Measurement parameters for CD spectra of CRD-BP KH variant . 
Photometric mode: D, HT Scanning speed: 20 nrnlminut 
Measure range: 240-195 run Baseline correction: ba eline 
Data pitch: 0.5 nm Shutter control: manual 
Sensitivity: tandard CD detector: PMT 
D.I.T.: 2 econd PMT voltage: auto 
I Bandwidth: 1.00 run accumulations: 
Start mode: in1n1ediately 
Final D pectra data point were converted fr m raw D ignal (mdeg) to mean 
elipticity (deg•cm2 dm r1) u ing the built-in pe traManager oftware uite (Jasco In .) by 
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m luding th ptical param ter f RD-BP nc ntrati nand uvet1 path-1 ngth; h r mall 
dif£ r n m RD-BP quantifi d c nc ntrati n c uld be ace unted [i r pri r t a final 
pe tra pl t. Finally, m lar elipticity alu wer c nvert d t mean r idu e lipticity, th 
c mmon unit t r pre nt pr tein ec ndary tructure analy i u ing Mi cr ft xcel . ata pl t 
were g nerat d u in g Kal ida raphT oft are. 
4.1.3 RD-BP econdary tructure e timation 
In order to tract additi nal quanti ta ti data fr m th 
RD-BP and the ariou ingl and d ubi KH mutant variant , ftwa re alg rithm were u d 
toe timate the fra ti on f a-h I i . ~- h t and un-coil ed m tif pre ent within each RD-BP 
ample fr m the mean re idu lipti ity (deg • cm2 dm r') value plot. umerical data points at 
1 nm interval were determined from a curve trace u ing built-in Ja co Spectra analysis oftw are 
from 195-240 nm and convert d to £, or molar circu Jar di chroi m (deciliter moJ!' -1 cm/\-1 ), and 
used a the raw input values for econdary tructure analy i w ith the K2D3 circular di chroi m 
web server (Louis-Jeune et al. 2011) using generated protein CD reference data sets from 
DichroCalc (Bulheller and Hirst 2009). 
4.1.4 CD monitoring of CRD-BP conformation upon RNA titration 
CD spectropolarimetry was used to monitor econdary structure content of CRD-BP 
following titration with multiple target mRNA regions previously found to bind through EMSA. 
KRAS , C-myc and Gli all had binding and non-binding fragments that were used for CD 
comparison, the sequences of which follow below. 
c-myc(+) 
1705-1792 
c-myc( -) 
1815-1886 
li (+) 
Gli(-) 
AC AGAUCCCGGAGUUGGAAAACAAUGAAAAG C AA UA UUAU CUUA AA 
AGC ACAG AUACAUCCUGU CGU AAG 
GAAGAGGA UUGUUG GAAA GA GAGAA AGUUGAAA A AAACUUGA CAG UA 
GGAA U UUGUGCG 
A U U GUAG AU AA U G GAU C 
AG U UAG UUUUUU AU A U G GAUG A 
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t:run at d er 1 n f ild-typ RD-BP lacking th RRM d mam c ntaining only 
KH 1 to KH4 wa al u din id nti al p rim nt with th rational b ing that if th RRM 
d mam ar in rt and d not pa1ti ipat m binding, r m al f them will amplify any 
chang in D ignal occuning ithin th KH d mam b rv d up n titrati n. r the e 
e p rm1 nt 0.1 em quartz cuv tt re u d for all ampleanaly i and th Ja coJ-815 
pectr p larimet r a u d nee again ith imilar param t r et; all fi ld a pre iou ly 
indicat d ( 4.1.2) xc pt an p d wa incr a ed to 100 m minut and nly 3 accumulations 
perfonned. Thi chang in data acqui ition param ter wa made becau e the higher protein 
concentration u ed in the e e perim nt c mpared to the mutant library analy i yielded lower 
noi e and pr duced cleaner pectra. oncentrated t ck RD-BP KHlt 4 ample were diluted 
into CD buffer (20 mM aH2P04, 200 mM aF, pH 7.4) to a final concentration of0.1 mg/ml 
(2 .33 11M) in 110 111 amples that al o included target RNA at three different concentration 
protein: RNA ratios: 16:1 (0.1 5 11M) 4:1 (0.58 J.!M) , and 1: 1 (2 .33 J.LM) . Protein-RNA mixture 
were incubated at 35 °C for 10 minutes, followed by 5 minute on ice, another 10 minute at 35 
°C and a fmal 5 minutes on ice immediately prior to CD scanning at 25 °C. For each RNA tested, 
three RNA-blank samples containing the target RNA molecule at identical final concentrations 
(three protein-RNA ratios each) were canned, and the resulting RNA-only pectrum ubtracted 
from the protein-RNA sample mixtures to judge the change specific to CRD-BP. For a more 
straight forward visual comparison of the various RNA's effect on CRD-BP conformation, the 
222 nm CD value for each sample, proportionate to the a-helical content of the mea ured protein, 
was plotted as a bar graph to help di tingui h any RNA that had a unique effect. 
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4.1.5 Generation of 18 RNA 
1 RN wa gen rat d fr m a M cri t T7 tr n ripti n kit ( nbi n) u ing 
lin ariz d pT7- l pla mid t mplat . inear 1 t mplate uitable .D r tran ripti n wa fir t 
dig t d in cir ular D 1m ith Hind Ill. 4 ~1 reacti n c ntaining (2 ll g) f p T7 - 1 pla mid 
D wa in ubat d ith 20 unit f I indiii ( w ngland i lab Inc.) D r 4 h ur at 3 7 ° 
foll w d by pr t ina K dig ti n in 0.5% diurn d cec l ulfa te D r 1 h ur at 50 ° . DN 
chloroform wa added and v rt d -D 1m2 minute at 1 ,000 rpm. To the upp r pha e 
(appr imately 50 Ill) 5 ~1 f M dium acetate and 100 Ill of 100% ethanol wa added, 
mixed and incubated at -20 ° for ne half h ur to allow linearized D t precipitate. DNA 
wa sub equently wa hed with 200 Ill of 70% ethanol, and fo llowing centrifugation the DNA 
p~llet wa re-su pended in 20 ~l of nuclease-free water. Purified linearized DNA wa then u ed 
as a template in the MEGAscript kit to generate approximately 100 11 g of pure RNA. 
4.1.6 T hermal stabili ty of CRD-BP-RNA complexes 
Overall stability ofCRD-BP wa a essed u ing a thermal ramp (Peltier temperature 
controller) coupled with CD monitoring (Jasco J-8 15) at 222 nn1. The wavelength 222 nm i 
proportiona l to the overall a.-helical content of the protein and i a good measure of protein 
denaturation. Protein melting temperature was calculated by fitting the molar eliptici ty to 
equation 1, using the built-in Jasco Spectral Analysis software for determining Tm, as defined by 
the temperature where 50% of the total elipticity i lo t. 
Equation 1. 
[min + (max- min) ] 
y = 1 + e[- k (x-Tm )] 
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RD-BP pr tein wa add d to a 110 ul r a ti n t a final c n ntr ti n f0.4 mg/ml (9. J..LM) 
in a 20 111M Tri - 1 and 200 mM a l buf[i r. Th wit h back t a 1 wa rationalized by th 
rela ed far- ab rbanc r quir m nt £ r mea uring nl at 222 nm ( chl rid i n trongly 
ab rb p larized light and int r£ r ith p tra acqui iti n bel w 2 0 run) . emp ratur wa 
incr a ed fr m 20 ° to 5 ° at a 2 ° /minute ramp-rate 0 c nd quilibration delay 0.5 °C 
pitch and th rwi e id ntical data acqui iti n param ter a previ u ly indicated ( 4 .1.2) . 
buffer- nly blank ubtracti n wa arried ut t tabli h a ba eline, as nly the chang in 
ignal i m a ured to det rmine melting temperatur and it inclu i n w uld have not chang d 
re ult . 
RNA ample w re added to RD-BP in 4 different rati pr tein toRN rati ( 1:1, 
4:1 16: l and 64 : 1 ). Th rmal denaturation xpenm nt included KRA ub-regi n A3 4 as the 
PC? itive binding RNA, and KRA -Al2, 18 and tRNA as negative binding te t RNAs. ach 
experimental condition was repeated in triplicate. 
4.1.7 Denaturing purification of CRD-BP KH1to4 
BL21 (DE3) E.coli cells were transfonned with pET-4l c-KHl to4 plasmid and expre sed 
in an identical fashion to section 2.1.3 , as with the full -length CRD-BP. Frozen pellet (4) were 
re-suspended in a denaturing buffer containing 8 M urea, and purified using a Qiagen mini-
colmnn in a manner identical to the full -length CRD-BP protein production except "buffer E'' 
(pH 4.9) was skipped , proceeding directly to "buffe r F" (pH 4.5). This provided higher 
concentration in the elution step wruch was followed by dialysis into a 2 M urea refolding buffer 
and fmally into a 0 M urea storage buffer . 
4.1.8 Native purification of RD-BP K.Hlto4 
B 21 (D ) . li ell w r h at- h k tran D rm d (2 .1.1) with pla mid p -4lc 
(4.l.ll)containingth truncat d dingregi n f - P KHl t KH4) and plat d n B 
agar containing 25 ~g/ml kanam in anti-bi tic and 11 d t gr w etnight in a 7 ° 
in ubat r. ppr imat l 20 c 1 m er icked fr m th ucc ful tran D tmant and were 
u d to in culate 1 f br th ntaining 25 ).l g/ml kanamycin and incubated at 7 ° until 
D6oo = 0.5 at which p int the cultur a indu ed with 1 mM I pr pyl-0- - 1-
thiogala topyran ide (IPT Bi Ba ic Inc. foll w d by a 6 h ur expre i n period at 37 ° 
ell were pelleted by entrifugati n at 4 ° , 2,100 xg, for 15 minute ( ub-divided into 4 
volume f 250 m1) which pr du d 4 cell pell et which were t red at - 0 ° . 
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ell pellet wer thawed on ice for 15 minute andre u pended in 12 ml non-denaturing 
lysis buffer (table 4.2). Ly ozyme (1 mg/ml) wa added to there u pended cell pellet and 
incubated for 30 minute on ice followed by nication ly i con i ting of 6 cycles of 20 second 
bursts (power level 5) - 40 second cool-down time . Lysate was ubsequently centrifuged for 30 
minutes at l 0,000 xg 4 °C. Lysate supernatant was mixed with 2 n1l of 50% Ni-NT A agarose 
resin slurry (Qiagen) and incubated on ice for 1 hour on a waver. The lurry wa then loaded 
onto a Qiagen mini-column and the beads washed twice with 4 ml of wa h buffer (table 4.2) 
followed by elution with 4 ml of elution buffer; collecting 0.5 ml fractions off the column. SD -
PAGE analysis was completed to assess the presence and purity of the fraction containing CRD-
BP KHl to4 with a final 3-stage dialysis step against a storage buffer consisting of 50 mM 
NaH2P04 , 200 mM Na 1, pH 7.4 using l 00 ~1 n1ini-dialy i units (Thermo cientific) . 
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Table 4.2. Buffer u ed in native purification of RD-BP KHI to4 
Elution buffer 
4.1.9 Denaturing on-column refolding purification of RD-BP KRlto4 
High c ncentrati n RD- P KH It 4 pr tein required the u fan ' on- I umn" pr tein 
refolding m thod hereby pr tein are d natured and then re-£ lded while still b und to aNi-
TA c lumn t a oid inter-mol cular aggr gate £ rrning. The pr ce i de cribed here and 
al o a vi ual guide can be r fened to (figure 4.1 ). BL21 (D 3) .coli cell were heat-shock 
transfonned (2 .1.1) with pla mid pET -41 c ( 4.1.11) containing the truncated c ding region of 
CRD-BP (K.Hl to KH4) and plated n LB agar containing 25 ~g/ml kanamycin anti-bi tic and 
allowed to grow overnight in a 37 °C incubator. Approximately 20 colonie were picked from 
the successful transfonnant and were u ed to inoculate 4x 1 L (4 L total culture) ofLB broth 
containing 25 ~g/ml kanamycin and incubated at 3 7 °C until OD600 = 0.5-0. 7 (each 1 L culture 
varied slightly at time of reading) at which point the culture were induced with 1 mM IPTG 
(Bio Basic Inc.) followed by a 6 hour expression period at 37 °C . Cells were pelleted by 
centrifugation at 4 °C, 2100 xg, for 15 minutes and cell pel lets stored at -80 ° . Cell pellet were 
resuspended and lysed in 48 ml of 8 M urea denaturing lysi buffer (table 4.3) and placed on a 
waver for 1 hour on ice. Following celllysi , the ly ate wa centrifuged for one half hour at 
10,000 xg (4 ° ) followed by filtration with a 0.45 ~m syring filter ( MD Millipore) yielding 
approximately 45 ml of cleared lysate. 
Eq. Sample inje t Wash 1 
Figure 4.1. Diagram of on -column refoldin g KHlto4 protein purification cheme. rea 
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con ntrati n rang fr m a rna f M t minimum f 0 M (% - denaturing ly i buffer) and 
i1nidazol rang fr In a rna f 250 mM t a minimum f 10 mM with an intennediate wa h 
c nc ntrati n of 52. m 
!eared 1 at wa load d nt an KT prime plu fa t-protein liquid chr matography 
machine (FPL E Healthcar Life u ing a 50 ml KTAprime up rl oop™ ( 
Healthcare Life cience ) ampl holder. !eared ly ate wa then inj ected over a 5 ml i-NT A 
Hi -trap™ co lumn ( Healthcar Life cience ) at a flow rat of 0.5 mllmin , with 50 ml f 
denaturing ly i buffer pumped through the up rl oop™, behind the amp le plunger to en ure no 
inadvertent nlixing with non-denaturing buffer. CRD-BP bound to the His-trap™ column was 
wa hed with 5 column volumes (25 ml) of denaturing ly i buffer at 5 ml/min. On-column 
protein refolding was then initiated, where urea concentration wa slowly reduced from 8 M urea 
to 0 M urea in the presence of oxidized/reduced glutathiones at a rate of 0.5 mllmin ( 100 ml 
program span) by progressively increasing the percentage ofrefolding/wa h buffer (table 4.3) 
passed over the column. This was accomplished by utilizing the AKTAprime plus mixing valve 
(from 0 to 100% refolding/wash buffer). A second wash step passing 10 colunm volumes (50 ml) 
over the Ni-NTA column at 5 ml/min was programmed followed by the final elution tep -
passing 25 ml of elution buffer at 1 ml/min over the Ni-NTA Hi -trap™ co lumn , collecting I .0 
ml fractions. Collected fractions were analyzed by SD -PAGE and the si pure t fraction 
pooled prior to a 3-stage dialy is against a final working buffer consi ting of 100 mM Tri - 1, 
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ca tt (Th nn cientific). h 4 kDa pr tein wa d ubly quantifi d ith a Nan dr p 
p ctr ph tom t r (Th rm c· ntifi ) u ing a al u1at d tin ti n c - ffici nt (Pr t aram -
EXP y b t 1 . 
' 
a t ig r t 1 2005) f 94 M-1 m-1 and additi nally u ing a B 
prot in quantificati n kit (Pi r h rm ci ntifi ). or cr tallizati n trial , the pr t in wa 
fw1h r nc ntrat d t 1 mg/ml u ing 10,00 MW ( 10 a) Amic n ltra 2 
ml cent:Iifugal filt r ( MD Millip r c rp .). 
Table 4.3. Buffer u ed in denaturing on-column refoldin g protein purification. H -
reduced fonn glutathi n idiz d D rm glutathione. 
Denaturing lysis buffer Refolding/wash buffer Elution buffer 
50JnM aH2P04 50 mMNaH2P 4 50 mMNaH2P04 
200 lnM a 1 200mM a 1 200 lnM NaCl 
1 0 lnM imidazole 52.8 lnM imidazole 250 1nM imidazole 
' 8 M urea 0 M urea 0 M urea 
- 1 mM GSH/0.1 mM GSSG -
pH 8.0 pH 8.0 pH 7.4 
4.1.10 Fluorescence polarization analysis of CRD-BP binding KRAS RNA. 
Fluorescence polarization (FP) spectra copy was used to confirm the RNA binding 
activity of CRD-BP KH1 to4 protein prepared by on-colunm refolding. A fluore cein-labelled 
KRAS probe was designed and synthesized by Integrated DNA Technologies Inc (IDT) ba ed on 
the KRAS-A34(b) fragment found to bind using EM A in ection 2.3 .2. The mfold RNA web 
server was used to fold the KRAS-A34(b) RNA fragment (57 nucleotides) in silica, and ba ed on 
the secondary structure prediction, a 44-nucleotide fragment containing the nucleotide 
compri ing the computed structured r gion was chosen. Binding reaction were a sembl d a 1 9 
~1 volumes containing RD-BP KHlto4 protein (0-1000 nM), KRAS FP probe (10 nM) in a 
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buffer imilar t M binding a a 2.1.6)· 20 1nM Tri - 1, 200 mM a 1 1 H 7.4. 
Imn1 diat ly fi 11 wing r a ti n a embly, c mp nent w r mi ed by mild centrifugati nat 
000 rpm in a tabl t p c ntrifuge fi r 10 nd , mi d by fli king, nd entrifuged again to 
po 1 th r action. Binding r acti n r th n incubated at 5 ° fi r 10 minut on ice for 5 
minut fi 11 w d b an ther 5 ° fi r 1 minut and 5 tninute n ice. lnt a 4-well 
microplat , 17 ~l f ach ampl reacti n m1 a add d and ub qu ently th t tal flu re cence 
and parall lip rpendicular Ou re cenc alu w re mea ur d u ing a y:nergy 2 Multi -mode 
Mi roplat Read rand n5 Read r ntr 1 and Data oftware (Bi tek In trument 
Inc.). ptical excitation filter and mi i n filt r were et t 4 5/20 nm and 52 /20 nm 
re pecti ely and y t m ga in et to auto-adju t with a read-height of7 .00 tmn . Fluore cence 
anisotropy value w replotted for each CRD-BP KHl to4 concentration ample in 
K~l ei daGraph™ graphing oftware to determine Kd. sapo itive control, wild-type full -length 
CRD-BP was u ed for compari on with Bovine Serum Albumin (BSA, Sigma Aldrich) being 
used as a negative control in otherwise identical experimental conditions. 
4.1.11 Construction of pET -41c(+)-CRD-BP KH1to4 plasmid 
Crystallization ofCRD-BP was al o attempted with a truncated f01m containing only the 
K.Hl to KH4 binding module (RRMl and RRM2 removed) which was sub-cloned into a 
pET4l c(+) that had been previously modified to contain no N-tetminu GST-tag sequence. The 
pl asm id vector was generou ly donated from Dr. Natalie trynadka 's X-ray cry tallography 
laboratory at the University of British Columbia and i ideal for protein expression oriented 
towards structural studies due to a thrombin cleavable 8x his-tag and no G T -tag. Ndei and 
Hindiii restriction enzymes (New England Bi lab Inc) were u ed to accomplish ub-cloning of 
K.Hlto4 RD-BP into p T4l c(+) plasmid . 
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IZ promotor ., I ac operator Xba! cbs .t:i!1eL 
3tta t ac gac t c c t t gggg ttgt g gc gg t a ttcccc t c t g a t ttttg ttt ac ttt g gg g t t c t t g 
Pstl Htndll 
BamHI BsrG! Asci Sal! 
at cggg t ccga ttc t gt c ggccttggcgcgcc t gc ggcg gc t ccg t cg~c g~ ttg t gcc cgcgg t g t gcnycy~~yc 
thrombin 
X hoi 
t c g gc cca cca cca cca cca cca cc c t t g tt 
~__:_.:.....:..:..:......; ______ r.,·l 
8HIS Tsg 
'igure 4.2. p T41c(+) - no G T pia mid multipl e cloning ite equ ence. ote the thrombin 
lea able 8 Hi -tag and lack of equen e . d 1 and Hindlll restricti n ite wer utilized 
r ub-cloning full-length and KH l t 4 R -BP coding equence . 
:RD-BP K.Hlto4 insert DNA generation by P R 
P R wa utilized to generat the D in ert (table 4.4): with wild-type RD-BP pia mid 
JET28b backbone) erving a th rea tion template . Primer wer de igned to amplify a 1 J 1 
ucleotide region of the coding equence encompassing KH 1 to KH4 a out! ined below. 
~RD-BP K.Hl to4 forward primer : 
>esign cheme: 5' [handle]-[Ndel]-(complementary region] 3' 
>NA sequence: 5' [ ACCA ]-(CAT A TG]-[ A TCCCTCT CGGCTCCTG] 3' 
ina! sequence: 5'-ACCACATATGATCCCTCTCCGGCTCCTG-3' 
:RD-BP K.Hl to4 reverse pr im er : 
>esign cheme: 5'[ complementary region ]-[1 Iind ll l]-[handle] 3' 
on-R .. DNA sequence: 5'[AAGCAA AGCAC AGAAG]-[ AG TT]-[AC A] 3' 
inal DNA sequence: 5'-A AAAG T CTTCT GT TGTTGCTT-3 ' 
*R.C. - reverse complement 
*handle (A A) not rever e-complement 
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T7 promotor ~ Xbal cbs ~ 
aa tta t c ga c t c c t a t gggg 1 ttcccct c t g a t aa ttttg tttaa c ttt g ., rgg g t t a c t t g 
EcoBI Pstl Hmdll 
BamHI BsrGI Asci Sac! Sal! 
t a t cgggat ccg ttc t gt c ggccttggcgcgcct gc ggcg gc t ccgt cgac g6ttgt gcc cgcggt gtgcnycy~~gc 
I l 
thrombin 
X hoi 
c t c g gc cca cca cca cc cca cca cca c t t g tt 
·-~..:...:..:..:...:......----.:..-- F t • 
8HIS Tsg 
Figure 4.2. pET41c(+) - no G T pia mid multiple cloning . ite equence. N te the thr mbin 
clea abl 8 Hi -tag and lack of equenc . de 1 and 1 indllf re triction itc w reutilized 
for ub-cloning fuJI-length and KH 1 t 4 R -BP coding equencc . 
CRD-BP K.Hlto4 in ert DNA generation by P R 
PCR wa utilized to gen rate the D A in ert (table 4.4)~ with wild-type RD-BP pia mid 
(pET28b backbone) erving a the reaction template. Primer were de igned to amplify a 1 J 13 
nucleotide region of the coding equence encompassing KH 1 to KH4 as outlined below. 
CRD-BP KH1to4 forward primer : 
Design scheme: 5' [handle]-[Ndel]-[complementary region] 3' 
DNA sequence: 5' [ACCA]-[CATATG]-[ATCCCTCT CGGCTCCTG] 3' 
Final sequence: 5'-ACCACATATGATCCCT TCCGGCT TG-3' 
CRD-BP KHl to4 reverse prim er : 
Design cheme: 5'[ complementary region ]-[Hindiii]-[handle] 3' 
non-R . . DNA equence: 5'[AAGCAA AGCACCAGA G]-[AAG TT]-[AC A] 3' 
Final DNA seq uence: 5'-A AA TG TGCT TTGCTT- '1! 
*R. . - reverse complement 
*handle (A A) not reverse-complement 
RD-BP KH1to4 amplicon DN equence: 
etc ccggct 
cca tccg aaa 
c g ggcgctgc 
g c a agatgat 
t cccctgaa 
ggaacctgaa 
acctcacgct 
gcagggccga 
ccatgagctt 
cagcttcatc 
gctccttcat 
tgggcgccat 
cctccatcaa 
ctggaccccc 
agaatttctt 
cagcagccgg 
ccg cagctga 
t taagatcat 
tggctcaagt 
cctggtgcct 
catcacaaaa 
ggagaaggcc 
cttggagatt 
gatcctggct 
gaagg ggag 
ctataaccc 
gcaggagatc 
gcagtcccac 
cagcgc gtc 
gcaggc ccg 
cat ggcaag 
gattgcacca 
agaggctcag 
tggtcccaag 
ccgtgtca c 
gg gg agtg 
cggacatttc 
taagcaacag 
acgcagtatg aggcgctat 
cagacgcagt ccaaaataga 
atcagcgtgc attcaacccc 
atgcacaagg aggcaaagga 
ca aacaac tcgtcgggcg 
caggacacag agacgaagat 
gagaggacca cactgtgaa 
atgaagaaag ttcgagaggc 
ctca ccctg ggc taacct 
cctcctcctc ccagcagtgt 
gagcaggaga tggtacaagt 
aagggccagc aca caaaca 
ccagaaacac c gac ccaa 
tcaaggccc agggaagaa 
gaggaagtaa age agagac 
ggcaaaggcg gcaaaacgg 
ccaagagacc agaccccgga 
tatgccagcc agatggctca 
caccagaag 
cattggcaag 
cgtgcatagg 
tgaaggc gc 
caccaaaacg 
actca tggc 
caeca ctca 
gggcgcca t 
ttacgagaac 
ggc gc g a 
caccggggc 
gttcatcccc 
ac ctcccgc 
ag cgaatg 
ctatggcaaa 
ccacatacgg 
gaatgagc g 
tgagaacgac 
gcggaaga c 
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a tee 
gaggg t g cca 
aaggagaatg 
tcctccgcgt 
gcagatgaag 
aaggaagggc 
cgctccag 
gagaactgtt 
gacg ggccg 
ggtctcttcc 
gctcccta a 
gcccaggctg 
ttcgccagcg 
gtcgtca ca 
ctaaaagaag 
gttccggct 
cagaacttga 
caag cattg 
cgagacatcc 
PCR mixture were a embled in triplicate and later combined to provide high working 
concentration. Each 25 ~-tl PCR reaction wa a embled according to table x and a then11ocycler 
scheme programmed for optimal amplification. High-fidelity Phu ion™ DNA polymera e ew 
England Biolabs Inc.) wa used in order to reduce likelihood of mutation during in ert 
amplification. PCR reactions upon completion were then run on a 1% agaro e gel at 120 V 
stained with 0.5 1-1- g/ml ethidium bromide and ubsequently gel-purified u ing a QIAEX II Gel 
Extraction Kit (Qiagen) following the recmnmended protocol. 
PCR thermocycle program: 
Step Condition 
1 98 °C 30 sec 
2 98°C 15 sec 
3 55 °C 30 sec step 5 - repeat 25x 
4 72 ° 2 min 
6 72 ° 10 min 
7 40 forever 
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Table 4.4. PCR reagent u ed to generate KHlto4-pET-41c(-G T) pia mid vector. 
volum 
2.5 Ill 
ector pla mid (p T41 c) £ r ub-cl nmg, hi h wa d nated fr m B a a 1 w 
concentrati on, mall lume ampl e, wa amplifi din a 10 ml H5a ~ .c li ce ll culture v !urn 
£ llowing heat- h k tran fonnati n (2. 1.1) and plating onto an LB agaro e plate with 25 llg/ml 
kana1nycin antibiotic. vernight-gr wth c lonie w re cultured in 10 ml LB broth volume (25 
llg/ml kanamycin) for 16 h ur , followed by pla mid purifi cati on using a QIAprep pin 
mini prep kit (Qiagen). Due to pET41 c being a low-copy plasmid two 5 ml culture volume were 
prepared eparate ly, each according to the manufacturer' recommendati ons and then combined 
by passing both plasn1id preparations over a ingle QIAprep spin column and eluted together to 
yield approximately 5 llg of plasmid D A (1 00 ng//ll , 50 )ll). 
Double-digest restriction endonuclea e reactions were setup for the in ert and pET4 1 c 
empty vector DNA sample in preparation for sub-cloning. Digest reaction were setup in 20 )ll 
volumes according to table 4.5 and allowed to continue for 2 hours at 37 °C. Digested DNA 
products were resolved on a 1% agaro e gel and gel-purifi ed from excised DNA bands using a 
QIAEX II el xtraction Kit ( iagen) fo llowing the recomn1ended protocol (note that KH 1 to4 
insert DNA elution i at room temperature while the larg r pET4 l c v ctor DNA is eluted at 50 
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Table 4.6. Reagent u ed for RD-BP KH1to4 pia mid ligation. Pla mid p T4l c(- T) MW 
appr imat ly 5 kb and KHlt 4 in rt 1.2 kb ; alu u d t calculat d molar rati s. 
Reagent 1:1 3:1 7:1 Vector onl~ 
lOX T4 buf:D r (NEB) 2j .. d 2 J.tl 2 ) ..tl 2 Jll 
KH1to4 DN_ 10 ng 5 ng 85 ng 0 ng 
p T41 D 50 ng 50 ng 50 ng 50 ng 
T4D liga e (NEB) 1 Jll 1 Jll l Jll 1 Jll 
H2 t 20 Jll to 20 Jll to 20 Jll t 20 Jll 
P R a u ed t cr n ~ r ucc fu i li ga ti n c ntaining the RD-BP KH1 to4 
m rt. were am pled dir ctl ff th L agar plate u ing a t rile loop and u ed to 
inoculate mall P R rea ti n tube . n reaction wa a mbl ed D r each colony ampled 
according to table 4_6 and run on a 1% agaro e gel for UV ethidium bromide det ction of 
appropriate band. ucce ful tran form ant were then u ed to inocul ate l 0 ml LB broth culture 
and pla mid pmified u ing the QIAprep pin miniprep kit (Qiagen) as de cribed previou ly for 
the empty pET4l c vector. 
DNA equencing was completed fo r three po itive clone plasmids to further confi rm the 
presence of correct DNA insert, and also to ensure no mutations were present in the equence. 
Plasmid samples were diluted to 100 ng/Jll and 10 J.!l volumes were shipped to M acrogen for 
next generation sequencing using three different equencing primers for each plasmid: T7 
promoter forward primer, T7 terminator rever e primer and a custom designed " KH I P" fo rward 
primer that anneal s to the 3' end of KH 1 DNA sequence. 
Primers used for DNA sequ encing of pET4lc-KHlto4: 
T7 promoter forward primer sequence: 5'- TAA TA A T A TATAGGG -3 ' 
T7 te1minator reverse primer equence: 5 ' - T AGTTATTG 
"KI-f 1 P'' forward prim r equence: 5 '- G T T TT G T 
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Table 4.7. Reagent for colon P R creening. 
PCR reaction mix Thermocycle program 
reagent volume ilil! temQera ture time 
lOXP R bufD r .5 ~1 1 95 ° 5 1nin 
d p (2.5 mM) .5 ~1 2 95 ° linin 
K.Hlt 4_F prim r 1 ~~ 54 ° 90 ec 
K.Hl t 4_R primer 1 ~1 4 72 ° 2 min 
Taq.P 1. 0.5 ~1 5 t t p 2 - 30X 
H2 25 .5 ~~ 6 72 ° 5 min 
4.2 Re ults and Di cu ion 
4.2.1 Circular Dicbroi m analy i of CRD-BP KH mutant va riant 
RD-BP KH single and double mutant variants harbouring the XX mutation u ed 
. previou ly for EM binding experim nt (3.3.1 and 3.3.2), were canned u ing a circular 
dichroism (CD) spectropolarimeter and far-UV pectra acquired from 240-190 m11 for each 
mutant protein. All protein amples were freshly dialyzed and refolded into CD buffer and were 
all between 1 and 3 11M concentration prior to loading into a 0.1 em quartz cuvette for D 
scanning. Acquired CD spectra for each KH mutant were remarkably imilar to wild-type CRD-
BP following conver ion from raw CD milli-degrees to mean residue elipticity (figure 4 .3). The 
mean residue elipticity unit accounts for differences in scanned protein concentration and return 
the average CD signal per amino acid residue, making inter-protein sample compari on more 
feasib le. Far-UV wavelength cans of wild-type CRD-BP reveal a pectrum characteri tic fa 
protein with mixed alpha-helix/beta-sheet structure wi th a strong broad p ak at 222 nm, 
indicative of a large alpha-helical component. This finding matche known tructur of KH 
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d mam-c ntaining pr t in a w 11 a ther pectra d ri ed from ingle and tand n1 KH 
domain pr t in ( ha t a. I 201 0; al erd eta!. 2007; lu11iel t a!. 2006) . 
It i inun diat ly lear up n in p ction f the R -BP KH mutant D p ctra that th 
global tructur ar remarkably imilar and do not h w any large di fD r nee in the locati n of 
p ctra p ak r the amplitude f ignal. ubtl e di f:G r nee d e i t between the pectra 
up n cl m p tion, m t n tably at wa elength I wer than 205 run, and higher than 230 nm. 
The dif~ r nc are m all and tr ngly ugge t tha t the verall fold of the vari u KH XX 
mutant appear to be maintain d. H w r as far- V pectra analy i i not a mea ure of the 
terti ary tructur f pro tein , it remain p ible that relative change in alpha-helix/beta-sheet 
orientation ha e occurTed a a re ult of intr ducing XXG mutation . A well , shift in the 
preci s a-he l i and ~- heet res idue boundaries are pos ibl e, so long as the overall fraction of 
each motif remain con tant. W ild-type CRD-BP wa scanned at 90 °C as a control for denatured 
protein (figure 4 .3D), and far-UV pectra showed weaker CD ignal a expected, notably in the 
208 run and 222 nm regions where protein econdary structure contributes strongly. 
Further tructural analysis involving econdary structure calculations from CRD-BP CD 
spectra were also completed with the aid of the K2D3 econdary structure estimation web erver, 
and the Dichrocalc online CD reference-spectra data base . Inputting the L1£ va lue , or mo lar 
circular dichroism (deciliter moJ!' -1 cm"'-1) at 1 run interva ls for each mutant produced highly 
similar final secondary structure estimations, varying by le s than a percent b tween each ample 
(table 4. 8). Given the ti ght overlap in CD spectra between wild-type RD-BP and the va1i ou 
mutant fonns, especially at the criti al wavelengths used t r omputing econdary tructure 
e timations, this result was expected and brings numetical cope a to th likenes of proteins 
within the RD-BP mutant library. 
A 
0 
E 
'0 
o' 
5 5000 
0 
CD 
~ 
RD B WT 
CRD B H1 
CRD BP KH2 
CRD 8 KH3 
.. CRD B H-1 ~ 0 ~ ~~------~------~-0. 
Lii 
CIJ 
:J 
~ 5000 
Q.l 
cr: 
c 
Cll 
CD 
~ o' 
c 
o' 
-0 
E 
'0 
~ 
E 5000 
u 
C> 
CD 
u 
~ 
u 0 
.. 
a. 
Lii 
CD 
:J 
u 5000 
-;; 
Cl> 
cr: 
c 
"' CD 
::E 
-1 o· 
;;:r 
270 
Wave length (nm) 
(;>-
730 
CRO BP WT 
CRO BP KH2 4 
...... - CRO BP KH3 4 
- ·0 CRO BP Y5A 
<l CRO BP 0 . :>?F 
220 230 i'!O 
Wavelength (nm) rr 
_g 
/ 
rf 
~ 
-~~ 
B 
0 
E 
'0 
5 ':iOOO 
0 
CD 
'0 
~ 
D 
o· 
-
0 
E 
'0 
-E 
u 
5000 
Cl 
Q.l 
'C 
~ 
u 0 
.. 
a. 
Lii 
CD 
:J 
'C 
"' 
';OOQ 
CD 
cr: 
c 
"' ., 
:'!: 10. 
200 
220 
93 
RD BP VVT 
RO t:5 KH1 2 
0 -B · KH1 -3 
o 0 OP KH1 4 
., RO BP KH2 3 
230 __.i-4 0 
Wavelength (nm) /J""' 
1.1 
/~ 
p' 
~~ 
~)l 
CR OP W1 
Wavelength (nm) 
210 240 
G.~-&e~ 
zy-0 
Figure 4.3. CD spectra of wild-type CRD-BP a nd KH mutant variants. ircular dichroi m 
spectra of(A) wild-type, KHl , KH2, KH3 and KH4; (B) wild-type, K.Hl-2 , KHl- , KHl-4, 
KH2-3 ; (C) wild-type, KH2-4 , KH3-4, Y5A, and D527E. (D) Wild-type CRD-BP pectral can 
at 90 °C as po itive control for denatured protein. All spectra generated from 8 accumulation 
using a Ja co J-8 15; protein scanned in 20 mM Tris- 1, 10% glycerol, 200 mM Na I, pH 7.4 
buffer. 
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Table 4.8. Protein econdary tructur e timation for RD-BP variants. K2D n ural n t 
ir ular di h ri m tructural d tenninati n w b erver wa u d inc njunction with ichr calc 
nlin p tra d tab a t g nerat timati n fr m £ ( d cilit r m }/\- 1 m/\- 1) 
CRD-BP variant 0/o a-helL~ o/o B- beet 0/ o Random coil 
Wild-type 67.51 9.00 23.49 
KHI 67. 2 . 9 23.59 
KH2 67.7 9.10 23.17 
KH3 7.51 9.02 23.47 
KH4 67.51 9.00 23.49 
KHI-2 67.55 9.12 23.33 
KHI-3 67.53 9.00 23.47 
KHI-4 67.4 9.06 23.46 
KH2-3 67.51 9.00 23.49 
KH2-4 67.51 9.00 23.49 
KH3-4 67.51 9.02 23.47 
4.2.2 Circular di chroism monitoring of CRD-BP-RNA binding in vitro 
Assessing whether or not CRD-BP undergoes a conformation change upon RNA 
interaction is impor1ant, as it may serve as a measure or indicator for RNA binding. Also, it 
sheds light on how the protein functions and can highlight the different relevancie of 
crystallographic structures publi hed with and without RNA bound . To determine if CRD-BP 
has such dynamic character, CD spectroscopy was u ed a before in a eries of RNA titration 
experunents with both high and low affinity RNA substrates. In addition to the full-length wild-
type form, a truncated ver ion of CRD-BP was created containing only the KH I to KH4 binding 
modu le (referred to from now on simply a "KH I to4"), and used · t n i el in the e 
experiments. The rationale behind this move to include KH 1 to4 wa that the fun tionall in 11 
95 
RRM don1ain ha b n t nnined not t c ntribut t RN binding affinity, and thu ar not 
lik 1 t hift fr m n c nformati n t an th r. H nee, inclu ion f th tatic RRM domain 
wa anticipat d a p t ntiall dulling an b erved change in D ignal temming fr m the KH 
domain and th re£ r r m ved. ull -length R -BP a e amined fir t, mea uring th 
mplet far- p trum fr m 1 0-260 nm and titrated with KRA 4, KRA Al 2, the c-
myc RD-r gi n, a n n-binding -m c regi n, a well a a pair f LI competit r 
lig nucl otide with relati el trong competiti n and w ak c mpetiti n, labelled Ll ( ) and 
GLI(-) re p cti 1 . Furth rmor , a a n gati e c ntr I fo r -ob ervable tructural changes, 
B A wa titrated with KRA 4 RN and p ctra obtained in an otherwise identi cal fashi n. 
Each ample wa pr par d in term of protein :RN molar ratio equivalents; 4: 1 and 1: 1 
preparation were completed and canned fo r ach RN ubstrate. It can be seen in figure 4.4, 
that the addition of any RNA ub trate- high affini ty or low affmi ty appears to induce a change 
in the CD spectra in a imilar fa hion. At all wavelengths, the mea ured dichroism reduced upon 
titration with RNA, however while there is a lack of specificity fo r the general effect, it can be 
seen that in every experiment (figure 4.4 A-C) , the stronger binding fragment wa able to induce 
a larger change at the same concentration. As RNA alone possesses CD character, it is important 
to subtract the RNA spectra measured at the same concentration from the titration samples; an 
RNA-CD blank. In fi gure 4.4D, BSA was measured with KRAS A34 and A l 2, and the RNA 
spectra subtracted, producing es entially identical D spectra refl ecting both the unchanging 
nature of BSA in the presence of RNA, and also validating the spectral subtraction technique in 
principle. A reduction in absolute molar elipticity, as observed in all CRD-BP-RNA titration , 
reflects an un-coiling effect of the various alpha-helice compri ing th protein a well as beta-
sheets. The effect i not absolute, as the D signal does not ba e-line lo ing only about 25% 
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Figure 4.4. CD spectra of CRD-BP titrated w ith vanous substrates. All ample are 
presented as a molar ratio of protein to RNA. with RNA concentration increasing from 4 :1 to 
1:1. (A) KRAS A34 i a high affinity substrate while KRA A 12 bind poorl y. RNA ub trate 
also included: (B) c-myc (+ )and c-myc (-)are strong and weak binding sub trate re pectively . 
(C) Gli ( +) and Gli (-) are strong and weak oligonucleotide competitor re pectively 'vVith (D) 
containing scans of BSA acting as a negative conformational hift control. 
structure, however a loss in structure doe reDect and le s stable and higher free energ) 
conformation. This is by itself an unlikely circumstance as RN binding is spontaneou, and doe 
not require energy input, however this energy barrier may be overcome by the free-energ) 
contribution of RNA binding, ati sfying charge and po sibly orienting h) drophobic rcsidm: s 
into more energy favourab le po itions . 
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urth r p nm ntal data a tracted fr m the e p ctra, c mparing mo t dir ctly the 
alpha-h li al cont nt f each titration ampl a 222 nm bar chart (figure 4.5). each D 
p tra wa m ured in tripli ate and graphed a~ the a erag f 11 a cumulati n , the 222 nm 
value in figur 4 .5 i an averag \\-ith err r bar repre enting tandard deviati n. Thi tracted 
222 nm data allo~ [! r r latively ea c mpan on of th R ub trate effect n RD-BP 
protein tructur . It can b a ily c n in the bar chart that indeed the tronger binding 
ub trate . mo t n tab!~ c-myc. labelled with "( + )" arc rei iabl more able to reduce the D 
ignal trength. alb it n marginally more than their vv aker binding"(-)" counterparts. As can be 
quick] d due d fr m the ra\\- 0- pectra in figure 4.40. B A here sh w no distingui hable 
pattern in prot in econdary tructur chang . with neither ub trate affinity (KRA -A ...,4 vs 
KRA - 12) n r R A cone ntration correlating Vvith the relatively mall change in 222 nm 
elipticity. 
Another important accompanying piece of data in CD experiments i the record d high 
tension voltage (HTV), essentially a mea ure of the required signal amplification or gain 
required to di tinguish noise from CD signal. Certain buffer or protein may absorb trongly in 
the far UV, resulting in higher voltages being required to acquire spectra. However, protein 
precipitating from solution also typically how strong increases in HTV. Patel e/ a/ . (20 12) 
proclai1n that ZBPl bound to RNA possesse reduced solubility compared to the prot in alone, 
which has been a major stumbling block in the quest for a ful l-length cry tal tructure of ZBP 1 
or any of it homo logs including RD-BP. Reduced olubility of the CRD-BP-RN complexes 
in the experiments presented here would indeed how lo of CD signaL as i ob erved . 
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Figure 4.5. MRE at 222 nm of CRD-BP titrated with RNA ub trates . All sample are 
presented as a molar ratio of protein to RNA with 4: l having lower RN concentration than 1:1 
and mean residue elipticity (MRE) presented a absolute value . (A) KRA A34 was dete1111ined 
to be a positive binding fragment while KRAS A12 binds poorly . (B) c-myc (+)and c-myc (-) 
are strong and weak binding substrates respectively. ( ) GLI ( +) and GLI (-) ar . trong and weak 
oligonucleotide con1petitor respectively with (D) containing 222 nm trace of B. A acting as a 
negative conformational shift control . 
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Figure 4.6. CD-HTV plots of CRD-BP sa mple titrated with RNA substrates. All samples 
are presented as a molar ratio of protein to RNA with 4:1 having lower RNA concentration than 
1:1 and measurements plotted as high tensions voltage (HT -voltage) . ( ) KRAS A34 wa 
detem1ined to be a high affinity substrate while KRA Al2 binds poorly. (B) c-myc (+ )and c-
myc (-)are strong and weak binding substrates respectively . (C) Gli (+ )and Gli (-)are trong 
and weak oligonucleotide competitors re pectively with (D) B A acting a a negative 
confonnational shif1 control. 
How v r, th HTV or gain would increase proportional] and appear different than that 
of wi ld type alone. As can be e n in figure 6, no uch difference ar vi dent ugg sting that 
low complex o lubi lity is not likely to be responsible for the CD reduction observed . I lowe\ er, 
considering RD-BP form . large multimer complexe a visible granules in cell ' , it cannot be 
100 
di unted that the formation f th larger mple ould be re pon ibl for lo of 
ignal, th r [! r p t ntiating th data a am a ure f granul :D rmation and not actual tructural 
chang ithin th pr t -in. tructural change in RD-BP and it homo! gs how veri lik ly, a 
it int racti n ith it e lf a a dim r. and with ther pr tcin uch as d nein and kin in w ithin 
micro-tubul a ciat granul i R dependent (B ian eta/. 200 ; ll avi n eta!. 1998; 
loannidi eta!. 2005; Ni 1 en era!. ~004) and pcrhap a protein-protein interaction motif is 
r ealed up n R binding a ugge ted by Wang ef a/. (1999). 
Furth r tructural tudie \\ere imilarly carried out with a Kll 1 to Kll4 RD-BP 
truncation c mpri ing only the R -binding module . The e p riment were done in an 
otherwi e id ntical fa hion except for an additional 16 : I, 1 \\- RN concentration ample wa 
included to te t for a lovver thre hold concentration boundary for the D effect. KRA -A34( ) 
and KRA -Al2(-) w reemployed again a well a several alternative ubstrate that were not 
expected to bind: '18S', 'Orflb'. · pike' and 'tRNA' which were all u ed to broaden the earch 
for potential RNA ub trates that do not cause the ob erved change in 'D spectra, which wou ld 
offer much tronger support for the notion that these conformation changes are induced by RNA 
binding. D monitoring of KH 1 to4 secondary structure titrated with any of the RNA ubstrates 
however did not uncover any particular RNA that wa ineffective at producing the previously 
observed reduction in D signal (figure 4.7 and 4.8) . 
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Figure 4.9. CD-HTV plots of KH 1 to4 
samples titrated with RNA substrates. 
All sample are pre ented a a molar ratio 
of protein to RNA with RN 
concentration increasing from 16: 1 to 1 : 1 
and measurement plotted a high ten ion 
voltage (l--IT-voltage). (A) KRA A34 i 
a high affinity ubstrate 'While KR 
A12 bind poorly . RNA sub trates (8) 
18 . (C) Orfl b. (D) Spike. and (E) tR A 
are not expected to po ess high affinit) 
binding character. 
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4.2.3 Thermal tability of RD-BP-RNA RBP comple e 
To furth r anal z the p t ntial for circular dichr i m to be u ed diagno tically in 
hara t rizing R -BP binding 'Aith vari u R target . m lting temp ratur f RD-BP. a 
d fined a 50o/o unii ld d prot in. 'A a det rmin d in the pr ence of various R target . In 
target f R -BP may ha e the potential to increase the overal l 
tabili t [ th mpl , b) reducing free-en rgy as are ult f pontaneou binding and increa e 
them lting t mp rature of R - P. pectro copy was again utilized to monitor the protein 
tructure at 222 nm in th pr ence f diffi rent RNA pcci , and the temp rature wa 
increa ed ufficiently to melt the pr t in. KR - 12 and KRA, -A34 w reanalyzed in compl x 
with KHl to4 truncated RD-BP. a w II a n gative control ubstr te 18 and tR RNA 
m I cui . with the pr vi u monitoring periment . multipl R A concentration were 
t ted including 1:1, 4:1. 16 :1. and 64:1 molar ratio . Importantly. protein concentration wa 
increa ed to 0.4 mg/ml (- 10 flM) for scanning. Thi d ci ion wa mad due to the ob erv d 
dramatic reduction in CD ignal at 222 nm (figure 4.7) with increasing RNA concentration. 
Because the ba eline 0 ignal prior to melting would be quite low and prone to noise a a result 
of RNA presence already. the overall quantity ofprotein-RNA complex wa increased 
ufficiently to achieve approximately 30 mdeg of raw CD at 222 nm. Re ult can be n 111 
figure 10, as determined melting temperatures (Tm) which were computed by Ja co Spectral 
Manager Thermal-denaturation software. nly the 64:1 and 16:1 amples (figure 4.10 A and B. 
respectively) were scanned due to visible precipitation of the RD-BP-RNA com pi x . in the 
4:1 and 1:1 sample ets. This precipitation wa not pre ent in the CD spectral analy i · sample 
and is attributab le mainly to the increa ·ed concentration of both protein and RN u ed and th 
apparent reduced so lubility ofthe complc cs compared to protein alone. 
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Figure 4.10. TMs of KHl to4 CRD-BP protein in complex with RNA substra tes. Plotted 
values were determined from 222 nm D amp le trac over temperature-ramping from 20 to 80 
0 and Tm calculated based on los of half CD signal. (A) RN A sub trate pre ent in a 64 :1 
protein :RNA mol ar ratio and (B) 16:1 in otherwise identical conditions. (C) xample Tm 
calculation from thermal melting curve of RD-BP KH 1 to4 protein ample with a sociated 
computed values. 
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ther r littl differ nee in m lting t mperature between the protein al ne 
and pr ampl (le than 4 ° ). p cted , th gr at t difD r nc between protein 
alon nd ample ith R a pr due d at th higher RN c n entration ( 16 :1 prot in to 
r, th differenc 111 m lting temperatur bet een KRA -A 12 and KRA -A34 
re mo t pron unced at the low r R c nc ntrati n (64 : 1 protein t RN ). While me 
electi ity can be e n in b th ncentration range . ith both 18 ~ and tRNA addition producing 
n gligibl dif[i rene in mea ured Tm. both KR L, _ 12 and KRA -A 4 ampl es generall y 
app ared to b within err r f each ther ~ ith po ibl a li ght bi a t ard the stronger binding 
ub trate K 4 in the I wer R concentration ampl e . Toe pl a in the more pr valent 
differ nee in KRA - 12 and KRA - 34 at lo\\- r concentrations compared to hi gh r, it could 
be that und r the D e perimental cond ition . there is a degr e of non- pecific binding, alth ugh 
it cannot be complete! non- pecific a 18 and tRNA compl exe hav ignifi cantl y lower Tm. 
In the context of u ing melting temperature to assess CRD-BP compl ex tability and RNA 
sub trate binding, the reduced so lubility of the complexe at the hi gh concentrati on required fo r 
Tm determination render the method limi ted . Improvements may fo ll ow by impro in g compl ex 
solubility by experimenting w ith alternati ve buffe r content , or perhap engineering a more 
soluble CRD-BP variant by geneti cally fusing a tag such a Fh8 or G T. 
4.2.4 CRD-BP KH l to4 protein crysta l 
Crystalli zati on of RD-BP was fir t attempted u ing our lab 's ex i ting \\-i ld-type. fu ll-
length RD-BP plas1nid con truct and standard prote in produ ti on protoco L v. hercb) a 
denaturing prote in purifi cati on scheme is empl oyed and refolded by removing urea \\ ith a 3-
stage buffer exchan ge process. ll owever, re fo lding in the di a lys is units appeared to have an 
effective concentrati on limit o f 0.7 mg/ml w ith additional prote in prec ipitating out of so lution. 
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ombin d ith increa d difficult con ntrating (clogg d filter-concentrator ) wh n thi limit 
wa approached, thi tandard pr parati n method wa det rmin d to b un uitable for cry tal 
pr t in pr parati n . dditionall ~ r g d mea ur , a 15 ml denatured ample at 0.7 mg/ml was 
nt to r. tr nadka' laborat ry at th m er it f riti h olumbia X-ray crystallography 
facilit wh reattempt to refold the protein ia dial al o fail d for imilar rea ons. 
I d cid d t con truct an alternative construct whereb th RRM d main wer removed 
(figur 4.11 ), a th re are large flexible region connecting the RRM domain to the Kl-11 to4 
RNA-binding module that l rea oned may affect the ability tore~ ld by our standard method . A 
PCR amplicon co ering th KH I t KH4 d main r gion wa generated for use in ub-cloning 
and pro ed t b th e pect d ize ( 1,122 nt) and of high purity as determined by agaro e gel 
analy i (figure 4.11 A). Both the D A in ert and p 41 c( + ) pia mid vector were ucce fully 
dig ted with d I and Hindlll producing ticky end and ligat d with DHSa .coli 
tran formant able to grow on LB-agar kanamycin plates. Pre ence of the KH 1 to4 insert wa 
confirmed u ing a digest analysi again on mini-prepped plasmid amples from uccessful 
transformants (figure 4.11 B). 
Expression in BL21 E .coli cell s successfully produced protein with imilar purity and 
expression levels a with the full-length con truct. Direct ize com pari on of the full-length 
CRD-BP (67 kDa) and KHlto4 truncation confirms the ab ence ofRRM1 and RRM2 domain , 
appearing at the expected 43 kDa (figure 4.1 2A). However, dialy is-ba ed refolding u ing our 3-
stage buffer exchange method again proved limited to appro imately 0.7 mg/ml. implying that 
the limiting aggregation factor is likely present within the KH 1 to KII4 region. 
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Figure 4.11. Plasmid pET41c(+)-CRD-BP KH1to4. (A) DNA agaro c gel analysi s ofPCR 
produ t panning d main KI I 1 to KI 14 of ' RI -B P gene. (B) Endonuc lease di gc t anal) ' is of 
pE 41 c(+)-CRD-BP KI 11 to4 using Ndel and J li nd Ill rc 'Oived on 1.5° o agarosc gel. Uncut and 
cut v ctor band can he seen at 5 kh and in ert DNA hands appear.' at c~pcctcd I I ~- hp (C ) 
Pia mid map of pET41 c( -+ )- ' RD-BP KJ II to4 . 
ati e prot in purifi ati n a ub equentl pur ued a de cribed in 4.1 .8. Fraction 
purifi d b thi meth d ntain d ignifi antly le protein. with mo t of the protein in th 
111 lubl fra ti n found in th p llet (figur 4.12 ). imilar r trictive re ult for native 
purificati n f R - P in r c mbinant tern ha e been dem n trat d previ u ly with 
Pr kipcak e/ a/. ( 199 ) and Du era/. ( ... 00 ) that pecificall indicat that most of the protein 
nd up in th in lubl fraction . 
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Figure 4.12. Comparison of native and denaturing KHl to4 protein purifications. (A) 
Denaturing protein purification - refolding facilitated by gradual removal of ur a via dialy 1 m 
3-stage buffer exchange cheme. Below: UV -spectrum of protein ample showing dominant 280 
nm peak; 260/280 : 0.61 (B) Native protein purification with imidazole eluti on. Below: UV-
spectrum of purified protein howing dominant 260 nm peak: 260/280: 2.08. 
While the reduced yield wa not entirely limiting. endogenous bacteria RN \\ere found 
to co-purify with the protei n in large amounts a ' determined by UV -spcctroscop; (figur 4.12B) 
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whi h uld lik 1 interfer ith r tallization and reduc lubility . pproache including 
n n- pe ifi RNa e uch a b nz na e tr atment t rid th pr tein f R A were c n id r d, 
ho e r c mbin d ith the 1 wer ield f thi method , periment c ntinued t find anoth r 
approach ith uperior re ult . third approach ca ll ed n- lumn r [! !ding was tri ed. llere th 
denaturing purificati n tep en ure olubili ation of the large oth rwi e in oluble fraction of the 
protein . Hi -tag binding to the i- T co lumn occur in M urea, which i then lowl y reduced 
to 0 M urea vera m th gradi ent prior t elution u ing co ne ntrated imidaz le a d scrib din 
cti n 4.1. 9. R uJ t fr m thi m thod v...e re e. ce llent. ff the co lumn. protein concentration 
approach d 2 mg/ml with n 1gn of pr cipitation. As we lL optimization of the proce s 
e entuall y1 lded >95°/o purity ample vvith mor tringent wa h-step . and furth er 
concentration up to 10 mg/mJ proved imple with no clogged filters (figure 4.13 ). To en ure 
this alternati e method v... a providing active protein till capable of binding RNA, fluore cence 
polarization (FP) technique was emplo ed. Thi technique expl oits the time-scale whereby a 
fluorophore re-emit plane-polari sed light and can detect the increa ingly random di tribution of 
un-bound, free tumbling labelled-RNA compared to protein-bound RNA measured a anisotropy. 
A fluorescein-labelled KRAS RNA probe based on previou EM A work (2.3.2) wa 
synthesized by IDT and used to as ess its interaction with the CRD-BP KH1to4 protein ampl e. 
It is evident according to the FP analysis in figure 13A that unlike the BSA negative bind ing 
controL the degree of anisotropy with full-l ength CRD-BP and the KHl to4 con truct increase 
considerably with concentrati ons similar to those seen in M A e ·per iment . Indeed upon clo e 
inspection. it can be seen that the KH 1 to4 vari ant appears to bind the RN substrat \\ ith higher 
affinity than the natural form . Calculation of the di . oc iati on con tant from an RN bound 
fraction plot (fi gure 4.13B) reveal a 3- fold increase in substrate arfinity for the Kill to4 variant 
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( 11. ± 7.1 nM mpar d lo 9 .6 ± 4. nM), po ibl implicating the RRM domain as a 
re tri ting 1 m nt in binding. 
A 200 
-- ---
~ 
.s 150 
>-
a. ~ 0 
~ ~ 0 
VJ I c: 100 I -f '-- CRD-BP Cll 
Q) __.,_ KH1 o4 
u 
c: --BSA 
Q) 
u 
VJ 
Q) 
... 
0 50 ::I 
u:: 
0 ~--~----~----~----~--~ 
0 :?00 400 600 800 1000 
Protem concentration (nM) 
c RD-BP KHJt 4 
B 
kDa 
- 250 
- 130 
- 100 
-70 
- 55 
- 35 
-25 
- IS 
'0 
c 
:;J 
0 
.0 
~ 
z 
a: 
c 
0 
; 
u 
ctl 
._ 
u. 
1 2 
08 
06 
I 
• £l 
04 I 
02 
/ 
/ 
/ 
/ 
CRD BP Kd 311 8 1 1 
_.__ KH 1 to4 Kd=93 6t34 1 
o ~--~----~----~----~--~ 
0 200 400 600 800 1000 
Protein concentration (nM) 
D 
Figure 4.13. CRD-BP KH1to4 construct binding activity and protein crystal. ll fi gure 
pertain to the CRD-BP construct containing only the KHl to KH4 domain binding module, 
excluding theN-terminal RRM 1 and RRM2 domai n . (A) Fluorescence pol ari zation/ani otropy 
RNA-binding activity as ay. CRD-BP KH 1 to4 confirmed to bind fluore cein-1abelled KRAS 
RNA probe u ing fu ll -length CRD-BP as a po itive contro l and B A a a negative binding 
control. (B) KH1to4 and fu ll -length CRD-BP Fluorescence ani otropy data u ing KR S RN 
probe converted to fraction RNA bound plot for di sociation con tant determination. (C) 0 , -
PA analys is of co lumn-refo lded RD-BP KJ I 1 to4 protein. (D) Po ' itive hit protein Ct). tal of 
Kl I 1 to4 in 0.4 f.! I mother liquor. 
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Perhap a fun ti n f the RRM d mam i t confl r enhanc d electivity .G r a giv n 
R ub trat , a ting a n gati e r gulat r f binding in om circum tanc . 1t ha be n 
d m n trat d that the RRM d main d n t c ntribute t a l wer Kd, h we r their conservation 
acr th ari u orth l g impli a u eful functi n, n f which c uld be the negative 
r gulation po tulat d h re. umer u Kl I It 4 pr tein preparation were delivered to Dr. 
tr nadka' X-ray cry tall graphy lab rator for cr tallizati n trial . lli gh concentration 
ample f I 0-11 mg/ml pr t in \\er hipped from our lab [i r direct entry into crystallization, a 
well a a 1 mg/ml prcparati n v.here a ubscquent thrombin digest allow d for removal of the 8 
X hi -tag pri r t c ncentration and cry tallization . Two trial cone ntration were etup (4 mg/ml 
and 8 mg/ml) B r cry. tal crcening v.ith three eparate crystal cr ening kit : Qiagen Ia ic 
uite, Qiagen P T uite. and Molecular Dimen ion JCSG-Piu ™ MD1-37 uite. N protein 
cry tals were produced from amples in our original buffer (20 mM NaH2P 4· 200 mM Na L 
pH 7.4), ho e\'er a ingle cry tal wa achieved that wa dialyz d into 0.2M lithium ulphate, 
0.1 M Tri - I pH 8.5, 40°/o v/v P G400 buffer and confirmed to fluore cc under V li ght, 
indicating that it was comprised of protein (figure 4.130). Unfortunately the phereolyte type 
crystal bore un uitable characteri tics for further study. including a twinned structure and thu no 
diffraction pattern was obtained despite the lengthy attempt. Further attempt to reproduce th 
crystal did not prove successfuL however data obtained from subsequent pre-cry tallization 
optimization tests did reveal some u efu l information pertinent to future attempt at crystalli~:ing 
thi s protein (figure 4.14 ). Buffer factor including sa lt, pH. and the buffer chemical it elf v.erc 
varied in a thermal aggregation experiment, whereby stabe lizing elements \\ere ~ ystematicall) 
tested for ability to prevent non-specific protein interaction. From these experiments conducted 
at the trynadka laboratory, we discovered that KI II to4 CRD-BP is ' tabili7 ~d significant!) b) 
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lower pH; pH c nferred a profound tabilizing ffi ct. High alt up t 500 mM Na 1 wa also 
d termin d t al 111 r a the temperature f aggr galion, albeit to a I r e tent than the pH 
ffect, and th f~ t fthe alt ~a al dep ndent on the buffer y tern u d. The pecific 
buffi r h i e had a tr ng impact n protein tabilit a w lL with M providing the 
gr at t d gree of tabilizati n a cording to the temperatur of aggregation p riments. Future 
endea r int cr) tallizing ' RD-BP will ertainl benefit from this kno ledge, a it is likely an 
id al torag and tran port buffer. a \Veil a being optimal for cr tallization trial . 
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Figure 4.14. Thermal aggregation buffer optimization for CRD-BP KHlto-1 . ( ) Prot in 
aggregation a a function of temperature in various buffer olution .. Data \~a produced from 
pectro copy experiments conducted at the Strynadka X-ray cry ' tallograph) laborator) . (B) f agg 
(temperature of aggregation , defined as temperature at v ... hich 50° o or protein is aggregated) 
calculated from aggregation intensity trace for CRD-BP in different buffer sy tems. 
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Chapter 5 
General Discussion 
5.1 Proj ect general overview 
he I KZ family f RN -binding pr t in include RD-BP a well a it ortholog u 
pr t in (IMP K , ZBP 1, and g l RBP ra) have multifaceted rol e including intracellular 
mRN 1 alizati n, nucl ar e p rt f mRN , tran ript tabiliza tion and tran lati nal 
regulati n. Their functi n i achi d thr ugh the interaction of 2 N-tenninal RRM domains and 
4 -t rminal hnRNP (heterogen u nuclear rib nucle protein)-K-homology domain (KH 
domain for hort) which functi on in combinati n to bind a vari ety of mRN A targets including c-
m yc, LI MDRl , I F-II among t other (Pr kipcak et al. 1994; oubi i et al. 2009; paranese 
and Lee 2007 · iel en et al. 1999). CRD-BP is spatiotemporally regulated, nonnally expre ed 
during the first 12 week of embryo gene is and disappearing into complete absence or scarcity in 
adulthood (Leeds et al. 1997). Human CRD-BP (IMP-1) i often re-expres ed in many cancer 
and has been dem onstrated to be important for tumour cell urvival as ummarized by Bell et al. 
(20 13). 
KRAS , a well established genetic driver of many cancers including colon, breast and lung 
tumours has recently been suggested to be an important oncogenic 1nRNA target of human CRD-
BP, increasing expression of KRAS protein in colon cancer cell line (Mongroo et al. 2011 ). 
Furthennore, while many studie focus on mu tated ga in-of-function KRA variants uch a 
KRAS 12v which con titutively activates downstream targets such a the PI3K, FR, and 
MAPK pathway , gene amplifica tion and overexpr i n of wild-type KRA al o a o iate with 
aggre iveness and poor re ponse to anti- R therapy in col r ctra l, ndometrial and non-
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mall c lllung cane r (Valtorta tal. 2013; Birkeland tal. 2012; a aki et al. 2011). De pite 
num r u and di attempt t targ t th KRA pr t in u ing mall molecule , antioncogene 
ribozyme , and p t-tran lational modification inhibit r , th re remain no effective mean f 
treatm nt D r KRA dri n cane r (r iewed in J ancik et al. 2011 ; llin et al. 2014) . Hence, 
th r i ne d :tl r n 1 appr ach t an ti -KRA therapies. The goa l of thi inve tigation wa to 
confirm and furth r charact 1ize them lecular interacti n betw een RD-BP and KRA in vitro 
a in cell , a well a pearh ad an att mpt t inten-upt the RD-BP-KRA mRNA interaction 
pecific anti en e ligonu l tide molecule . 
5.2 M apping of the CRD-BP bindin g sites on th e cod ing region a nd 3' UTR of KRA 
mRNA using th e electroph or etic mobili ty shift assay 
Determining the binding potential ofKRA mRNA and determining a smaller segment 
of the mRNA molecule that retained affinity for CRD-BP was an important endeavor. It offered 
the opportunity to confinn previously reported results regarding the interaction between KRA 
mRNA and CRD-BP protein using an alternative experimental method, and also to nan·ow down 
a more precise sub-region containing the nece ary sequence infonnation required for binding. 
Knowledge of a minimum binding sequence not only contributes to the goal of detennining an 
mRNA target consensus sequence, but opens up options for other methodologi es to tudy CRD-
BP-KRAS mRNA interaction. For in tance, to use the flum·e cence polarization spectroscopy to 
study nucleic acid-protein interaction, nucleic acid mu t be larger than 90-mer (Hafner eta!. 
2008). 
Tlu·ough the use of PCR and in vitro transcription, [12P] -labelled fra gment f KRA 
mRNA were synthe iz d and tested for RD-BP affinity u ing M f the ~ i cour 
fragm nt ach appr imat ly 200 nu leotide in length fl ur were di c v r d to bind with 
m d rat affinity in th nan m lar rang ( ecti n 2.3 .2). Thi finding confirmed previou ly 
publi h d r ult that indi at IMP-1 (9 % id ntity t RD-BP) bind KRA mRN in the 
coding r gion and al the 3' TR (Mongr eta/ . 2011) but al o lucid a ted multiple 
attachment ite ithin both fthe e mRN reg1 n . umer u RD-BP-KRA mRNA 
atta hm nt it 1 n t urpri ing and thi notion i upp rted by Niel en et al. (1999) and 
ik a tal . (2006) wh r 
mRNA and ' TR f 
e eral IMP-1 binding ite were found n the 5' UTR of IGF-Il 
44 mR re p ctiv ly. imilar conclu ion w r drawn regarding 
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FMR1 mRN in which multiple IMP1 protein were ugge ted to bind in the coding region and 
3 TR (Rackham and Br wn 2004 ). 
KRAS n1RNA ub-region ' ' po ed the hi ghest affinity with a measured kD of 
177.9± 18.4 nM, with the other binding fragments : , D and F having at least 2-fold lower 
affinity (figure 2.6). This fragment size compare well to literature defined target (table 5.1 ). 
Further truncation analysi of the KRAS-A sub-region identified ' KRA -A34 , a 93 nucleotide 
fragment which binds CRD-BP with similar affinity. KRAS-A34(b), a smaller 57 nucleotide 
region located near the 3' end of the parent KRAS-A fragment, also retained ability to fmm a 
larger molecular weight complex with CRD-BP, albeit with reduced affinity as detetmined by 
EMSA (figure 2.18). It also became apparent that with the progressive whittling down of KRAS-
A to KRAS-A34(b) sequence length has a general impact on the overall affinity of this RNA 
target and specificity only becomes apparent when comparing RNA fragment f imilar ize a 
inKRAS-A12/KRAS-A34 (92 and 93 nt, respectively - figure 2.13) and KRA -A34(e)/KRA -
A34(b) (57 and 57 nt - figure 2.17 and 2.18). Indi ations that other targ t may follow thi 
pattern stem from a imi1ar truncation study u ing P I, a KH domain ntaining prot in in 
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hila r lat t R -BP, h r additi nal qu nee flanking a c r lement ntributed to 
a l r Kd ( hmi l t al. 2 
Table 5.1. VI KZ mR tar t lZ 
RNA-binding protein mRN target Target size (nt) Reference 
IMPl I -II 162 Niel en(l99) 
CRD-BP -myc 182 Bern tein ( 1992) 
IMPI Tau 600 Atla (2004) 
ZBPl ~-actin 54 Farina (2003) 
IMPl FMRl 7 Rackham (2004) 
IMP- I P BP 22 Patel (2005) 
YglRBP gl ( ~) 340 Mowry ( 1992) 
IMPI Hl9 17 Runge (2000) 
PSI II 69 Siebel (1990) 
KRA - 4(b) RN quence wa analyzed u ing mfold RNA-:fl lding oftware to a e 
po ibl tructure recogniti n in the :fl nn of tern I op m tif: . tructured core of the RNA 
mol cui c mbin d with inclu ion of putati binding I ment id ntifi d fr m literature: 5'-
- ' 5 ._ 
' 
C GACA -3 · and 5'- AC - ' (2.3 .4) ub equently a ll owed the 
identification of a 44-mer fragment u ing flu re cence polarization pectro opy (Patel eta!. 
2012 Git and tandart 2002, Ro eta/. 1997). Development of the KRA -A34(b)-ba ed 
fluore cence polarization probe wa in trumental in the binding capacity a e sment forth 
truncated RD-BP KH 1 to4 protein, a well a o ther molecular endea or in ur lab ratory 
including mall molecule inhibit r cr ening. Notably none f the mention d quence I em nt 
appear to be able t bind the protein by it elf, how ver it ha be n propo d that they do 
contribute in tandem with other elements, to a hi gh affinity interaction lik ly ea h mediated b a 
eparate KH d main opening the pos ibility of man combination binding ·cqu nee ( hao eta/. 
2010) . 
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Whil a mall ub t f qu nee lement pr p d do help explain KRA binding, 
many r c gniti n elem nt pr claim d :fl r th VI KZ pr t in family don t xplain KRA -
4(b) binding ith RD-BP. tably, a fa irly con i tent n ti n i that RNA target contain 
high f nu 1 id c ntent and it and tandart (2002) howed that ind eed poly- /p ly-U 
h m p lyn1 r ar m re capabl of c mp ting away Vg lRBP-VL _. mRNA interaction in vitr 
KRA - 4(b) attribute nl y 44% f it c mp ition to uridin or cyto ine, an alternative 
m chani m than imply high c ntent mu t be re ponsibl e forth binding of thi region. It i 
lik ly that multipl m echani m xi t forb th binding and granul e fo rmation in vivo. KRA a 
well a c-myc both app ar to form a hom dimer with an intermedi ate band between free RNA 
and the larger compl (figu re 3.2) while ZBP1 how no uch intennediate band and 
corre ponding ize exclu ion chromatography data al o ugge t a monomeric specie ( hao et 
a!. 201 0). The ame group al o found no cooperat ivity with a Hill coefficient of approximately 1, 
in contra t to KRAS RNA binding (Hill coeffic ient approximately 1.9 - see figure 2.8) as well 
binding to c-myc and CD44 RNAs (Barne et al. 20 14 ). Krissinel and Henrick (2007) computed 
a free-energy of dis ociation calculation and al o suggest that homodimerization of VI KZ 
proteins is unfavourable and thus the phenomenon may be an artifact of the experimenta l 
conditions used in EMSA as suggested previou ly by N ielsen eta!. (2004 ). 
5.3 Testing the specific anti-sense oligonucleotide inhibitors against the CRD-BP-KRAS 
mRNA in teraction in vitro using EMSA 
The benefit of eliminating RD-BP interacti n wi th its various target mRNA are largely 
apparent (Iatmidis el a!. 2005 ; Elcheva eta!. 2008; Mongroo eta!. 2011 ), however IMP 1 
knockdown in T47D and MDA23 1 human breast cancer cell cau d increa ed in a iven due 
t r du ed I alizati n f -cadh rin mRN ( u t a!. 2011) . -cadherin, along with another 
RD-BP target ~-actin ha a c ll-cell adhe i n r le, fannin g the core structure of focal 
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adh ion that reduce migrati n and mitiga te inva ivene (Berx t a!. 1995; Birchmeier and 
Behr n 1 94) and becau e IMPl i able t bind and tran Jationally repr ss E-cadherin mRNA, 
I KZ pr t in may ha anti-pr l i~ rativ function a well. Furthenn re, direct knockdown of 
RD-BP in human K562 Jeuk mia cell r ulted in increa ed cell proliferation (Liao et a!. 2004 ). 
Whil complica ting a th rap utic trategy con id erably, the mixed nature of CRD-BP ' pro-
gr wth and anti -gr th fac tor ju tifie the target- pecific approach our lab pur ue , as opposed 
to imply trying to down-regulate or otherw i e inhibit CRD-BP function entirely, although many 
cancer would till r p nd po itively from a general inhibition of RD-BP due to increased 
chemo- en iti ity ( raig eta!. 20 12). A target specific approach would allow a per onalized 
treatment of CRD-BP-po itive cancers, preferentially driving down pecific oncogene 
expre s1on. 
Work on identifying effective, pecific molecular inhibitors of the CRD-BP KRA 
mRN A interaction was an ultimate goal of this re earch and the attempt was spearheaded by 
designing multiple 23 to 24-mer DNA-based anti - ense oligonucleotide molecule that were 
complementary to sub-regions spanning the entire length of the KRAS-A region in a contiguou 
fashion (Table 2.8). EMSA assays were used to test the effectiveness of each oligonucleotide at 
breaking the interaction in vitro, as evidenced by the loss of super hi fted [32P]-labelled b und 
fraction RNA in complex with CRD-BP; an approach adopted from King eta!. (2014) . By 
titrating increasing amounts of anti-sense oligonucleotide mol cule in to a CRD-BP-KRA 
mRNA binding reaction, from 1 to I 000 fo ld molar excess, two candidate were re ealed a 
good molecular inhibitors. Labelled a SM-6 and M-7, each pr ed c n id rabl m r efTe tive 
than any f th th r candidate m lecule , panning KRA nucleotide po ition 116-138 and 
1 9-161 f the ding r gi n re pectiv ly (figure 2. 19). M-2 di played virtually no ability to 
c mp t away th binding int racti n a det rmined by EM and i considered evidence of 
high quenc p cificity £ r int rrupting th KRA - RD-BP interaction under the e 
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e pcrim ntal c nditi n figure 2.2 1 and 2.22 lane 13- 17). omplem ntary annealing of 
the olig nucle tid t th M-6 and M-7 p ition ffectively rna ked the RNA nucleotides in 
the KRA - tran cript and thu pre nt d proper RD-BP acce s to the binding sequence. 
Altemati ly, a ignificant RN tructure change induced a a re ult of the oligonucleotides 
binding c uld al explain the effect, however thi model require that RD-BP recognize 
pecific RNA tructural element a a mechani m of binding which i as of yet unconfirmed. 
Regard! of the mechani m, the re-appearance of this region a a potential CRD-BP interaction 
ite further support earli er KRA mapping finding which sugge ted that the KRA -A34(b) 
region covering nucleotide positions 129- 185 fa lls within the M-6 and SM-7 coverage, and 
likely contains important binding information (refer to figure 2.24 for graphic representati on). 
The SM-6 and SM-7 DNA molecule were sub equently used as po itive controls for inhibitor 
of the KRAS-CRD-BP interaction in small molecule screens, as well as erving a potential 
proto-drugs in cell-based KRAS inhibition as ays with SM-2 continuing to serve as a negative 
control (Wang et a!. 201 5). 
5.4 Examining CRD-BP KH domain requirements for binding KRAS mRNA in vitro 
VI KZ fan1ily of proteins contain 2 N -terminal RRM domain (labelled RRM 1 and 2) 
and 4 -terminal KH domains (labelled KH 1 through 4). The imporianc of d tennining th 
sub-set ofKH domains required for high affinity bind ing to KRA mRNA t m from a ba ic 
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1en p r p ti e in und r tanding th n genic function f RD-BP. uch kn wledge i al 
1m t1ant in a plied re ar h a it pr id riti cal in[! nnati n for the de ign of p cific 
inhi it r again t th n g ni c fun ti n f RD-BP. differ nt RN tran cript appear t 
ha e dif£ r nt KH d main requir m nt il r bind ing, m lecul efil cti e at bl eking a pecific 
KH d main rna pr dictab l nl affe t a ub et f RN targ t . Kn wledge f th unique KH 
d main r qu irem nt il r hR m I ul w uld all w Ia ifica ti n f the vari u RNA 
and p tentiate pr di ti n f th multiple targ t a given inhibit r r c mbination thereof w uld 
ha 
T appr ach th pe ific KH d main requirement il r RD-BP t bind KRA mRNA, 
multipl e pla mid n truct containing RD-BP variant each harbouring either a ingle XX 
mutation in n of th il ur KH domain (KH 1, KH2, KH3 and KH4 ), r combinati on f 2 
GXX mutation -each imu ltaneou ly pre ent in 2 eparate KH d main (KH 1-2 , KH 1-3 , 
KH 1-4, KH2-3, KH2-4 and KH3-4) a de cribed in greater detai l ( ecti on 3.1. 1 ). Each XXG 
motif exi t a a fle ible loop between the 1st and 2nd a-helix f type I KH domain and directly 
interact with the RNA target of KH domain containing protein ( ri hin eta!. 2001 ). Mutation 
of the fi r t glycine to an a partate (table 3.1) ha previou ly b en demon trated to ab li h the 
ability to bind RNA, pre umably through teric hindrance from the larger ide chain, or from 
charge repulsion - both a partate and the RN backbone po e negative charge (Lewi ct a/. 
2000; Lin el a /. 1997; Paziewska eta/. 2004; Fenn eta/. 2007; Jone. and chedl 1995). 
Furthe1m ore, limiting the mutation to 2 XX motif: i rationa lize by the fact that no R A 
target ob erved thu far ha been demonstrated t bind ith d1ything le , than 2 Kll domain,. 
ach mutant protein wa then subj ected to M binding a , ay u ·ing the KR , - probe and 
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th f£ ct ach mutati n c mpared t wild -type then a d. Th c-myc RD (coding 
r g1 n d t rminant - wh r RD-BP bind ) RN wa utilized a a po itive contr l. 
u ing any f the ingl RD-BP KH mutant al ne abrogated th ability f 
RD-BP t bind th [ 2P]- lab lled KRA RN alm t entirely (fi gure .1 and 3 .2). Mutation in 
KH 1 wa r p at dl een t impact the binding t a lightl y le er ext nt, but wa till required 
£ r th high affinity binding di p layed by th wi ld-type control. Hollingworth et al. (201 2) 
imilarly c n lud d that th K.H l d main played a mitigated role forK RP RNA binding (an 
RNA binding pr t in imilar to ZBPl in the tudy, c ntain.ing 4 type I KH domain ). The KH4 
mutati on nth th r hand appeared to ha e the large t effect, independently reducing the bound 
fra ti n of RNA aln1o t entirely. Intr duction of a econd mutati on in any combination of KH 
domain proved ufficient to entirely inhibit any trace of binding under conditions u ed in the 
electrophoretic a ay . This re ult was expected given the impact of a single KH mutation on 
KRAS binding. 
5.5 IP-qRT PCR analysis of CRD-BP KH domain requirements for KRAS mRNA 
binding in HeLa cells 
Complementary expe1iments using RD-BP-FLAG immune-precipitation and RT-qPCR 
also strongly agreed with the KRAS EMSA data. Mammalian expression vectors (pcDNA) 
harbouring each of the KH mutant variant genes were transfected into HeLa cell and ubj cted 
to anti-flag CRD-BP pull-down combined with RT -qPCR u ing KRA p cific primer ( ction 
3.2.3 ). Results revealed a similar pattern as with EM A experiment , with ingle and double KH 
mutants displaying relatively less association with KRA mRNA in cell than the wild-typ fOJm 
(P=0.01) . Notably w hile the KHI mutant precipitated appro imately 1 0-fold le KRA mRN 
compared to the wild-type, the other single KH mutant were nearly I 000-fold I , miiToring th 
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pre 1 u ly di u ed M r ult (figure 3.5). Intere tingly the conclu ion drawn from both 
th P rim nt upp rt an ti n that all KH d main are requir d for RNA binding, at lea t 
to th high affinity r gi n f KRA mRN amined in thi tudy. 
Thi nclu i n i ech d wi th g lRBP rep011edly binding the VL equence in Vg l 
mRN u ing all £1 ur KH d main ( it and tanda11 2002). imilarly, IMP-1 truncation 
e p riment by iel n el a!. (2002) dem n trate clearly that neither th RRMl -2, KH 1-2 or 
KH -4 dido main were capable of hifting H 19 RNA u ing M A, with the minimum 
requir ment being all fi ur KH domain . In th arne study, removal of any KH domain also had 
inhibitory effects on granu le formation in IH 3T3 cell . Bridging the evolutionary gap to the 
Dro ophila ortholog P I, once again only the pre ence of all four KH domains wa conducive to 
RNA binding, and an extended interaction urface along the tandem KH domain wa propo ed 
that highlighted the inter-KH domain geometry as in important element in binding (Chmiel et al. 
2006). In contra t other group have focussed on the KH3-4 didomain and show that KH3 and 
KH4 are nece ary and sufficient for binding of some mRNA targets (Farina eta!. 2003; Nielsen 
eta!. 2004; Chao eta!. 201 0) . Intere tingly, Barnes eta!. (20 14) wa able to how that 
simultaneous mutation in KH3 and KH4 did not abrogate binding ofCRD-BP with CD44 
mRNA, yet taken together, the culmination ofCRD-BP/VICKZ experiments focussing on KH 
domain involvement in RNA binding strongly suggest a sub trate specific model of binding with 
perhaps two classes: i) KH3-4 didomain dependency and ii) KH 1, 2, 3 and 4 dependency. 
5.6 Structural analysis of CRD-BP KH va riants containing point mutation in the 
GXXG motif at the KH domain 
As the introduction of mutations in a protein can ha drastic folding on~ equen ·e for 
a/~ topo logy, an important feature of the RD-BP KH mutation e pcriment wa tn.1 ·tural 
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anal i u ing circular dichr i n1 ( D) pectr polarim try of each mutant variant. In ection 
4 .2. 1 th D p tra forth wild-type RD-BP, ingl KH mutant and double KH mutants can 
b en t ary minimally b tw n the pr tein wi th only mall variation predominantly at 
a 1 ngth b low 205 nm and high r than 23 0 nm (fi gure 4. ). ach RD-BP mutant wa 
canned time ( accumulati n ) and xperiment complet d in triplicate; the re ulting far-UV 
p tral cm s ar repre ntati e of 24 can and while the averag d spectra did how very small 
de iati n b twe n ampl , the v ra ll [i ld i lik ly identical and within enor of pi petting. 
H n th D e idenc for pr per KH d main fo ld ing strongly sugge t that the ob erved 
change in KRA affinity with the ari u GXX mutations ( ection 3.3 .1) were not due to 
perturbed global tructure or de tabilization of neighboring CRD-BP domains and further 
validate the relati ve role for each KH domain in binding KRA mRNA. 
GXXG t GDDG mutation in the KH3 and KH4 domains within ZBPl (GKKG and 
GKGG to GDDG re pectively, to be more specific) has been demonstrated to not have a 
significant impact on domain structure as detetmined by superimposition of 15N- l H HSQC 
spectra and CD thermal denaturation experiments. In the same paper, all four KH domain in 
KSRP, a related RNA binding protein with hi gh sequence similarity to CRD-BP, were similarly 
shown to maintain structural integrity with the introduction of the GDDG double mutation 
(Hollingworth eta!. 20 12) . In PSI protein KH domains , a highly conserved isoleucine po itioned 
irmnediately adj acent to the canonical GXXG motif was mutated to asparagine, and CD analy i 
of both secondary structure content and thermal sta bility also revealed that no major t1uctural 
changes resulted. Structural tabi lity as ev id nc d from the RD-BP mutation periment 
presented here and from other groups, strongly sugge ts that whi le the ubiquitou G .~ XG loop i 
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ab lut ly riti cal :D r tabl RN int ra ti n, it doe n t app ar to contribute to the ttuctural 
integrity fKH d mam . 
5.7 Monitoring ligand-induced conformational change in full-length CRD-BP and the 
KH1to4 truncation variant 
Pr t in c nfi rmati n change are an inherent property of many nucleic acid (NA) 
binding pr tein u h tran cripti on fa tor , whi ch can undergo large ca le shift in a -helical 
content upon binding , uch a REB - a b/Zip type tran ctiption factor that bind a 32 bp 
D equ nee (M 11 t a/. 2002). D pectro copy i a choice technique for anal yzing 
conformation change in biomolecules, e pecially proteins where concentration and stability 
re traint can be limiting factor . CD pectro copy also allow the examination of secondary 
tructure hift in many pro teins with regard to binding of li gands, including small rnolecul , 
bio-polymer and nucleic acid and is u ed extensively in thi area (Gray 201 2). As CRD-BP is 
an RNA binding protein, we investigated the possibility of it undergoing a conformational hi ft 
in secondary structure upon ligand interaction with KRAS RNA. This avenue, if fruitful would 
open up additional mean of as essing sequence specificity for CRD-BP by CD monitoring 
secondary structural changes associated with high affinity RNA target , as detenn ined by EMSA 
or other methods. Fmihennore, characterizing CRD-BP structural changes upon binding would 
complement crystallographic and NMR data with and without RNA pr sent for the entire 
VICKZ family of proteins. 
To approach the assessment of a possible RD-BP stru tu ra l change upon RNA binding, 
far-UV (190-250 nrn) D spectra were gathered for both th wild-type protein and a KH I to4 
truncated mutant containing only the fou r KH domain RN A binding module . Truncated RD-BP 
wa generated for thi s puJ1JO e, as it ha been how n that the RRM domain d n t b th m 'lve 
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bind RN t any ap r ciabl affinity (mM rang ) and thu it wa rationalized that pre nee of 
th RRM domain w uld lik ly nly mitigate any change in D ignal ( it and tandart 2002 · 
1 en t a!. 2002). r both RD-BP ariant a library of potential RNA targets were titrated 
int lution at pr t in:RN m lar ratio varying from 16: 1 t l : J and ub equently catmed 
u ing a J a co J- 15 D p ctr polarimeter t arch for evid ence f econdary tructure 
change . Due t th inherent D acti ity f nucleic acids, oluti ns of the RNA sub trate alone 
were al cann d and the pectra ubtract d from the protein-RNA c mbination pectra u ing 
an in-hou ftware (Ja co pectraManager) o a to i olate changes a sociated with RD-BP. 
Examinati n of th various full-length and KH lto4 RD-BP pectra revealed intere ting 
finding . Fir tly, both ver ion of CRD-BP di played a rapid reduction of CD ignal at the 208 
nm and 222 nm peak upon addition of RNA (figure 4.4 and 4. 7). The change in the pectrum 
equat s to a reducti on in ov rail a/~-topology, achieving a more unstructured fonn. uch change, 
while le s comn1on among NA-binding protein (as opposed to undergoing an increa e in 
secondary structure) ha been reported previou ly for the human tt·anslin protein. Translin binds 
both RNA and DNA targets with a particularly high affinity for mi crosatellite repeat and 
telomeric repeats and reduces in total a-helicity from 67% to 50% upon binding as detennined 
using CD spectroscopy (Jacob et al. 2004; Kaluzhny eta!. 2005). However unlike translin, the 
reduction in total a-helicity in CRD-BP was mo tly non-specific, as non-binding negati e control 
RN As were also able to generate the effect. 
Upon close exmnination of the protein-RNA CD spectra howe er, there wa a trend for 
the hi gher affinity RNA to more effectively induce the lo s of a-helicity at equi alent 
concentrations (figures 4.5 and 4.8). Thi wa the case for all te t d RNA , and th ere uJt 
suggest that an equilibrium exists between bound and un-bound RD-BP conD nnational form , 
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with high r affinit targ t hifting RD- P t a b und tate m re readily. Howev r becau e the 
rall f£ t a g n rall y n n- p cific, it i lik ly that RD-BP i capabl e f tructurally 
pr rganizing it elf in the pr nc f any R prior t ttling d wn n a high affinity 
u nc , p rhap ~ r 1-dim n i nal annmg r ther purp 
. lnde d th r nucleic acid-
binding pr t in ha be n h wn t ha e th pr o d n n- p cifi c pre rganiz ing capacity, 
u h a th eukar ti c a t tran cri pti n fa t r 4 in which n r lati n wa vid ent betw en 
the ub tr t affin it and ind u ti n [ in r a ed a-heli city. The reported increa e in N4 
a-heli it did h e er ar fr m 22-5 %depend ing n ub trate binding affinity, mu ch like the 
ca app ar t be ~ r RD-BP ( han cl a/. 2007). 
De pit th larg change in D ignal, it till cannot be aid w ith ce1iainty that RD-BP 
actuall y change tru tural ly upon RN binding becau e imiJ ar effec t are ob erved when 
c mpl e e begin to precipitate or aggregate. A Patel eta!. (20 12) reported a reducti n in ZBP 1 
protein olubil ity when bound to RNA, it i po ibl e that the ob erved reduction in tructure 
pre ented here could re ult from micro-precipitation, aggrega ti on, or granule format i n, although 
no precipitate wa detected after centrifugation of the sample ( orrea and Ramo 200 ). 
Furthermore, hmiel el a/. (2006) perfonned imilar experiments with the Dro ophila P I 
protein (73% identi ty, 80% imilarity in the KH 1 to KH4 region) and found no ub tantial 
change in secondary tructure upon binding target RNA, although the D data wa n t hown in 
the published work fo r further cru tiny. Inter tingly, regard le of h w the ob rv d D change 
i occurring, the KH 1 to4 truncation did not appear to have the am ub. trate -pecificity for 
inducti 11 of the a-helical loss, a both KRA -A34 and KRA - 12 at I : I molar ratio w r abl 
to achi eve the effect with equal competiti cnc. (figure 4.7 ), pcrhap. implicatmg the RRM 
domain a binding regu lator . 
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5.8 RRM1-RRM2 didomain a a nega tive regulator of RNA-binding 
I pr P that th RRM1 -RRM2 did main may increa e targ t electivity by functioning 
a a n gati r gulat r f RN binding. Thi wa first evid nt after fluore cence polarization 
binding perim nt nduct d on the KH 1 t 4 truncation protein. The e exp riment 
r p atedly c nfirmed (thi binding a ay wa c mpleted fo r every KHI to4 protein ampl 
deli er d to th B X-ray ry tallography facil ity) that the KH l to4 variant wa able to bind 
KRA RNA with nhan d affinity, wi th a Kd nearly l/3rd that of full -length RD-BP; KHlto4 
Kd = 93.6 ± 4. nM and fu ll -1 ngth Kd = 311.8 ± 67 .1 nM re pectively (figure 4.13B) . While 
RRMl and RRM2 domain in RD-BP are not capable of binding RNA independentl y (Git and 
tandart 2002; iel n eta/. 2002), they may recognize certain equences and affect the KH I to4 
binding module through inter-domain cooperativity. Alternatively they may play a more static 
role providing additional steric restrictions to a lock and key fi t fo r CRD-BP RNA target . 
However finiher expe1i ments with additional RNA targets will be needed to test thi hypothe i . 
If substantiated a regulatory role for the RRM domains may explain the aggres ive clonogenic 
growth of several breast cancer cell lines that have only recently been di covered to expre s a 
KHl to KH4 CRD-BP isofonn (Fakhraldeen eta/. 2015) . 
5.9 Assessing CRD-BP-RNA complex stability using thermal shift analysi 
Stability of a protein is another factor that can change with ligand binding and i oft n 
used as a tool to aid protein crys tal fonnation (Vedadi eta/. 2006) . n incr ase in the melting 
temperature of a protein, or a th rmal shift, i a c mmon mea ure of prot in tability and change 
in Tm are typically measured using either th indire t thenno.Ouor method, whi h u n n-
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P ific flu re nt dy that bind hydr ph bic prot in urface , or the more direct D 
m nit ring of ndary tructur (re iewed in Lavind r tal. 2009). Measuring the D signal 
at 222 nm a el ngth 111 t r pre nlati of a-helical cont nt) over a temperature range allows 
the prot in un:fl lding t be m nitored accurately and a Tm (midpoint of thermal denaturation 
CUI ) an b ub qu ntly calculated fr m the melting curv to compare mutant protein , 
h m g , and al pr t in tability change a are ult of ligand binding (Layton eta/. 2011). 
th u l e pl red tructural analy i revealed no clear way of distinguishing 
wh th r r n t RD-BP wa binding a p tential RNA target, and although a minor correlation 
b tw en R affin it and a-helicity reduction was apparent, and no ligand-induced thermal hift 
xperim nt ha e been reported for VI KZ protein , the D thennal hift a say was pur ued in 
another attempt to de elop a novel method of a se sing RNA affinity for CRD-BP. In theory a 
high affinity interaction may stabilize the protein significantly and be detectable with tlli 
method as a hift in melting temperature. 
Initial work in developing thjs method proved difficult a the solubility of the protein-
RNA complex appeared to reduce with increasing amounts of RNA approaching a 1:1 
protein: RNA ratio and large amounts of precipitate could be recovered from cent1ifugation. An 
increased concentration of the complex compared to the CD structural scanning was nece ary 
however for determining melting temperature, due to the fact that the necessary CD ignal at 222 
nm was so strongly reduced upon addition of the RNA (refer to ection 4.2 .2) . Thus the ratio of 
protein to RNA was kept quite high at 16:1 and 4: 1 with protein con entration at appro imately 
10 JlM. Dete1mination of melting temperature wa accomplished as per section 4.1.6 and th 
resulting Tm 's compared in figure 4.10 where it can be seen that while there was a small incr a 
in melting temperature of 3.5 °C upon addition of KRA -A34 RN , the cf~ twa not 'P ciii, 
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a KRA - 12 a] indu d a imilar change at b th c ncentrati n (Tm = 4 . 9 ° for both) . 
mpar d t th 1 nd tRN (Tm = 41 .5 ° and 42. 0 ° re p ctively) negativ contr 1 
RN h r, ther a a larger in r a e in Tm indicating that th r i m degr e f 
p ifi it . It i tih n ting that hile M wa able t h w that KRA -A 4 had hi gher 
affinit .G r RD-BP th n K - 12 (figur 2.1 ), it wa till! wer than that fth e initial 
par nt fra gm nt K 
n t id nt in th 
betw 
the effect f RN 
- , indicating that K - 12 may have c ntained a weak binding ite 
a a and c uld b re p n ible .G r the imilar Tm change b erved 
. Whil in rea ing th R cl r t a I : 1 rati may b tter di tingui h 
ith different RD-BP affi niti e , the difference in Tm between the hi gh and 
1 w affinity RN can a! be een to decrea e with increa ing concentration of th RNA, 
ugg ting that th m th d b c me even le en itive a more R A i added . Thi ran 
mewhat c unter-intuiti e to our initial e pectation and impli e a non- pecific effect that may 
be explainable by non- pecific RNA binding or ubiquitous lo e m olubility, although 
precipitation in the e ample wa not ob erved . In genera l, thermal hift analy i of RD-BP a 
a method for a e ing R A target affini ty proved limited, a the difference in Tm were very 
mall and did not con·elate well with RNA binding. 
5.10 CRD-BP KHlto4 protein cry tal 
No complete cry tal structure for CRD-BP or any of the VI KZ protein current! exi t , 
with the closest be ing a tructure olved for the KH and KH4 didomain of IMP I b und to a 
mall egment of RNA ( hao eta!. 20 1 0) . Whi le thi tructure has clucidat d an R -lo ping 
binding mechani m, with anti-parallel binding surfa on oppo itc sides of the di -domain, it ha 
n t explained the di ver ity of mRNA target. r been suffic ient to gcn 'rate a c nscnsus bm hng 
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'-"-'l-., .. ,itating th n ed D ram r c mpl te mod 1. For thi purp se, a KH1 to4 RD-
BP truncati n ati ant wa ynthe iz d containing a1nin acid 196 to 566 (N BI R ference 
qu nc e1i ng the D ur KH d main . The preci e po ition of truncation 
h en ba ed n pr 1 u tudi ; the -te1m inu p ition ba ed on the ucce ful hao et 
al. (2010) IMP! cry tal c n tiuct, and the N-t rminal baed on KHl to KH4 functional studies 
iel n t al. 2002) . Phy i 1 gi al rele anc of a KHl to KH4 cry tal structure tems from a 
recent work re ealing the pre nee of a RD-BP plice vari ant in human brea t cancer cell that 
nly contain th K.Hl t KH4 region and i nece ary [! r clon genic growth (Fakhraldeen et al. 
2015). hi kingly thi di covery ugge ts that RD-BP i underrepre ented in many cancer 
tudie a antibodie pecific to the N-tetminal deletion will not detect this CRD-BP i oform . 
Al o the K.Hl to KH4 vmiant retain fu ll RNA binding capacity as well as the full -length 's 
propen ity for protein-protein dimerization (Niel en et al. 2004 ). 
onventional native preparation of the fu ll-length CRD-BP and K.Hl to4 truncation 
yielded low qu antiti es of soluble protein, a complication previou ly reported by Du et al. (2008) 
Git and Stand art (2002) and Prokipcak et al. (1993) as well as high levels of RNA contamination 
(figure 4.12B). presumabl y from endogenously bound E.co li RNA. Furthermore, our lab' s 
existing denaturing protein purification protocol also proved limited to refolding concentrations 
of less than 0. 7 mg/ml as well as issues concentrating to high level . Eventually a denaturing, on-
column refolding method was developed that allowed for both high concentration of RD-BP 
with no RNA contamination ( 4.1.9) and thi s method was used to begin cry tallization tri al in 
collab rati n with the Dr. Strynadka X-ray crystallography laboratory at UBC. Though "'e era! 
attempts produced onl y fa l e positive (mo tly in pho phatc buf~ r) , a single hit with cond ition · 
0.2M lithium sulphate, O.lM Tris pH 8.5, 40% v/v P 400 produced aU -fluorescent cry tal 
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but wa not f high en ugh quali ty£ r further tudy (figure 4.1 3D). Optimizati n experiment 
calculated a t mp ratur f aggregati n £ r RD-BP KH 1 to4 of near 4 1 ° in mo t buffer 
te t d (fi gur 4 .14) which matche perfectly with the melting temperature a determined by D 
th rmal hift p riment ( 4.1 ° ) c nfirming the high temperatur en itivity of this protein 
which rna e plain th diffi ultie encount r d in the e cry tallization attempts. In addition, the 
KH1 -KH2 didomain ha been tudied u ing oluti n NMR, and wa determined to po e 
inherent fl e ibility not pr nt in th KH -KH-4 di domain, poss ibly impacting the ability to 
fonn a table cry tal nucleati n ite (Du et al. 2008) . Whil th cry tal hit wa ultimately 
un uitable for X-ray diffraction data collection, thermal aggregation experiments found that pH 
6, high alt and ME buffer ( 4 .2.4) were all tabilizing factor and are highly relevant for future 
CRD-BP cry tal pur uits . 
5.11 Summary & concluding remarks 
CRD-BP and the orthologou VICKZ protein family member , including human IMP- I , 
have been implicated in several fom1 of cancer, as well as playing criti cal ro le in the early 
stages of embryogenesis (Elcheva et al. 2008; Fakhraldeen et al. 20 15; Joannidi s eta/. 
2001 ;Nielsen et a!. 1999) . CRD-BP achieves its effects ( confening enhanced transcript stability, 
translational regulation, and mRNA localization) through binding nlRNA in the cytoplasm and 
nucleus (Doyle eta/ . 2000) . Despite demonstrated importance in gene regulation and expan i e 
international research efforts, there remains no model that fully characteriz s VICKZ protein . In 
this work the molecular interaction between CRD-BP and target mRNA was tudied, focusing 
' 
on KRAS - a proto-oncogene that when mutated (G 12V) or overe pres ed lead. to 
mi sregulation of cell growth through induction of the downstream effector pathway : mTOR, 
PI3K, MAPK, and FR (Radzioch cl a/. 2010; Birkeland ct a /. 201 2; Va ltm1a ct a!. _0 13; 
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a aki t a!. 2011 ). It ha b n d mon trat d by M ngroo t a!. (2011) that RD-BP positively 
regulat KRA pr i n in c lorectal cancer cell lin . Knockd wn with RD-BP- iRNA 
di play d a 5 % reducti n in KRA in W -480 and induction of RD-BP with a ma1nmalian 
e pr ect r n arl tripled KRA level in LIM2405 cell . Uncoupling RD-BP expr sion 
with KRA ignalling u ing inhibit r m l cu] e may therefore pr ve to be a valuable strategy in 
battling KRA -dri en ca ncer . 
Mol cul ar d tail p rta ining t the RD-BP-KRA mRNA interaction how direct 
binding ith th c din g reg i n and ' TR, a detennined th ro ugh V-cr slinking (Mongroo et 
a!. 2011 ). o further pecifi city of a binding equ ence or indication of actual binding affinity is 
known which prompted the KRA mapping experiments for CRD-BP binding (section 2.3.2). 
KRA mRNA wa found to bind CRD-BP in both th e coding region and 3'UTR using M A, 
confun1ing previous fmdings of Mongroo eta!. (20 11 ). Indeed multiple binding ite were 
di scovered within both regions with at lea t two present in the coding region (1 -185 and 388-
61 0) and two present in the 3 'UTR (568-793 and 97 1-11 55). The hi ghest affinity RNA fragment 
"KRAS -A" covered nucleotide pos itions 1-185 in the coding region and the di sociation con tant 
calculated to be 177.9 ± 18.4 nM. Further EMSA ana lysis of KRAS-A revealed a 57 nucleotide 
minimum CRD-BP binding sequence (129- 185) KRAS-A34(b), as well as fragments posses ing 
virtually no affinity for CRD-BP, confinning orne specificity of binding. The predicted n?fold 
secondary structure of the KRAS-A34(b) ub-rcgion, covering nucleotides 129-185, a well as 
the raw prnnary RNA sequence, will add to a growing library of earchable RN tructure and 
sequences for determination of a consensus bi nding motif for RD-BP. Furthem1ore, th mall 
size of the KRA binding region allow for fu ture fluore c n e p larization ba ed high-
throughput creens for potential mall molecule inhibitors . 
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RD-BP lik many RBP utiliz multiple RNA-attachment ite to achieve high affinity, 
high p cificity interacti n . F ur K-h m logy (KH) domain con titute the primary RNA 
binding m dule, with tw -terminal RRM d main al o pre ent; the precise purpose of the e 
tw domain r main unclear. pecific KH d main requirement for binding appear unique to 
each mRN tran cript, implying that ari u hart binding element on the RNA act in 
c mbination with th pr tein . The high affinity KRA -A sub-region (nts 1-185) wa examined in 
conjunction with KH mutant variant f RD-BP to detennine which if any domain wa 
pr d minantly re p n ibl e for binding. B th M and i1nmune-precipitation coupled with RT-
qP R analy i in H La cell revealed a imilar patten1 of KRA a ociation, trongly supporting 
the notion that KRAS require all four KH domains to tabilize the interaction, with a omewhat 
mitigated role for KH 1 domain . Thi re ult optimistically suggests that drugs found capable of 
blocking any of the four KH domains wi ll strongly inhibit the CRD-BP-KRAS mRNA 
interaction, in cells and in vi tro, making KRAS a lucrative opp01iunity among CRD-BP target . 
Traditional drug discovery often proceed with random te ting of generated small 
molecule libraries, searching for a desired effect among thousand or millions of candidate 
(reviewed in Hughes eta!. 20 1 0) . The use of specific anti-sense oli gonucleotide inhibitors that 
bind mRNA and reduce translation, or interaction with nascent proteins is relatively new, and 
requires specific knowledge of the target mRNA but can indirectly inhibit a protein target 
(Henning and Best, 2002). To date there i no published work on inhibitors designed to abrogate 
the interaction between CRD-BP and KRAS mRNA, in vitro or in vivo. Thi the is pre ent , two 
DNA-based anti-sen e o ligonucleotide inhibitors (section 2.3 .3, M6 and M7) again t th 
RD-BP-KRAS mRNA interaction that were developed with th knowledge gained from th 
KRAS minimum binding equence (section 2 .. 1 ), the mo t ef[i ' ti w1th an I ~o of 11 . nM . 
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Th m t pr bable m chani m ofth ir inhibition is complementary Wat on- rick base 
pairing, ma king th KRA RN binding quen e/ tructure from RD-BP and th reby 
inhibiting int racti n . rl ap f th n1inimum binding equ nee di c v red in ection 2.3.1 
with th anti- n lig nucle tid inhibit r target regi ns doubly impli ate the KRA -A34(b) 
r g1 n (nt : 129- 1 5) a imp rtant b r RD -BP interaction with KRA RNA. There earch into 
DN -ba d lig nucl e tid inhibit r pre ented here ha laid the groundwork for future cell-
ba ed a ay u ing M6 and M7 to target KRA , and may join the other hopeful anti-KRA 
therapeutic trat gi with fur1her d el pment. dditionally, M7 and M2 have found fu11her 
u e a a po iti e control in flu ore cence polarization based creening of proto-drug for anti-
RD-BP activity in our laboratory. 
econdary tructure analy is of the RD-BP protein revealed a highly structured protein 
with primarily a-helical (69%) compo ition, in-line with other KH domain-containing protein 
(Chao eta!. 2010; Valverde et al. 2007; Chmi el eta!. 2006). Further an alysis of the CRD-BP KH 
mutant library concluded that introduction of the GXXG mutations used to study KH domain 
requirements in RNA binding did not compromise the global structure of the protein. 
Remarkably little variation was apparent between the CRD-BP KH mutant proteins CD pectra 
and provides compelling evidence that the GXXG loop region between the fir t and econd a-
helix does not contribute any structural integrity to the protein. FUiiher CD analysis hawed 
quantifiable changes in secondary structure upon binding RNA implying that CRD-BP may hav 
multiple forms, one conformation stabilized by RNA binding. The effect wa general! non-
pecific with all RNA able to induce the hift, but the degree of change did app ar to cotTelat 
with RNA target affinity suggesting ome specificity ( 4.2.2). Intere tingly with the rem val of 
the RRM domains, the pecifici ty wa mitigated betw en KRA - l ~and KR -A3 4 RNA 
137 
targ t (high and 1 w affinity re pectively) ugge ting ome role in pecificity for the RRM 
d main . upp rting thi n ti n i the flu re cence p lariza tion binding as ay completed, 
c mparing th full -length RD-BP t a g nerat d KHlto4 truncati n variant (4.2.4) . Kd 
compari n re al a triking 3-fl ld increa e in affinity with the removal of the RRM domains. 
no functi n ha et be n attributed to the RRM domain in VICKZ proteins, confirmation of 
thi ef~ ct with th r RN target may a cribe a novel negative binding regulator fun ction to the 
RRM domain . 
lnterd main g metry w ithin th e ''KH I to4" binding modul e is key to understanding and 
predicting RD-BP mRN target , a ugge ted by Chao et al. (201 0) and evidenced by the 
appearance of bipartite equence requirement fo r ~-actin "zipcode" RNA. Currentl y there i no 
cry tal tructure of full -length CRD-BP or any of the VICKZ protei ns, with onl y a tructure of 
the KH3-KH4 didomain availabl e to scru tinize. However, as KRAS requires all four KH 
domain , a more complete tructure is necessary to understand how binding occurs. Despite a 
thorough attempt to obtain a diffraction pattern and crystal structure of CRD -BP, no cry ta l 
suitable for structure dete1mination were obtained. A single large pro tein crystal posse sing 
twinned character did grow in 0.2M lithium sulphate, O.l M Tris-Cl pH 8.5, 40% v/v PEG400 
buffer, however it was deemed not sui ta ble for X-ray diffraction. Fonnation of a crystal doe 
however suggest that the specific KH 1 to4 construct described in this thesi can potentially 
crystallize and future efforts in complex with an RNA target may be more successful. 
xi 
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